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ABSTRACT
Though modern medicine has greatly improved detection and treatment of breast cancer
and overall survival rates are around 85%, this disease is still the second most fatal cancer
in Canada. Once the cancer becomes metastatic, it is considered incurable and treatment
strategies are directed towards maintenance of the disease rather than curing it. Another
hurdle to breast cancer treatment is the severity of side effects from chemotherapeutics, for
example cardiotoxicity and hepatotoxicity, that are sometimes fatal. Dexamethasone (Dex)
is a synthetic glucocorticoid (GC) that has been shown to be effective at reducing the less
severe side effects of chemotherapeutics, such as nausea and inflammation. There is
growing concern that Dex interferes with the effectiveness of anti-cancer drugs because of
chronic suppression of the immune system, which has been implicated in cancer
progression in some inflammatory diseases. The use of natural health products (NHPs) to
treat inflammation is a growing field of research to find alternatives to synthetic GCs and
many are already on the market. To study the toxicity of drug combinations there needs to
be an efficient model that accurately incorporates immune response and organ toxicity.
Zebrafish have become an increasingly used animal model to study human cancer and drug
toxicity because they are cost effective and can be used for high throughput assays. Using
a zebrafish model optimized for this work, we show that Dex increases the metastatic
potential of breast cancer cells and accentuates the cardiotoxicity and hepatotoxicity of
embryos when treated in combination with cyclophosphamide but not with paclitaxel. We
also show that the NHP, Nutria plus, has anti-inflammatory and antioxidant properties and
may be a beneficial supplement for treating inflammatory diseases and preventing cancer
drug toxicity. Together these results show that the ubiquitous use of Dex in clinics should
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be re-evaluated. We also studied cell cycle regulation of mammary acini development and
cancer metastasis. We show, for the first time, that increased expression of the cell cycle
regulator, Spy1, leads to multi-acinar mammary alveolar structures in vitro, and leads to
increased metastasis of breast cells in an in vivo zebrafish model, introducing Spy1 as a
potential target for treatment of metastatic breast cancer.
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CHAPTER 1

GENERAL INTRODUCTION

1

Overview of Human Mammary Gland Development and Architecture
The mammary gland is an organ than continually undergoes rounds of proliferation,
apoptosis, and structure remodeling during menstrual cycles, pregnancy, lactation, and then
after weaning. This requires a strict balancing act between pro-survival and pro-apoptotic
cues to maintain the ability to repeat the cycles of gland remodeling without developing
cancer as evidenced by the fact that many pathways known to initiate cancer progression
are the ones mediating normal mammary gland development (Hardy, Booth, Hendrix,
Salomon, & Strizzi, 2010; Moses & Barcellos-Hoff, 2011; Wagner & Rui, 2008). To
understand the progression of breast cancer, it is first important to know how the breast
goes through normal development.
Embryonic and prepubertal development
Male and female mammary glands follow the same developmental pattern throughout
intrauterine growth. During embryonic development the mammary gland develops from
the ectoderm and mesoderm germ layers, which respectively develop into the epithelium
and the surrounding mesenchyme. This early development of the gland relies on signaling
between the epithelial and mesenchymal layers (Javed & Lteif, 2013). In humans, distinct
mammary cells can be seen at 4-5 weeks gestation (Medina, 1996). At 35 days gestation
proliferating epithelial cells form paired lines on either side of the embryo called a
mammary crest or mammary bands. By 6 weeks gestation this crest has mostly disappeared
except for bilateral mammary buds in the thoracic region. These buds are composed of
layers of mammary epithelium that proliferate and extend into the mesenchyme in response
to factors which are excreted by mesenchymal cells (Cowin & Wysolmerski, 2010; Cunha
et al., 1995; Sakakura, Sakagami, & Nishizuka, 1982). By approximately 14 weeks
2

gestation, a distinct mammary bud can be seen invading into the underlying dermis with
identifiable central and basal epithelial cells as well as mesenchymal cells that are
differentiating into stromal components such as fibroblasts, adipocytes, endothelial cells,
and smooth muscle cells. The basal cells of this primary bud are distinct from the
surrounding basal epidermal cells by the loss of staining for cytokeratin 14 (K14), a basal
epithelial cell marker (Javed & Lteif, 2013; Jolicoeur, Gaboury, & Oligny, 2003; Petersen
& Polyak, 2010; Tobon & Salazar, 1974). Proliferation continues and secondary buds form
and elongate from the primary mammary bud into the mesenchyme. At 21 weeks gestation,
the cells of the secondary buds co-stain for K14 and K19, a luminal cell marker (Petersen
& Polyak, 2010). Inner cells come together and form two distinct layers; inner, secretory
epithelial cells and outer, contractile myoepithelial cells. The nipple is formed from smooth
muscle fibers and the areola is derived from the surrounding ectoderm. These ductal
structures continue to develop through the third trimester with approximately 15-20
secondary branches forming (Hens & Wysolmerski, 2005; Javed & Lteif, 2013). At birth,
infants have secretory cells that have evidence of milk in the Golgi apparatus which shows
that lactogenic and contractile cells have differentiated enough from one another to provide
functionality (Jolicoeur, et al., 2003).
After birth, the breast tissue remains palpable and persists during the first 6 months
of life. There are sex differences in size and persistence of palpable tissue with females
having larger and more persistent nodules (McKiernan & Hull, 1981). Although there are
no discernable differences in the cellular structures of the male and female gland up to 2
years of life (Anbazhagan, Bartek, Monaghan, & Gusterson, 1991), there are differences
between each individual’s gland and when each gland reaches a certain stage of

3

development. By 8 months of age the lobules of the gland regress but epithelial ducts
surrounded by myoepithelial cells are still present (Anbazhagan, et al., 1991; Javed & Lteif,
2013). These events are summarized in Figure 1.1.

4
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Figure 1.1. Sketch of human embryonic mammary development.
Mammary cells are apparent starting at around 4 weeks gestation in the mammary ridges.
By week 6 a primary bud has formed extending into the dermis. At week 14 the primary
bud has lost K14 staining and into the second trimester secondary buds form that are K14
and K19 positive. Later in the third trimester the ducts that are forming are lined with inner
K19 positive cells and outer K14 positive cells. By term, the fetus has a nipple and
rudimentary alveolar units that are capable of milk production. After birth fat cells
accumulate and the nipple differentiates. The inset shows a cross-section of an alveolus
with an outer basement membrane, outer myoepithelial cells and inner luminal cells.
Adapted from (Pansky, 1982).
5

Pubertal development
The rudimentary ductal structures of the mammary gland persist until puberty, when the
production of sex hormones in females stimulate remodelling (Monaghan, Perusinghe,
Cowen, & Gusterson, 1990). At this point the ductal structures begin to mature, elongate,
and the main ducts branch off into several terminal lobular ductal units (TLDUs), each
encased and separate from the other by stromal tissue (Cardiff & Wellings, 1999). Alveoli
form at the end of the TLDUs and a few new alveolar structures are added after each
menstrual cycle but the gland is still composed of mostly stromal tissue (Monaghan, et al.,
1990).
Pregnancy, lactation, and involution
Hormonal changes during pregnancy cause extreme remodelling of the mammary gland to
allow for lactation after birth. Prolactin and progesterone are responsible for initiating the
proliferation of alveoli cells during pregnancy (Brisken, 2002). Parenchymal tissue
replaces the stromal tissue as alveoli structures are formed and cell differentiation
predominantly happens after mid-pregnancy (Richert, Schwertfeger, Ryder, & Anderson,
2000). In humans, the alveoli are present at puberty but become more numerous and more
differentiated after pregnancy and progesterone signaling.
The signaling cascades responsible for alveolar development have been primarily
dissected in mice but these pathways are similar in humans. Progesterone signaling induces
mammary cell differentiation during early pregnancy by activating the cytokines,
interleukins 4 (IL-4) and 13 (IL-13). These cytokines will then activate signal transducer
and activator of transcription 6 (STAT6) to promote cell proliferation and a commitment
of luminal cells to alveolar lineage by inducing gene transcription of GATA3, which has
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been shown to be the most highly enriched transcription factor in pubertal mouse mammary
glands (Haricharan & Li, 2014; Khaled et al., 2007; Kouros-Mehr, Slorach, Sternlicht, &
Werb, 2006; Oliver, Khaled, Frend, Nichols, & Watson, 2012). At this same time, during
early pregnancy, STAT6 expression decreases and STAT5 expression increases to allow
for generation and maintenance of alveolar progenitor cells (Yamaji et al., 2009).
In humans, the alveolar cells become highly polarized with columnar luminal
epithelial cells being tightly, but discontinuously, surrounded by the myoepithelial cells
(Figure 1.1). Transcriptional targets of STAT5 include β-casein and whey acidic protein
(Dong et al., 2010; Haricharan & Li, 2014). β-casein, a milk protein, can be seen in the
alveoli cells after the 15th week of pregnancy and can be used as a marker of functional
differentiation as it is not found in non-pregnant mammary glands (Suzuki et al., 2000).
In late pregnancy and lactation, STAT5 expression, activated by prolactin mediated
activation of prolactin receptor, is sustained and it has been shown that STAT5 expression
is required and sufficient to induce proper alveolar morphogenesis and lactogenesis in mice
(Cui et al., 2004; Dong, et al., 2010; Haricharan & Li, 2014; Yamaji, et al., 2009). Studies
on lactating women showed that lactation was initiated when there was a sudden decrease
in estrogen and progesterone but that the pituitary gland must secrete prolactin for
successful lactation (Tyson, Khojandi, Huth, & Andreassen, 1975). Infant suckling
stimulates the pituitary gland to release hormones and in a healthy woman the secretory
epithelial cells will continue to produce milk until a time when weaning and involution
occur (Tyson, et al., 1975).
Involution is a very complex stage of mammary development which involves
strictly regulated processes so that the gland can return to the pre-pregnancy state and be
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ready for future pregnancies and lactation. After weaning, the gland is remodelled once
more and is returned to a state that is morphologically similar to the pre-pregnancy gland
through a process known as involution. The removal of the suckling stimulus at weaning
leads to cessation of the secretion of milk from the lumen which causes a series of signaling
cascades which stop milk production (Rennison et al., 1993). Feedback Inhibitor of
Lactation (FIL), identified as a subset of milk proteins found in the whey of many different
mammals’ milk, accumulates in the lumen of the alveoli when milk is not expelled by
suckling and begins the involution cascade. FIL works by changing the structure of the
Golgi apparatus and endoplasmic reticulum to inhibit protein trafficking and protein
secretion which allows the proteins to accumulate in the cell (Rennison, et al., 1993; Wilde,
Addey, & Knight, 1989). In one study to determine the affect of FIL on cells, after only
one hour of adding FIL to cells, the Golgi apparatus no longer exhibited perinuclear
localization but was diffused throughout the cell (Rennison, et al., 1993). In this same
study the endoplasmic reticulum was also disrupted but both processes were reversible with
the removal of FIL.
The major regulator of apoptosis during involution is STAT3, which is activated
by phosphorylation of transforming growth factor β3, as seen in a study where deletion of
STAT3 blocked mammary gland involution (Haricharan & Li, 2014; Humphreys et al.,
2002; Nguyen & Pollard, 2000). As the cells become apoptotic, they start to lose their tight
junction due to a cleavage of E-cadherin and translocation of β-catenin to the nucleus and
the epithelial cells of the alveoli become phagocytic to begin clearing of the dead cells
(Fornetti et al., 2016).
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In the second phase of involution, the gland begins major remodeling and
proteolysis occurs to remove components of the extracellular matrix (ECM). These late
stages of involution are marked by increasing expression of certain proteases, such as
plasminogen which activates matrix metalloproteinase (MMP) family members (Lamote,
Meyer, Massart-Leen, & Burvenich, 2004). Once the MMPs become active and start
removing the basement membrane, cells which did not die in the first phase of involution
will now become apoptotic and the involution will become irreversible (Watson, 2006).
The MMPs are kept inactive until this later stage of involution by tissue inhibitor of
metalloproteinases to ensure the first phase of involution is reversible but once MMPs are
actively clearing the gland the involution is irreversible (Fata et al., 2001).
The final stages of involution include recruitment of macrophages to clear the
secretory structures, deposition of ECM proteins by fibroblasts, and adipocyte
differentiation, all of which will bring the gland back to the stage resembling pre-pregnancy
(Flanders & Wakefield, 2009; O'Brien et al., 2010).
Role of stem cells in development
Although massive rounds of apoptosis happen during involution, the mammary gland will
retain the ability to reconstitute and undergo subsequent rounds of lactation. Regenerative
capacity is dictated by the presence of multipotent adult mammary stem cells (MaSCs),
cells which can differentiate into the different lineages needed for the gland to function.
MaSCs were first described, in 1959, as a population of cells capable of self-renewing and
reconstituting the gland upon transplantation (Deome, Faulkin, Bern, & Blair, 1959).
MaSCs have impressive potency and even a single stem cell has the capacity to reconstitute
an entire gland (Shackleton et al., 2006).
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There are still a lot of unanswered question regarding MaSCs but the current most
accepted model of mammary cell hierarchy can be summarized as follows: embryonic
multipotent stem cells can self-renew or give rise to unipotent basal and multipotent
luminal progenitors. Although hormone signaling is critical for mammary epithelial
mitosis, MaSCs lack expression of estrogen receptor (ER), progesterone receptor, human
epidermal growth factor receptor 2, and interestingly express high levels of epidermal
growth factor receptor, K5/6, and the myoepithelial marker p63 (Boecker et al., 2018;
Memmi et al., 2015). These basal and luminal progenitors can self-renew or
asymmetrically divide to give rise to basal cells and ductal or alveolar cells, respectively.
Ductal and alveolar cells can be ER positive or negative. An alternative model suggests
there are, in fact, separate unipotent ductal and alveolar progenitors and not just luminal
progenitors that can differentiate into the separate lineages (C. O. dos Santos et al., 2013;
E. Lee, Piranlioglu, Wicha, & Korkaya, 2019; Lloyd-Lewis, Harris, Watson, & Davis,
2017; Medina, 1996; Visvader, 2009).
With the advance in techniques of tissue dissociation and fluorescence activated
cell sorting, cell surface antigens corresponding to MaSCs began to be described
(Sreekumar, Roarty, & Rosen, 2015; Stingl, Eaves, Zandieh, & Emerman, 2001). Although
these methods have greatly improved the way that stem cells can be studied, there is a lot
of heterogeneity in cell surface marker expression during development which contributes
to conflicting data. The consensus for human MaSCs is that the most primitive basal cells
have the highest expression levels of cluster of differentiation (CD) 49f (α6-integrin) and
low expression levels of epithelial cell adhesion molecule (EpCAM). Luminal cells have
lower expression of CD49f and high expression of EpCAM (Stingl, Raouf, Eirew, & Eaves,
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2006; Visvader, 2009). There are bipotent human mammary epithelial progenitors that also
stain positive for CD49f and EpCAM but do not stain for mucin1, a protein that regulates
pluripotent stem cells (Hikita, Kosik, Clegg, & Bamdad, 2008; Stingl, et al., 2006).
Staining of human breast tissue for these markers found that only cells contained in the
ducts had the capacity for self-renewal, clonal growth, and bi-potency and a population of
cells expressing both keratins K19 and K14 was only present in the ducts (Villadsen et al.,
2007). In addition to cell surface markers, the expression of high aldehyde dehydrogenase
1 activity has been described in cells possessing stem cell properties including the ability
to reconstitute a functional gland (Ginestier et al., 2007; Kuperwasser et al., 2004;
Visvader, 2009). In summary, stem cells regulate the ability of the mammary gland to
undergo multiple rounds of pregnancy, lactation, and involution when the alveolar
structures are no longer need. Stem cells are critical for maintaining normal function of the
gland but required strict regulation to avoid continuous activation of the cell cycle.
Cell cycle regulation
Another important level of regulation during mammary gland development is the cell cycle.
The cell cycle is a ubiquitous process whereby cells are guided by various signals to make
choices that determine their fate, for example, divide to form two daughter cells or exit the
cycle to enter a resting state. The cell cycle is divided into phases named G1, S, G2, M and
a phase named G0 whereby a cell has exited the cell cycle and remains dormant or quiescent
until further cell division is required (Nakamura-Ishizu, Takizawa, & Suda, 2014; Pardee,
1974). G1 is the first “gap” phase whereby cells either decide to exit the cycle in
unfavourable conditions or commit to divide and proceed to increase in size, produce
mRNA, and synthesize proteins that are needed for DNA synthesis which occurs during S
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phase (Loddo et al., 2009). In the next “gap” phase, G2, cells double in size in preparation
for mitosis, M phase, where the cell will split into two equal daughter cells (Schafer, 1998).
Cells will then make the decision to exit the cycle into G0 to remain until needed, terminally
differentiate, senesce (cells irreversible cease to divide), or progress through G1 and enter
the cell cycle again (Loddo, et al., 2009; Stoeber et al., 2001).
Positive cell cycle regulation is mainly through the CDKs which were first
characterized in yeast, in which a single CDK (Cdc28 in budding yeast and Cdc2 in fission
yeast) was found to regulate the cell cycle through interactions with cyclin (so named
because of their cyclic expression during the cell cycle) partners (Lim & Kaldis, 2013;
Nurse & Thuriaux, 1980; Reed, Ferguson, & Groppe, 1982). In mammals there are many
CDKs and cyclins and the mammalian cell cycle is generally seen to be regulated by the
CDK4/6/Cyclin D complex in G1, CDK2/Cyclin E/A complex at G1/S transition, and
CDK1/Cyclin B complex at G2/M (Schafer, 1998). There are currently 21 known CDKs
(Axtman, Drewry, & Wells, 2019) characterized by a conserved catalytic core which
includes an adenosine triphosphate (ATP)-binding pocket, PSTAIRE-like cyclin-binding
sequence motif, and a T-loop activating motif (Lim & Kaldis, 2013). These elements work
together as the mechanism of CDK activation where cyclins or cyclin-like proteins
associate with the CDKS at the PSTAIRE domain which displaces the T-loop and exposes
the substrate binding site, meanwhile the ATP-binding or active site is made ready for the
activating phosphorylation (Lim & Kaldis, 2013; Pavletich, 1999). CDKs are also
regulated by phosphorylation at specific threonine (T) and tyrosine (Y) sites, which vary
for the different CDKs, to activate or inhibit the activity of the CDK (Schafer, 1998). For
example, CDK2 is one of the main regulators of the G1-S phase of the cell cycle and is
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phosphorylated at the inhibitory sites T14 and/or Y15 by Wee1, after cyclin binding,
followed by phosphorylation at the stimulatory site T160 by CDK activating kinase
(CDK7/Cyclin H) but this complex remains in an inactive state until T14 and Y15 are
dephosphorylated by the phosphatase Cdc25A (Bartova, Otyepka, Kriz, & Koca, 2004;
Rudolph, Epstein, Parker, & Eckstein, 2001; Stevenson, Deal, Hagopian, & Lew, 2002).
Although traditional cyclins require these phosphorylation and dephosphorylation
events to activate the CDK complex, Speedy or Spy1 encoded by the SPDYA gene, which
has no homology with the cyclins, can activate CDK1 and CDK2 independently of
phosphorylation by CDK activating kinase (Cheng, Gerry, Kaldis, & Solomon, 2005;
Cheng, Xiong, Ferrell, & Solomon, 2005; Karaiskou et al., 2001). Spy1 was first isolated
from a Xenopus cDNA library screen (as xSpy1) in rad1 deficient yeast (S. pombe) as a
cell cycle regulator that could overcome the G2/M checkpoint after ultra violet (UV)
damage (Lenormand, Dellinger, Knudsen, Subramani, & Donoghue, 1999). In an
independent screen for regulators of meiotic maturation in xenopus oocytes, Speedy
proteins were identified as enhancing meiotic maturation of oocytes as compared to
progesterone (Ferby, Blazquez, Palmer, Eritja, & Nebreda, 1999). In this study the proteins
were referred to as rapid inducer of G2/M progression in oocytes proteins (RINGO).
A human homolog to xSpy1, Spy1, was identified using a testis cDNA library and
was found to be expressed at low levels in various tissues but highly expressed in the testis
(Cheng, Xiong, et al., 2005; Porter et al., 2002). Specifically in mammary tissue, Spy1
protein was found to be localized to epithelial cells with weak or absent expression in the
myoepithelial cells and adipose tissue (Golipour et al., 2008). Protein and mRNA analysis
showed a cyclic pattern of expression in the breast with low expression in the virgin gland,
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higher expression in early pregnancy, expression levels decreasing for late pregnancy and
lactation, and then levels increasing again during involution. In this same study, treatment
with mitogen-activated protein kinase (MAPK) inhibitors significantly decreased Spy1.
Inducing c-Myc expression in cells elevated Spy1 expression suggesting Spy1 regulation
is downstream of both MAPK and c-Myc (Golipour, et al., 2008). Spy1 not only has the
ability to activate CDKs but through the Spy1/CDK2 complex, is also able to override cell
cycle checkpoints (McAndrew, Gastwirt, Meyer, Porter, & Donoghue, 2007; Porter, KongBeltran, & Donoghue, 2003).
Healthy cells have natural checkpoints or restriction points at specific times in the
cell cycle to ensure they won’t divide when there are unfavorable conditions like
insufficient nutrients or DNA damage. These checkpoints are defined as “a biochemical
pathway that ensures dependence of one process upon another process that is otherwise
biochemically unrelated” (Elledge, 1996; Schafer, 1998). For example, an early cell cycle
checkpoint is the amount of growth factors. In the presence of sufficient growth factors,
cells in G0 can be stimulated into G1 and progress through early G1 where the checkpoint
is the timing in which removal of growth factors no longer halts the cell cycle and the cell
will continue into S phase in the absence of sufficient growth factors (Schafer, 1998). In
G1 and G2 there are DNA damage checkpoints that will activate DNA damage repair or
cell death pathways if DNA cannot be repaired.
Different types of genes will regulate biological checkpoints to halt the cell cycle
if necessary. One of the most well known “guardians” of these checkpoints, is the tumour
suppressor p53. The G1 DNA damage checkpoint was first reported to be completely
dependent on p53 regulation as evidenced by p53-null cells that did not arrest in G1 in
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response to DNA damaging agents (Little, Nagasawa, Keng, Yu, & Li, 1995). However
other later studies were able to show p53-independent G1 checkpoint activation indicating
p53 is not always required for this checkpoint (Deeds, Teodorescu, Chu, Yu, & Chen, 2003;
Vaziri & Faller, 1997). Upregulation of p53 induces transcription of many genes, including
the cyclin dependent kinase (CDK) inhibitors, of which there are two families; inhibitors
of CDK4 (INK4) and Cip/Kip members. The INK4 family contains p16INK4a, p15INK4b,
p18INK4c, and p19INK4d which specifically inhibit CDK4/6 by competing with D-type
cyclins to prevent binding (Canepa et al., 2007). The Cip/Kip family includes p21Cip1,
p27Kip1, and p57Kip2 and can inhibit a wide range of CDKs by their ability to directly bind
to both the CDK alone and when they are in complex with cyclins (Evans, Rosenthal,
Youngblom, Distel, & Hunt, 1983), and CDKs (Sherr & Roberts, 1999).
Previous research has shown that the CDK2/Spy1 complex is able to phosphorylate
p27 which leads to its degradation (McAndrew, et al., 2007; Porter, et al., 2003). This is
one important mechanism of Spy1 mediated regulation of the cell cycle. Proper cell cycle
regulation is key in maintaining normal function of the mammary gland and because Spy1
is able to enhance cell cycle progression independently of the cell’s natural inhibitory
mechanisms, it is crucial to further determine how Spy1 is regulating normal mammary
morphogenesis and how altered Spy1 expression can affect normal gland development.
Comparison of human and mouse development
What we know about the distinct structures of human embryonic and pubertal mammary
development has mostly been obtained from tissues taken during necropsies but when
studying the distinct stages of pregnancy, lactation, and involution, human tissue samples
do not provide sufficient information (Anbazhagan, et al., 1991; Jolicoeur, et al., 2003;
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Monaghan, et al., 1990; Tobon & Salazar, 1974). For obvious reasons, gene manipulation
in the human breast in vivo is not performed so animal models, primarily mouse, have been
developed to study gland development as well as which genes and hormones are essential.
Both human and mouse glands develop from the same ectodermal layer which forms
distinct milk buds; 1 pair in humans and 5 pairs in mice (Cardiff & Wellings, 1999). These
buds will later become the mature mammary glands. The mouse gland has a persisting fat
pad that remains throughout development whereas the human gland has immature fat cells
early in development but a distinct fat pad is not found later on even though there is an
abundance of fat cells (Anbazhagan, et al., 1991; Cardiff & Wellings, 1999; Javed & Lteif,
2013). The major difference in gland structure between species in the terminal functional
units of the gland which is mostly hormone regulated. The human gland has a complex
ductal system with five to ten main ducts extending from the nipple and each duct contains
a separate lobe with its own ductal system and collagenous stromal tissue with the
functional unit being referred to as a TLDU. The mouse gland contains a single primary
duct that branches into five to ten secondary ducts with terminal end buds (TEBs) or
“lobulo-alveolar” units. (Cardiff & Wellings, 1999; Richert, et al., 2000). Even though
there are some structural differences in the development of the gland, the alveolar units are
very similar and so mice are a very useful model for investigating the signaling pathways
involved in assuring that the alveoli function properly during lactation and then are cleared
during involution.
Mammary Gland Microenvironment
The mammary gland can be compartmentalized into the epithelium and the stroma, the
latter being comprised of mesenchymal cells surrounded by the ECM. Mesenchymal cells
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include fibroblasts, adipocytes, and immune cells (Weigelt & Bissell, 2008) (Figure 1.2).
Together these components make up the mammary microenvironment. The
microenvironment plays in integral part of normal mammary development as well as
cancer progression.
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Figure 1.2. The mammary microenvironment.
The mature alveolus is made up of epithelial cells surrounded by contractile, endothelial
cells. These structures are held together by a thin basement membrane. In the surrounding
microenvironment, the breast has many adipose cells, immune cells, fibroblasts, ECM
components, and blood vessels. Each contributing to the signaling to signaling cues
essential for mammary development and homeostasis. Made with BioRender.
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Characteristics of the mammary ECM
The ECM is important in maintaining the structural integrity of the gland as well as
providing regulatory signals to the epithelium (Schedin & Keely, 2011). ECM fibers
assemble in non-random orientation to provide matrix support and adhesion sites to the
surrounding cells. The major structural component of the ECM is fibrillar collagen which
provides ligand binding sites for many receptors as well the structural support (Maller,
Martinson, & Schedin, 2010). The basal lamina or basement membrane is a highly
organized compartment of the ECM that separates the epithelial cells from the less
structured, collagen I-rich ECM compartments and is composed of collagen IV, laminins,
entactin, and proteoglycans (Monaghan, Warburton, Perusinghe, & Rudland, 1983;
Schedin & Keely, 2011). This structural regulation of the ECM is maintained by growth
factors which signal to fibroblasts that will deposit stroma and arrange collagen (Schedin
& Keely, 2011).
Cell-ECM interactions play a role in almost every process of mammary gland
development and maintenance (Muschler & Streuli, 2010). For example, the laminins,
laminin-1 in particular, cooperate with lactogenic hormones to promote differentiation of
mammary cells, inducing expression of β-casein, and maintain proper cell polarity of
epithelial cells (Alcaraz et al., 2008; Bissell & Bilder, 2003; Slade, Coope, Gomm, &
Coombes, 1999; Streuli et al., 1995). Laminin-5 (or laminin-V) binds to its receptors to
allow for the branching of mammary cells as was shown in three-dimensional (3D) culture
assays where normal breast cells did not show the branching morphogenesis when laminin5 function was inhibited (Stahl, Weitzman, & Jones, 1997).
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One of the other major regulators of cell-ECM interactions are the integrins which
are cell surface receptors for various components of the ECM, including vitronectin,
fibronectin, and collagen (Ganguly, Pal, Moulik, & Chatterjee, 2013). There are 18 α
subunits and 8 β subunits that can form 24 different heterodimer pairs that are capable of
binding to different substrates (Takada, Ye, & Simon, 2007). The possible integrin subunits
and some of their corresponding ligands are described in Table 1.1. It is important to note
that this is not an exhaustive list of integrin ligands and others have been described (Takada,
et al., 2007).
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Integrins

Ligands

α1β1

Laminin, collagen, Semaphorin 7A

α2β1

Laminin, collagen, Echovirus 1, tenascin

α3β1

Laminin, thrombospondin, vascular endothelial growth factor (VEGF-A)

α4β1

mucosal vascular addressin cell adhesion molecule, Vascular cell adhesion
molecule-1 (VCAM-1), fibronectin

α5β1

Fibronectin, fibrillin, thrombospondin,

α6β1

Laminin, thrombospondin

α7β1

Laminin

α8β1

fibronectin, nephronectin

α9β1

Tenascin, VCAM-1, VEGF-A, VEGF-C, VEGF-D, and hepatocyte
growth factor

α10β1

Collagen

α11β1

Collagen

αVβ1

Laminin, fibronectin, osteopontin, vitronectin

αLβ2

Intercellular Adhesion Molecule (ICAM)-1-5s

αMβ2

ICAM-2, fibrinogen, heparin

αXβ2

ICAM-1, iC3b, fibrinogen, heparin, factor X

αDβ2

VCAM-1, vitronectin, plasminogen

αIIbβ3

Fibrinogen, fibronectin, von Willebrand Factor,
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αVβ3

Fibrinogen, vitronectin, von Willebrand Factor, thrombospondin, fibrillin,
tenascin, platelet endothelial cell adhesion molecule, fibronectin,
osteopontin, MMP, VEFG-A

α6β4

Laminin

αVβ5

Osteopontin, thrombospondin, vitronectin, fibronectin, fibrinogen

αVβ6

fibronectin, osteopontin, fibrillin, tenascin, vitronectin

α4β7

mucosal vascular addressin cell adhesion molecule

αEβ7

E-cadherin

αVβ8

Vitronectin

Table 1.1 Integrins and their ligands.
A summary of possible intergrin subunit and their main ligands. Adapted with permission.
(Niu & Chen, 2011).
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The activation of integrins is very complex and been shown to be dependent on
talin binding to the cytoplasmic tail of the integrin (Chinthalapudi, Rangarajan, & Izard,
2018). Ras associated protein 1 (RAP1), a small guanosine triphosphate hydrolase
(GTPase), and phosphatidylinositol 4,5-bisphosphate (PIP2) synergize to promote talin
activation of integrins (Bromberger, Zhu, Klapproth, Qin, & Moser, 2019). RAP1 also
regulates E-cadherin mediated cell-cell adhesion as seen in ovarian carcinoma cells where
RAP1 inhibition led to a loss of E-cadherin from the cell surface (Price et al., 2004). RAP1
is regulated through extracellular signaling by cyclic adenosine monophosphate and
calcium, among others (Bos, de Rooij, & Reedquist, 2001).
Downstream signaling of integrins includes many pathways, mostly through focal
adhesion kinase (FAK) activation, which can then activate other kinases and regulate
processes such as cell adhesion, cell survival, migration and polarity as depicted in Figure
1.3.
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Figure 1.3.Integrin signaling pathways.
Integrin activation leads to signaling in a multitude of pathways which are involved in
many cell processes essential for mammary development. Activation of integrins can, in
turn, activate FAK which will signal downsteam to survival, migration, adhesion, polarity,
and differentiation pathways such as extracellular-signal-regulated kinase (ERK), RhoA
and Rac (Legate, Wickstrom, & Fassler, 2009).
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Immune response in the mammary gland
The immune system plays a role in all bodily organs but is especially influential in the
mammary gland during gland morphogenesis as the changing stroma is populated by
immune cells. The immune system is a double-edged sword of the mammary gland. It can
protect the gland from infection and promote normal morphogenesis but when held in a
chronic state of activation can lead to transformation and cancer progression. The main
immune cells in the mammary gland are macrophages, T lymphocytes, eosinophils and
mast cells (Need, Atashgaran, Ingman, & Dasari, 2014). These immune cells are influenced
by hormonal changes in both mice and humans. In the human gland, ERα down-regulates
the nuclear factor-kappa B (NF-κB) pathway to stimulate macrophage cells (Murphy,
Guyre, & Pioli, 2010; Need, et al., 2014) which are necessary for both proper ductal
branching during puberty and also clearing of apoptotic tissue during involution (GouonEvans, Rothenberg, & Pollard, 2000; Masso-Welch, Merhige, Veeranki, & Kuo, 2012).
Fibroblasts, macrophages, mast cells, and eosinophils, but not basophils, T, or B cells, are
found in the stroma immediately surrounding the developing TEBs of pubertal mouse
glands suggesting a role in maintaining stem cells (Coussens & Pollard, 2011). Later in
development, when branching is not occurring, the macrophages are found within the
adipose tissue and not surrounding the ducts (Coussens & Pollard, 2011). Macrophages are
critical for the stem cell niche, as mice depleted of these cells had significantly reduced
mammary gland regenerative capacity when transplanted with mammary stem cells
(Gyorki, Asselin-Labat, van Rooijen, Lindeman, & Visvader, 2009). Both innate and
adaptive immune cell populations are found in high abundance during alveolar
morphogenesis, pregnancy, and lactation. These cells migrate through the alveolar lumen
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into the milk to provide antimicrobial properties to the milk and antibodies which transfer
immune protection to nursing young (Atabai, Sheppard, & Werb, 2007; Coussens &
Pollard, 2011).
Chemokines and cytokines are other immune components that are secreted by the
different cell types, including epithelial cells, fibroblast, adipocytes, and immune cells.
These secreted factors play many roles in the mammary gland such as promoting (IL-1, IL6, IL-8, tumour necrosis factor-alpha (TNFα)) and down-regulating inflammation (IL-10),
and enhancing tissue growth by recruiting macrophages and eosinophils when needed
(Coussens & Pollard, 2011; Need, et al., 2014; Riollet, Rainard, & Poutrel, 2000). IL-4 and
IL-13, through downstream STAT6 signaling, are important regulators of mammary cell
differentiation as shown in mouse knockout experiments where alveolar morphogenesis is
reduced in both STAT6–/– and IL-4–/–/IL-13–/– animals (Khaled, et al., 2007).
In summary, immune response is not only for protection against xenobiotics, but is
a regulation that takes place throughout normal development and is essential for a normal
functioning mammary gland.
Breast Cancer
According to GLOBOCAN statistics, in 2018 cancer killed a combined total of over 9
million people worldwide (Bray et al., 2018). In over 100 countries breast cancer was the
leading cause of cancer mortality for women, accounting for about 15% of cancer deaths
(Bray, et al., 2018). In Canada, breast cancer is the second deadliest cancer, behind lung
cancer, and it is estimated that in 2019 approximately 5000 Canadian women will have
died from this disease (Canadian Cancer Statistics 2019). Males represent only about 1%
of all breast cancer patients primarily due to the differences in mammary gland
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development between the sexes (Liu, Johnson, & Ma, 2018). Historically, survival rates
for breast and other cancers were low, but after many advances in detection and treatment
of primary breast tumours the survival rate has risen dramatically. Today, most deaths are
due to tumours that metastasize to vital organs for which there is currently no cure. The
drastic difference in the survival rates between metastatic and non-metastatic breast cancer
makes it necessary to improve treatment options for those with metastases.
Breast cancer subtypes
Breast cancer is a multifaceted disease and can be classified into molecular subtypes which,
with the advancements in transcriptomic and proteomic assays, are continually being
further divided based on characteristics such as molecular signatures, morphological
differences, and treatment response. The subgroups found within the major subtypes are
continually being redefined (Dai et al., 2015; Russnes, Lingjaerde, Borresen-Dale, &
Caldas, 2017) and it is impossible to provide a comprehensive list of clusters that have
been discovered but it is important to note that there is heterogeneity within the subtypes.
The major subtypes are classified as Luminal A and B, human epidermal growth factor
receptor 2 (HER2)-enriched, basal like, claudin-low, and normal-like (Sarmiento-Salinas
et al., 2019; Visvader, 2009). These subtypes are divided based on cell receptor status (ER,
PR, and HER2) and abundance of proliferating cells (through Ki67 antigen staining within
the nucleus) within the tumour sample. Luminal A can be summarized as ER+/PR+/HER2/Ki67-, grade 1/2 disease, good patient outcome. Luminal B is more proliferative with
ER+/PR+/HER2-or+/Ki67+ signature, grade 2/3 disease, and intermediate patient
outcome. Luminal A and B cancer cells have genetic signatures most similar to
differentiated luminal cells. HER2-enriched cancers are ER-/PR-/HER2+, grade 2/3
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disease with poor patient outcome. These cancers are proposed to have been derived from
luminal progenitor cells (Visvader, 2009). Basal breast cancer is ER-/PR-/HER2- with
grade 3 disease and poor outcome. It has been shown that these basal cancer cells are very
similar in genetic profile to luminal progenitor cells (Visvader, 2009). Claudin-low breast
cancer are ER-/PR-/HER2-, claudin-low, and express low levels of cell adhesion and
luminal genes. Their gene signature most closely resembles mesenchymal cell signatures
(Malhotra, Zhao, Band, & Band, 2010; Visvader, 2009). Normal-like breast cancer is
ER+/PR+/HER2+/Ki67-, can be grade 1/2/3 and has intermediate patient outcome (Dai, et
al., 2015; Russnes, et al., 2017). Cells from normal-like cancer have gene signatures that
heavily overlap with MaSCs (Visvader, 2009).
Breast cancers have also been subtyped based on morphology and staging as
follows: Ductal carcinoma in situ develops inside of the ducts and is not invasive but has
high potential to become invasive; invasive or infiltrating breast cancer, which is divided
into invasive ductal carcinoma and invasive lobular carcinoma, has cancer cells that invade
outside of the normal ducts and lobules into the surrounding stroma; metastatic breast
cancers have cancer cells that have spread to other organs of the body such as lymph nodes,
lung, bone, brain, and liver; inflammatory breast cancer causes edema of the breast and the
cancer cells do not form typical tumours thus making it hard to identify on mammograms
(Feng et al., 2018; Malhotra, et al., 2010).
Breast cancer progression
As necessary as the stem cells are for normal mammary gland development and function,
they are, in part, responsible for the progression to malignancy. Tight regulation of the stem
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cell population is needed to keep the balance between regenerating the gland as needed but
exiting the cell cycle when growth is no longer required.
There are three central models of breast cancer propagation that have been proposed
but should not be taken to be mutually exclusive as none of the models can accurately
explain findings from all tumours (Shackleton, 2010). First, the cancer stem cell (CSC)
model proposes that tumorigenic stem cells stably generate more tumorigenic clones of
themselves but also generate phenotypically different non-tumorigenic cells. In this theory,
the cancer initiating cells are rare cells that are distinct from the bulk tumour and can
potentially lose their tumorigenicity through asymmetric division (Dick, 2008; Kreso &
Dick, 2014; Shackleton, 2010). The clonal evolution model is based on cells acquiring
genetic mutations that give them a malignant advantage over other cells. The genetic
heterogeneity of tumours suggests divergent clones can arise from cells within the tumour
bulk and can help explain why a subset of tumour cells acquire drug resistance (Nowell,
1976; Shackleton, 2010; Visvader, 2009). The final model is termed the interconversion
model (or phenotypic plasticity model) and proposes that cells can go back and forth
between malignant and quiescent states. The plasticity of cells is well documented and so
it is possible that the malignant potential of cells in not necessarily intrinsic, as the CSC
model suggests (Gupta, Chaffer, & Weinberg, 2009; Shackleton, 2010). These models are
depicted in Figure 1.4.
Whether stem cells initiate cancer or cancer has already been initiated when the
cells become stem-like, studies have be able to isolate different stem cells from the different
classified breast cancer subtypes lending to the theory that different stem-cells drive
different types of breast cancer (Perou et al., 2000).
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Figure 1.4. Different models of tumor heterogeneity.
(A) Clonal evolution or stochastic model suggests that all cells are capable of renewal and
tumorigenesis through acquisitions of mutations. (B) According to the cancer stem cell
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(CSC) model tumour contain a heterogenous population of cells organized in a hierarchy
where only a small subset of CSCs has the ability to self renew and generate a large
population of differentiated daughter cells by unidirectional conversion. (C)
Interconversion or phenotype plasticity model suggests that differentiated cells can be
return to an undifferentiated state or stem cell-like state given the appropriate stimulus.
Tumour heterogeneity is achieved through this bidirectional conversion between CSC on
non-CSC. Modified from: (Jayachandran, Dhungel, & Steel, 2016).
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Some mechanisms of breast cancer stem cell (BCSC) regulation are depicted in
Figure 1.5. These are pathways that regulate MaSCs in the normal gland but become
deregulated in tumourigenesis (Czerwinska & Kaminska, 2015; Sin & Lim, 2017). For
example, in breast cancer, Wnt pathway inhibitors, Wnt inhibitory factor1, Secreted
Frizzled-Related Protein 1, and Dickkopf-related protein 1 are often methylated and
silenced in breast cancer which leads to aberrant activation of the Wnt pathway and
acquisition of a stem cell phenotype (Klarmann, Decker, & Farrar, 2008).
BCSCs are also implicated in resistance to breast caner treatment because of their
enhanced DNA repair mechanisms, their lengthened cell cycle, and increased activity of
membrane transporters which can evade chemotherapies designed to target fast growing
cells (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 2003; Czerwinska &
Kaminska, 2015; Zhou et al., 2001).
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Figure 1.5. Schematic representation of signaling pathways that control maintenance of
BCSCs.
In the presence of Wnt ligand, β-catenin is stabilised, translocates to the nucleus and
induces gene expression by binding to transcription factors such as T-cell factor/lymphoid
enhancer-binding factor (TCF/LEF). In Notch signaling, ligand binding causes the receptor
fragment to be cleaved by TACE (TNF-α ADAM metalloprotease converting enzyme) then
γ-secretase to create NICD (Notch intracellular domain), which forms a complex with
transcription factors RBPJ and CSL (CBF1/Suppressor of Hairless/LAG-1), and activates
the expression of target genes. Sonic Hedgehog (SHH) binds to Patched (PTCH), which
constitutively represses Hh pathway activity through its interaction with a transmembrane
protein Smoothened (SMO). Shh-bound PTCH activates SMO and activated SMO releases
GLI1 (Glioma-Associated Oncogene Homolog 1) from the cytoplasm, and, in turn, GLI1
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translocates into the cell nucleus to regulate gene expression. Activation of TGF-β type I
and type II receptors activates the receptor kinases and phosphorylation of the R-Smads,
binding with co-Smad 4, which translocates to the nucleus (Czerwinska & Kaminska,
2015).
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Cell cycle regulation in breast cancer
Malignancy occurs when cells gain the ability to overcome the natural restriction and
checkpoints in the cell cycle that are meant to prevent uncontrolled cell division (Schafer,
1998). One protein able to overcome these restriction points is Spy1. It is able to override
the G1/S cell cycle checkpoint in the presence of p21, which is a potent inhibitor of
Cyclin/CDK2 complexes, CDK2/Cyclin A in particular, at this checkpoint (Karaiskou, et
al., 2001; Sherr & Roberts, 1999). It is proposed that in the presence of Spy1, p21 has a
lower binding affinity to CDK1 and thus is unable to inhibit the complex (Karaiskou, et
al., 2001). Spy1 was also shown to be able to overcome p27 inhibition by directly binding
to p27 and CDK2 and this resulting complex is able to phosphorylate p27 on T187 to target
it for degradation and prevent it from inducing cell cycle arrest (Porter, et al., 2003). It was
also determined that Spy1 could activate CDK2 in the presence of genotoxic stress to
override the DNA damage response which may lead to tumorigenesis (E. A. Barnes, Porter,
Lenormand, Dellinger, & Donoghue, 2003).
Specifically in mammary tissue, HC11 mammary cells expressing exogenous Spy1
were shown to increase the rate of lobular development in a mouse mammary gland
transplant model and by 13 weeks post transplant, there were large, invasive tumours in
83% of mice (Golipour, et al., 2008). Spy1 was found to be upregulated in epithelial cells
isolated from breast-invasive ductal carcinoma samples, invasive lobular carcinoma
tumours, and breast cancer cell lines (Al Sorkhy et al., 2012; Zucchi et al., 2004). Further
investigation found that the Spy1 chromosomal loci (2p23.2) may be a site for increased
risk of breast cancer in women under the age of 50 (Arason et al., 2010; Smith et al., 2006).
More recently, in a study using zebrafish xenotransplants, Spy1 has been implicated in
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resistance to tamoxifen (a drug used to treat ER+ breast cancer) through activation of the
ERK1/2 pathway. This activation was independent of mitogen-activated protein kinase
kinase (MEK) activity but dependent on Ras and Raf activation (Ferraiuolo, Tubman,
Sinha, Hamm, & Porter, 2017). Spy1 has also been implicated in the progression of
colorectal cancer, glioma, liver cancer, ovarian cancer, and neuroblastoma (Q. Jin et al.,
2018; Ke et al., 2009; Lu et al., 2016; Lubanska et al., 2014; Lubanska & Porter, 2014).
Conventional cyclins also play a role in breast cancer processes. In a transgenic
mouse model of Cyclin-D1 overexpression, 75% of mice formed adenocarcinoma after 18
months, suggesting its oncogenic potential. This model suggested a weak oncogenic
potential based on the long latency of tumour formation, however in humans it is
overexpressed in 30-60% of breast cancers (Alle, Henshall, Field, & Sutherland, 1998;
Wang et al., 1994). The cyclin D2 gene is often methylated in breast cancer and
overexpressing D2 in mouse mammary gland blocked alveolar differentiation with a low
frequency of tumour formation (Evron et al., 2001; Kong et al., 2002; Sutherland &
Musgrove, 2004). Cyclin D3 overexpressing mice developed normal mammary gland prepregnancy but after repeated pregnancies, 73% of mice developed tumours (Pirkmaier et
al., 2003). Expressing cyclin E1 during pregnancy and lactation resulted in papillary
projections during pregnancy that disappeared during the resulting involution and after 813 months only 10% of mice had developed tumours. Again, suggesting cyclin E1 as a
weak oncogene in the breast, however it was shown to be abnormally expressed in ~40%
of breast cancers with the protein being expressed as different isoforms ranging from 3550 kDa (Bortner & Rosenberg, 1997; Keyomarsi et al., 1994). Cell cycle regulation is a
very important process in tumour formation as an active malignant tumour needs dividing
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cells. The cell cycle is also an important part of treatment efficacy which often requires
cells to be actively dividing for the drugs to be effective.
Cell Metastasis
Breast cancer remains a fatal disease for many women because of the ability of some cells
to become metastatic, invade through the ECM, leave the primary tumour site, and
establish a secondary tumour in vital organs such as the bones, brain, liver, and lungs.
Invasion is a natural process that is needed for normal mammary gland development,
however improper cell-ECM interactions can disrupt the homeostasis of the gland and lead
to breast cancer and metastasis (Berrier & Yamada, 2007; Lock, Wehrle-Haller, &
Stromblad, 2008).
Metastasis happens as a series of steps beginning with aberrant proliferation of cells
to form a primary tumour. Cells that lose cell-cell adhesion properties, via E-cadherin and
catenin misregulation (Chao, Shepard, & Wells, 2010), can disaggregate from the primary
tumour site and invade through the basement membrane and ECM by way of MMPs and
other proteases (Deryugina & Quigley, 2006).
The integrins and growth factors have been described as the most important
mediators of metastasis through their bi-directional signaling abilities (Ganguly, et al.,
2013). They are particularly important once a metastatic cell has reached the blood vessels
and requires adhesion to blood cells to survive. In one study, constitutive αvβ3 activation
was shown to increase breast cell metastasis in tail vein injections in mice, through
adhesion and interaction with platelets (Felding-Habermann et al., 2001).
β1-integrin was reported to be expressed in infiltrating ductal carcinoma cells and
was correlated with worse disease-free and overall survival in patients with invasive breast
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cancer (P. B. dos Santos, Zanetti, Ribeiro-Silva, & Beltrao, 2012; Jonjic, Lucin, Krstulja,
Iternicka, & Mustac, 1993; Yao et al., 2007). Morini et al.(2000), were able to show that
α3β1 was highly expressed in metastases as compared to the primary tumour site in patient
samples and that α3β1 activity was necessary for MMP-9 protease activity and migration
of MDA-MB-231 cells.
β1-integrin can bind to many different α partners which can activate different
downstream signaling pathways including a canonical pathway where integrins binding to
their ligand and recruit FAK which autophosphorylates and associates with c-Src. This
active FAK/Src complex can recruit and activate, through B-Raf, ERK and MAPK (Hou
et al., 2016; Lambert, Ozturk, & Thiagalingam, 2012; Seguin, Desgrosellier, Weis, &
Cheresh, 2015). The FAK/Src complex can also activate Ras which will, in turn, activate
the Raf-MEK-ERK pathway. This β1-integrin/ERK pathway has been linked to metastasis,
survival, and chemoresistance (Aoudjit & Vuori, 2001; Mierke, Frey, Fellner, Herrmann,
& Fabry, 2011; Parvani, Galliher-Beckley, Schiemann, & Schiemann, 2013; Seguin, et al.,
2015). A summary of the β1-integrin/ERK signaling pathway is depicted in Figure 1.6
(Barkan & Chambers, 2011).
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Figure 1.6. β1-intergin signaling pathway in active and inactive conformation.
Modified with permission: American Association for Cancer Research© (liscense #
4695401314095) and Barkan and Chambers 2005, Clin Cancer Res; 17(23); 7219–23.
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Inflammation and Breast Cancer
The link between inflammation and cancer was proposed in 1863 by Rudolf Virchow who
noted the presence of leukocytes in cancerous tissue (Coussens & Werb, 2002). It is known
now that inflammation alone is not the cause of cancer, however it is thought to be
favourable for cancerous cells to be in an environment with sustained and elevated
inflammation (DeNardo & Coussens, 2007). There is a balance that has been observed
where immune responses are critical for fighting cancer but chronic activation of these
same immune cells contribute to cancer progression (DeNardo & Coussens, 2007). In
breast cancer specifically, reduced overall survival of patients has been associated with
systemic increases in inflammatory markers (Al Murri et al., 2006; Pierce et al., 2009).
During an acute inflammatory response, T helper 1 (Th1) CD4+ and CD8+ T cells
can directly induce tumour cell death and will indirectly lead innate immune cells, such as
macrophages, to attack tumour cells. Innate leukocytes are recruited by immunoglobulin
factors secreted by B-cell lymphocytes to target the tumour cells (DeNardo & Coussens,
2007). In contrast, during chronic inflammation Th2 CD4+ cells will supress the tumour
cytotoxic activity of CD8+ cells. Innate cells are now polarized to protumour functions via
cytokine secretion (IL-4, IL-13, IL-10, IL-6 and transforming growth factor beta (TGFβ)
(DeNardo & Coussens, 2007). Innate tumour cells will accumulate in the tumour tissue and
promote tumourigenesis and survival.
The immune response is not only implicated in anti or pro survival cues within the
tumour but also contributes to tumour cell invasion (Radisky & Radisky, 2007). The
urokinase-type plasminogen activator (uPA) receptor system, which can also activate the
integrins as shown in Figure 1.6, plays a key role in ECM degradation during invasion and

40

high levels of uPA is correlated with poor survival in breast cancer patients (Duffy, 2004;
Mahmood, Mihalcioiu, & Rabbani, 2018; Meijer-van Gelder et al., 2004). Breast cancer
cells are able to activate the surrounding immune and endothelial cells to produce uPA
which ultimately leads to activation of the MMPs and increased degradation of the ECM
to allow for cell invasion (Egeblad & Werb, 2002; Radisky & Radisky, 2007).
Interestingly, proteases are required for cell invasion but not for cell migration because the
cells can take on an amoeboid type of migratory behaviour (Friedl & Wolf, 2003; Wolf et
al., 2003).
MMPs, in humans, are a family of 23 proteases that can regulate the tumour
microenvironment through cleavage of almost all ECM components (Egeblad & Werb,
2002). Activation of proMMPs requires the removal of the propeptide prodomain, which
keeps the MMPs in the inactive form, through proteolysis, usually by other MMPs or serine
proteinases (Egeblad & Werb, 2002; Nagase, Visse, & Murphy, 2006). MMPs are often
highly expressed in metastatic cancer patients, as seen with MMP-2 and MMP-9 expression
being highly upregulated in tumour samples from breast cancer patients and shown to
increase invasion in breast cancer cells (Boire et al., 2005; Jones, Glynn, & Walker, 1999;
Kondapaka, Fridman, & Reddy, 1997; Pellikainen et al., 2004; Stuelten et al., 2005).
Accurately recapitulating inflammatory and metastatic processes in a laboratory
requires models beyond traditional two-dimensional in vitro cell culture techniques, which
has led to the development of more accurate models to study the interactions between the
mammary microenvironment and progression to tumourigenesis.
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Breast cancer treatment
The above-mentioned properties and regulators of breast cancer will determine the
treatment path that a doctor will follow. The current breast cancer treatment pathways as
described by Cancer Care Ontario (2018) are divided at diagnosis between ductal
carcinoma in situ, invasive breast cancer, distant metastases, and local/and or regional
recurrence. Ductal carcinoma interventions are usually either breast conserving surgery or
total mastectomy, followed by radiotherapy, and an optional endocrine therapy of
tamoxifen for 5 years. For invasive carcinoma recommendation is for surgery and then
based on surgical results, genetic and sub-typing factors patients are treated with endocrine
therapy (tamoxifen), chemotherapy (ex. doxorubicin, cyclophosphamide, paclitaxel),
and/or targeted therapy (Herceptin or pathway inhibitors). Sadly, for patients with distant
metastases the recommended treatments include only palliative treatment, radiation and
surgery, highlighting that metastatic breast cancer is considered incurable before treatments
options are even tested for efficacy (2018). Recurrences are analyzed and categorized as
being in one of the three other diagnostic groups and treated appropriately.
One common type of chemotherapy used in breast caner treatment are alkylating
agents, such as cyclophosphamide, that substitute alkyl groups for hydrogen atoms on the
DNA which inhibits protein synthesis and induces cell death (Brock & Hohorst, 1967;
Kanekal, Fraiser, & Kehrer, 1992). Another type of drug is the taxanes, like paclitaxel,
which stabilize microtubules to arrest the cell in G2 and prevent further cell division
(Horwitz, 1992, 1994). The cytotoxic nature of chemotherapies, although necessary for
cancer treatment, leaves patients with many temporary and permanent side effects.
Chemotherapies have reports of hair loss, nausea, fatigue, loss of appetite, and more
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seriously heart and liver toxicity (Fraiser, Kanekal, & Kehrer, 1991; Hurd, 1973;
McDonald et al., 2003; Subramaniam, Cader, Mohd, Yen, & Ghafor, 2013; van Boxtel et
al., 2015).
Dexamethasone (Dex) as an immunosuppressant
To counteract the nausea, loss of appetite, and possible allergic reactions caused by
chemotherapies, patients are given Dex as a standard practice. Dex is a synthetic GC that
binds to the GC receptor in the cell cytoplasm and then transports to the nucleus to bind to
the GC response elements of DNA to either induce or repress transcription of target genes
(Chu et al., 2014). GCs regulate up to 100 genes in a cell and likely get their antiemetic
properties from their ability to supress the immune response and serotonin receptors as well
as other regulatory actions related to nausea (P. J. Barnes, 1998). Patients are usually
administered Dex prior to and post treatment with the chemotherapeutics to prevent some
of the side effects. The timing of Dex administration has been recently studied to determine
toxicity of pretreatment with Dex but this particular study did not have a control “no Dex”
group (Cook, McDonnell, Lake, & Nowak, 2016) and there are very few recent studies to
report the severity of chemotherapy side effects with Dex administration compared to no
Dex administration (Cook, et al., 2016). One older study was completed in 1974 with
preterminal gastrointestinal cancer patients where the Dex administered group had an
overall survival of 5.2 weeks and placebo group had an overall survival of 6.6 weeks. The
patients that received Dex had improved strength and increased appetite so the study
concluded the deceased survival time was worth the better quality at end of life (Moertel,
Schutt, Reitemeier, & Hahn, 1974). This is the reality of most of the clinical studies that
report the side effects of Dex after chemotherapy because patients are recruited who are
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already terminal and may have decreased organ function, in the case of metastatic patients,
so it is difficult to distinguish which side effects are caused by Dex and which are from the
progression of the cancer (Cook, et al., 2016; Moertel, et al., 1974).
More concerning for breast cancer patients is the fact that there have been recent
studies that show Dex and activation of the GC receptor mediate metastasis to distant sites
in triple negative breast caner cells (Obradovic et al., 2019) and Dex increases cell survival
in paclitaxel treated breast cancer cells (Crozier & Porter, 2015). The plethora of
contradicting clinical reports that Dex suppresses cancer progression or promotes it
highlights the need to dissect its role at the cellular level and determine its regulation on
specific cellular processes by using translational research models that can then be applied
to a clinical setting.
The use of natural health products (NHPs) as immune modulators and antioxidants
Because of the detrimental side effects seen from long term use of many synthetic
glucocorticoids, like Dex, and even non-steroidal anti-inflammatory drugs, such as
ibuprofen and aspirin, there has been a movement towards using naturally derived products
or NHPs. Health Canada defines NHPs as “vitamins and minerals, herbal remedies,
homeopathic medicines, traditional medicines, probiotics, and other products like amino
acids and essential fatty acids” and must be safe to be sold without a prescription (Natural
Health Products, 2018). Studies of different anti-inflammatories have shown some positive
effects against breast cancer cells. Interestingly, Cardomonin, a chalcone (aromatic ketone)
isolated from Alpiniae katsumadai, is a known anti-inflammatory agent and was able to
induce apoptosis in MDA-MB-231 breast cancer cells through inhibition of Hypoxiainducible factor-1α (HIF-1α) which led to increases mitochondrial oxidative
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phosphorylation and induced reactive oxygen species (ROS) accumulation (J. Jin et al.,
2019). ROS is usually seen as detrimental for people as it benefits metabolism of breast
cancer cells but over-accumulation in the cell leads to excessive damage and apoptosis
(Starkov, 2008). Although excessive ROS in cancer cells can lead to cancer cell death,
antioxidants that remove ROS are being reported as effective for use as cancer preventives
with the intention that preventing ROS accumulation with add a protectant from cancer
development (C. Y. Chen, Kao, & Liu, 2018; Chikara et al., 2018; Goodman, Bostick,
Kucuk, & Jones, 2011; Lin, Gong, Song, & Cui, 2017; Padayatty et al., 2003).
Antioxidants are also being studied for use as chemotherapy co-medication.
Production of ROS are implicated as the cause of adverse side effects of chemotherapies,
especially alkylating agents, because of the free radicals released when the drug interacts
with DNA (Joensuu, 2008). Chemotherapies are systemic drugs and as such ROS can
accumulate in the heart, liver, and other vital organs to cause serious toxicity in cells
outside of the tumour area (Singh, Bhori, Kasu, Bhat, & Marar, 2018). Antioxidants may
be able to remove the ROS accumulation in these vital organs and help prevent toxicity of
chemotherapeutics although this needs to be studied further to determine if antioxidants
are beneficial or detrimental to cancer patients (El-Sheikh, Morsy, & Okasha, 2017; Ozben,
2014, 2015).
Modeling Mammary Development and Tumourigenesis in 3D Cell Culture
Normal human mammary development has primarily been studied on tissue obtained from
necropsies or from patients undergoing some form of mammoplasty (Anbazhagan, et al.,
1991; Jolicoeur, et al., 2003; Monaghan, et al., 1990; Tobon & Salazar, 1974). Human
mammary tumours, on the other hand, are taken from living patients, but the gland is
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already in a malignant state so the very first stages of early tumour progression are difficult
to study in humans which has led to other models being developed to study which genes
and hormones are essential for proper gland development and how this may link to the
initiation and/or progression of breast cancer. Although mouse mammary glands develop
differently than human glands, the alveolar structures are almost identical which provides
an excellent model of alveolar development and cancer initiation (Anbazhagan, et al., 1991;
Cardiff & Wellings, 1999; Javed & Lteif, 2013). While they provide a wealth of scientific
information, mouse studies are very expensive and time consuming. It has become
necessary to develop models that will provide a biologically relevant environment to study
cell behaviour but also one that is cheaper and faster than conventional in vivo mouse
models. 3D in vitro cell culture and zebrafish xenotransplants are two model systems that
were developed to address the disadvantages of mouse models.
Conventional in vitro cell culture systems consist of growing cells on twodimensional (2D), plastic culture plates which allow the cells to proliferate but deprives
them of many of the environmental cues that would be present in an in vivo system.
Culturing the cells in the presence of a relevant ECM is an important step in the study of
mammary gland morphogenesis and breast cancer initiation. An ECM mixture was isolated
from Engelbreth-Holm-Swarm mouse sarcoma cells that contained known components of
the basement membrane and was biologically active, allowing cells to form polarized
structures similar to those found in vivo (Kleinman & Martin, 2005; Qu et al., 2015). This
ECM, marketed as Matrigel or Cultrex® basement membrane extract (BME) (containing
primarily Laminin I and type IV Collagen), can be used with many different cell systems
and is especially advantageous for studying duct and alveoli development in mammary
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cells. One of the most common cell lines used in 3D in vitro human mammary studies are
MCF10A cells and their derivatives (Qu, et al., 2015). Long term culture of normal,
untransformed mammary epithelial cells is difficult and so the isolation of immortalized
MCF10A cells makes them an asset to mammary gland research. MCF10A cells were
derived from cells which were originally isolated from a female undergoing a mastectomy
to remove fibrocystic tissue but who had no signs of abnormal or diseased tissue (Soule et
al., 1990). These cells were spontaneously immortalized in culture, allowing for a cell line
for long-term studies, and show a loss of the chromosome locus containing the p16 and
p14ARF genes. They are also lacking ER expression but have wild-type p53 (Debnath,
Muthuswamy, & Brugge, 2003; Qu, et al., 2015; Soule, et al., 1990). Importantly, the
MCF10A cells are able to form polarized acini with hollow lumens when cultured in
basement membrane extract that resemble alveolar structures found in human breast tissue
(Debnath, et al., 2003; Soule, et al., 1990). The one major caveat of using MCF10As is that
they do not always form the same tight junctions that are found in the human breast. For
example, MCF10A cells do not express the apical polarity protein, zonula occludens,
which should accumulate on the apical side of the cells, against the lumen (Plachot et al.,
2009).
MCF10A acini formation has been extensively described (Debnath, et al., 2003;
Soule, et al., 1990; Underwood et al., 2006) and follows the same developmental steps in
normal culture conditions. This makes it a great model for gene manipulation because any
developmental changes to the acini can be easily recognized. They will also develop a
lumen that is larger in size than that found in vivo but will maintain its size from day 12 to
day 20 in culture as shown by few cells staining for the proliferation marker, Ki67, and no
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cells undergoing cell death in the single layer of cells that form the lumen (Underwood, et
al., 2006).
Untransformed MCF10A cells do not engraft into immunodeficient mice, however
when Dawson et. al (1996) transformed them with c-Ha-ras, the cells were able to form
nodules that persisted long-term, formed hyperplasia, and sporadically become
tumorigenic. These engraftments were collected from the mice and cultured to create the
MCF10AT1 (AT1) cell line (Dawson, Wolman, Tait, Heppner, & Miller, 1996). Serial
xenografts and isolation of resulting tumours led to the development of the malignant
MCF10CA1 and MCF10DCIS lines (Santner et al., 2001). These cell lines present an
advantageous in vitro tool to study breast cancer progression as they phenotypically
represent early to late stage breast cancer when cultured in 3D ECM assays.
Although this model has the above advantages over 2D cell culture techniques, it
still does not incorporate all of the elements of the immune system that are important
regulators of mammary morphogenesis and metastasis. Using an in vivo model that has an
intact immune system is a more accurate way to study breast cancer metastasis and
treatment efficacy.
Using Zebrafish to Model Human Cancers in vivo
Zebrafish models have many advantages over in vitro models because of their distinct, well
characterized development, high fecundity, and intact innate but delayed adaptive immune
systems. Together these attributes provide a low-cost, high efficiency model for human
cancers.
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Zebrafish morphological development
Zebrafish embryos will develop asynchronously, even eggs from the same clonal strain,
same clutch and raised in the same uncrowded conditions (Streisinger, Walker, Dower,
Knauber, & Singer, 1981; Westerfield, 1993). For this reason, staging embryos based on
morphology is more accurate than strictly based on time post fertilization without
microscopic examination of morphology. Early embryo development can be divided into
stages or periods described in depth by Kimmel et al. (Kimmel, Ballard, Kimmel, Ullmann,
& Schilling, 1995). Development begins with the zygote period, which lasts approximately
45 minutes (mins) from time of fertilization until the first cell cycle. The next stage is the
cleavage period which includes cell cycles 2-7 and this period lasts only about 1 hour (hr)
and 45 mins. The blastula period lasts from hr 2 1/4 to hr 4 2/3 and first has rapid cell
cycles (8-9) followed by longer asynchronous cycles. The epiboly (the spreading of the
blastoderm over the yolk cell) appears in the dome stage of this period. The gastrula period
lasts longer (hrs 5 ¼-10) and involves gastrulation and convergence of the cells into the
embryonic shield, ending with the appearance of the tail bud. The segmentation period (hrs
10 1/3-22) contains the development of the somites which are paired mesodermal segments
that are the precursors for muscle, cartilage, and bone and will remain apparent until
adulthood (Stickney, Barresi, & Devoto, 2000). Primary organogenesis, early movements,
and the tail are visible during this period. The pharyngula period, from hrs 24-42, contains
the stages where the body straightens away from the yolk sac, the fins develop, and
circulation and pigmentation begin. The final period is the hatching period, from hrs 4872, and this is when cartilage develops in the head and pectoral fin, hatching occurs, and
finally in hr 72 the larval stage begins with the appearance of the protruding mouth and
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food-seeking behaviour. The stages are described by hr below in Table 1.2 and depicted
pictorially in Figure 1.7.
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Hrs at
Period

28.5°C

Zygote period
1-cell

Description
The newly fertilized egg through the completion of the first

0

Cleavage period

zygotic cell cycle
Cell cycles 2 through 7 occur rapidly and synchronously

2-cell

.75

4-cell

1

8-cell

1.25

16-cell

1.5

32-cell

1.75

64-cell

2

Blastula Period

Rapid, metasynchronous cell cycles (8,9) give way to

128-cell

2.25

lenghtened, asynchronous ones at the midblastula

256-cell

2.5

transition; epiboly then begins

512-cell

2.75

1k-cell

3

High

3.33

Oblong

3.67

Sphere

4

Dome

4.33

30%-epiboly

4.67

Gastrula period

Morphogenetic movements of involution, convergence,

50%-epiboly

5.25

and extension form the epiblast, hypoblast, and embryonic

germ-ring

2.67

axis; through the end of the epiboly

shield

6

51

75%-epiboly

8

90%-epiboly

9

Bud

10

Segmentation Period

Somites, pharyngeal arch primordia, and neuromeres

1-somite

10.33

develop; primary organogenesis; earliest movements; the

5-somite

11.67

tail appears

14-somite

16

20-somite

19

26-somite

22

Pharyngula period

Phylotypic-stage embryo; body axis straightens from its early

Prim-5

24

curvature about the yolk sac; circulation, pigmentation, and

Prim-15

30

fins begin development

Prim-25

36

High-pec

42

Hatching period

Completion of rapid morphogenesis of primary organ

Long-pec

48

systems; cartilage development in head and pectoral fin;

Pec-fin

60

hatching occurs asynchronously

Protruding-mouth

72

Early larva; swim bladder inflates; food-seeking and active
avoidance behaviours

Table 1.2. Early stages of Zebrafish development.
Summary of the early developmental stages of the zebrafish beginning with fertilization
and ending with the early larval stage. Table was modified from stages described by
Kimmel et al., 1995 (Kimmel, et al., 1995).
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Figure 1.7. Staging series for key developmental timepoints in early zebrafish
development.
h=hour. Modified from (Kimmel, et al., 1995).
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Zebrafish immune system development and maturation
One of the advantages of using zebrafish embryos over mammals, in modeling human
cancer in vivo, is the delay in development of an adaptive immune system that allows for
xenotransplantation and engraftment of human cells without the need for immune
compromised embryos. It has been shown that adult zebrafish possess all blood cell
lineages that mammals do, however the adaptive immune system is not fully mature until
approximately 4 weeks post fertilization (Lam, Chua, Gong, Lam, & Sin, 2004; Meijer &
Spaink, 2011; Trede, Langenau, Traver, Look, & Zon, 2004).
Innate immune system
The innate immune system develops almost immediately in the zebrafish embryos with
hematopoiesis being initiated during the first day of embryo development when the
hemangioblasts differentiate into myeloid cells and erythroid cells are formed (Bertrand &
Traver, 2009; Lam, et al., 2004). This primitive immune system is set up to protect the
embryo from infection and ensure survival of the embryo.
The first line of defense for the embryos are the pattern recognition receptors that
are cell-surface receptors that will recognize invading pathogens and initiate the immune
response (van der Vaart, Spaink, & Meijer, 2012). The most well-known class of pattern
recognition receptors are the 10 proteins in the Toll-like receptor (Tlr) family. Zebrafish
have many orthologs of mammalian TLRs and some fish specific Tlrs (Jault, Pichon, &
Chluba, 2004; Meijer et al., 2004) that will recognize lipopeptides, double-stranded RNA,
and flagellin, amongst other foreign particles (van der Vaart, et al., 2012). Activation of
the Tlrs will lead to activation of transcription factors in the Nfκb and Stat families,
amongst others (Ordas et al., 2011; van der Vaart, et al., 2012).
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Nucleotide-binding-oligomerization-domain

like

receptors

will

recognize

pathogens, that have escaped the Tlrs and have made it to the cytosol, and then activate
Nfκb, Mapk, and caspase-1 pathways which will lead to the production of proinflammatory cytokines such as the interleukins (Il-1β, Il-2, Il -4, Il -6, Il -8, Tnfα, etc.). Il10 is an anti-inflammatory cytokine but can also be secreted in response to
lipopolysaccharides (G. Chen, Shaw, Kim, & Nunez, 2009; Secombes, Wang, & Bird,
2011; Shiau, Monk, Joo, & Talbot, 2013). As in humans, the immune response is crucial
for proper development, for example Il-3 is needed to promote survival and proliferation
of hematopoietic stem cells (Robin et al., 2006).
Adaptive immune system
The thymus, T cells, and B cells, as well as other components of the adaptive immune
system are conserved between mammals and zebrafish making it an appropriate model for
immune studies (Trede, et al., 2004). The thymus begins developing around 48 hrs post
fertilization (hpf), although there is no interaction between the thymus epithelium and T
cells until around 3 weeks later (Lam, et al., 2004). T cell precursors are present in the
thymus beginning at about 72hpf as seen by rag-1 expression however in situ hybridization
was unable to detect T cells outside of the thymus during the first 3 weeks of development
(Langenau et al., 2004). It is not until 4-6 weeks post fertilization that zebrafish begin
producing antigens as demonstrated by Lam et al. who immunized zebrafish with bacteria
to determine the timing of antigen production (Lam, et al., 2004).
Using zebrafish to model human cancer
This late onset of adaptive immunity function allows for zebrafish to be used in human
cancer xenograft studies as the human cells will not be rejected by the embryo if implanted
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before maturation of the adaptive immune system. This property was first exploited by Lee
et al. in 2005 who injected primary human melanocytes and malignant melanoma cells into
a 3.5-4.5hpf embryo and determined that the microenvironment of the fish could influence
the human cells (L. M. Lee, Seftor, Bonde, Cornell, & Hendrix, 2005). The normal
melanocytes were found in the skin of all of the transplanted embryos where as the
malignant cells were dispersed throughout the embryos because of their dedifferentiated
state (L. M. Lee, et al., 2005). Since then, numerous labs have studied cancer processes in
the zebrafish xenograft model. Cell metastasis can be quantified by injecting cells into the
yolk sac of the embryo and since it is an enclosed organ, cells have to actively invade
through the syncytial layer to get to the body of the embryo (Kimmel & Law, 1985). Some
examples of xenografts using breast cancer cells have shown that cells isolated from
mammosphere stem cell assays will invade and migrate at rates high than cells from
monolayer cultures (Eguiara et al., 2011) and that depletion of αv-integrin in breast caner
cells impaired metastasis of implanted cells (Li et al., 2015).
Another important set of assays that have been developed in zebrafish are those
pertaining to cancer drug toxicity, efficacy, and discovery. Zebrafish provide a high
throughput platform to test many compounds, at many different concentrations, very
quickly (He et al., 2013; McGrath & Li, 2008; Veinotte, Dellaire, & Berman, 2014). Their
transparency until later in the larval stage (2+ weeks) make monitoring organ development
and toxicity in live embryos possible. Combining drug treatment with xenografts allows
for monitoring of drug efficacy in vivo (Pruvot et al., 2011). Also, because zebrafish have
orthologs of 71% of human proteins and 82% of disease-causing humans proteins, they
provide a very useful model for drug discovery and in xenograft models cells will be
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exposed to similar metastatic influences, such as Mmps and cytokines that are present in
mammals (Howe et al., 2013; Letrado, de Miguel, Lamberto, Diez-Martinez, & Oyarzabal,
2018).
Zebrafish are emerging as an attractive model to study human cancer in vivo
because of its intact immune system and a microenvironment that is similar to human, it is
much cheaper than mouse models and it is more high throughput due to large egg clutch
size, small embryo size, and transparent body of the embryo.
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Hypothesis and objectives
This work will use a zebrafish translational model optimized in our lab to investigate the
effects of anti-inflammatories, both synthetic and natural, on breast cancer cells and
investigate their efficacy in vivo. Secondly, this work will investigate the role of Spy1 in
mammary morphogenesis and metastasis.
We hypothesize that Dex contributes to breast cancer cell metastasis and enhanced
toxicity of chemotherapeutics and that NHPs offer alternative methods to prevent
inflammation in vivo. We also hypothesize that Spy1 expression is tightly regulated during
normal mammary gland morphogenesis and altered expression of Spy1 will play a pivotal
role in breast cancer metastasis processes.
These hypotheses will be addressed through the following objectives:
•

Determine the effects of Dex treatment on breast cancer metastasis in vitro and in vivo

•

Determine the toxicity of Dex treatment in combination with chemotherapeutics in a
zebrafish model

•

Standardize a translational zebrafish model to study human cancer in vivo for use in
industry and evaluate the efficacy of NHPs as anti-inflammatories and antioxidants
using this model

•

Elucidate the role of Spy1 in normal mammary morphogenesis and breast cancer
metastasis
The zebrafish model proposed in this work will provide the tools needed to perform

high throughput drug assays in academic and industrial research settings. Most importantly,
data obtained from this research will provide a better understanding of inflammatory
processes faced by breast cancer patients during their treatment and how breast cancer
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progresses to become metastatic. Ultimately, we hope to provide some insight into breast
cancer processes and improve the treatment options for metastatic breast cancer so it will
no longer be considered an incurable disease.
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CHAPTER 2 DEXAMETHASONE ENHANCES BREAST CANCER CELL
MIGRATION
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Introduction
Breast cancer is a heterogeneous disease that can be classified into subtypes based on gene
expression profiles or histological presentation of levels/presence of hormone or growth
factor receptors, e.g., estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2)/neu (Reis-Filho & Tutt, 2008; Weigelt,
Baehner, & Reis-Filho, 2010). These receptors serve as molecular targets for many
conventional anti-cancer therapies, e.g., tamoxifen and trastuzumab (Herceptin). ERpositive and PR-positive cancers generally fall under the luminal genomic subtype, while
those lacking ER, PR and HER2 amplification, called triple negative breast cancer
(TNBC), tend to fall under the basal or claudin-low genomic subtypes. Approximately 15%
of breast cancers are triple negative. Statistically this group represents a younger population
and the disease is among the most aggressive, in part due to the lack of directed therapies
(Abramson, Lehmann, Ballinger, & Pietenpol, 2015). Most breast cancer related deaths are
due to metastatic spread of the disease and not the primary tumour itself (Weigelt, Peterse,
& van 't Veer, 2005). For metastasis to occur, several important cellular characteristics are
needed and include the ability to: survive (elude apoptosis) and grow/proliferate at the
primary tumour site; invade through boundaries at the primary site; move or migrate,
whether in circulation or within neighboring tissues; extravasate into a secondary site; and
finally, survive and colonize the secondary site (Zhang, Ma, & Fan, 2010). TNBC and
metastatic ER-positive or PR-positive disease relies heavily on standard of care
chemotherapy and do not have protocols specifically targeting metastatic cancer
(Abramson, et al., 2015).
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Chemotherapy has saved countless cancer patients’ lives over the past twenty years
(Printz, 2011). Unfortunately, these treatments, and in many cases the vehicle in which
they are dissolved, cause unwanted side effects. To lessen and even prevent many of these
side effects, glucocorticoids (GCs), e.g., dexamethasone (Dex), are administered in
advance of chemotherapy (Kloover, den Bakker, Gelderblom, & van Meerbeeck, 2004).
Dex mediates anti-emetic effects through the GC receptor (GR). Active GR can regulate
gene expression of approximately 10% of the human genome (Buckingham, 2006). Active
GR is involved in development and regulation of a plethora of physiological processes
including, but not limited to: inflammation, blood pressure, sensitivity to catecholamines,
neuronal and glial cell activity, brain, breast, and bone development, homeostasis of body
temperature, as well as carbohydrate, protein, and lipid metabolism (Buckingham, 2006).
Moreover, GCs can affect cellular process of division, survival, apoptosis, migration and
invasion which are critical processes also implicated in metastasis of cancer (Hayashido,
Shirasuna, Sugiura, Nakashima, & Matsuya, 1996; Zheng, Izumi, Li, Ishiguro, &
Miyamoto, 2012).
Given the heavy dependency on Dex during chemotherapy treatment, and the vast
cellular processes affected by this potent steroid, we and others have examined the effects
of Dex on breast cancer cell biology. The literature has established that Dex has
demonstrated effects on overriding cell death processes initiated by chemotherapy drugs in
several solid cancers including breast cancer (Crozier & Porter, 2015; Mikosz, Brickley,
Sharkey, Moran, & Conzen, 2001; Runnebaum & Bruning, 2005). Recently, Obradović et
al. determined that glucocorticoids were able to promote breast cancer metastasis in mouse
patient derived xenograph (PDX) models and MDA-MB-231 transplants (Obradovic et al.,
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2019). However, they did not distinguish between triple negative and ER+ patient
transplants, nor did they transplant ER+ cell lines into the mice. Despite these advances,
whether different subtypes of breast cancer are differentially affected by Dex has not been
investigated.
In this work we demonstrate that that GR levels correlated to breast cancer subtypes
with highest expression found in the TNBCs and relatively low expression found in luminal
breast cancer cell lines. Treatment of breast cancer cells with Dex increased overall cell
numbers, invasiveness, and migratory capacity, compared to non-treated cells, and TNBCs
demonstrated the most pronounced phenotypes in response to Dex. This work, while still
far from providing any clinical conclusions, has profound implications for breast cancer
treatment that warrant further investigation.
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Materials and methods
Cell culture
Human breast cancer cells MCF7 (HTB22; ATCC); MDA-MB-231 (HTB26; ATCC),
Hs578t (HTB126; ATCC), and MDA-MB-468 (HTB132; ATCC) cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma). T47D cells (HTB-133; ATCC)
were cultured in RPMI-1640 Medium (Sigma) with 2 units/ml of insulin (Sigma). SK-BR3 cells (HTB-30; ATCC) were cultured in McCoy’s 5A Medium (ATCC). All cells were
supplemented with 10% fetal bovine serum (FBS; Sigma) and 1% Penicillin and
Streptomycin and were maintained in an atmosphere of 5% CO2 at 37˚C. For passaging,
seeding, and quantification of cell numbers, cells were collected with 0.25% trypsin and
counted using the TC10™ Automated Cell Counter (BioRad).
Compounds and antibodies
The following antibodies were used at a dilution of 1:1000: actin (MAB1501R; Chemicon)
and GR-α (3626-1; Epitomics). Secondary antibodies used were horse radish peroxidase
(HRP)-conjugated anti-mouse IgG (A9917; Sigma) and anti-rabbit IgG (A0545: Sigma).
Charcoal (C6241; Sigma), paclitaxel (T7402; Sigma), Dex (DN1187; BioBasic), and RU486 (Mifepristone; M8056; Sigma).
Immunoblotting
Samples were lysed with 0.1% NP40 buffer supplemented with Leupeptin (10ug/ml;
BioBasic), Aprotinin (10μg/ml; Sigma), and phenylmethylsulfonyl fluoride (PMSF)
(1mM; BioBasic). Samples were analyzed by 10% sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to a polyvinylidene
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difluoride (PVDF) membrane. Primary antibodies were applied and incubated over-night
at 4°C at dilutions specified above. Proteins were detected via treatment with Perkin-Elmer
Enhanced Chemiluminscence reagent/ enhanced chemiluminescence (ECL) Western Gel
Substrate (Perkin Elmer) and quantified using FlourChem HD2 software (AlphaInnotech;
Perkin Elmer).
Apoptotic assays
Caspase 3/7-glo assay (Promega) was used to measure the apoptotic state of treated cells.
24hrs post-treatment cells were collected via trypsinization and lysed. 50µl of CaspaseGlo® 3/7 reagent was added in each well of a white-walled 96-well plate containing 50µl
of lysis buffer as blank, negative control cell lysates, or treated cell lysates with the final
concentration of 1µg/µl. Contents were gently mixed in the wells using a plate shaker at
300-500rpm for 30sec. Cell lysates were incubated at room temperature for 30min and the
luminescence of each sample was measured using Wallac Victor 1420 plate reader.
Migration assay
Cells were seeded (1 x 105) in 500μL of serum-free media in Falcon Cell Culture Inserts
(Becton-dickinson) in the wells of a 12-well cell culture plate with 1ml of complete media
(serum-free control). Cells were treated with either ethanol (vehicle control) or different
concentrations of Dex and incubated for 24hrs. Following treatment, the inserts were
carefully removed, cells that did not migrate through the pores and therefore remained on
the upper side of the filter membrane were gently separated, and the migrated cells were
quickly stained with 400μL of 1% Crystal Violet in 2% ethanol for 10min. The inserts were
then submerged in water to remove excess Crystal Violet and air-died. Different views of
the cells attached to the membrane were imaged using a Leica inverted fluorescence
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microscope. The crystal violet was then released with extraction buffer, containing 10%
acetic acid, and the absorption of the samples was measured at 590nm using a Wallac
Victor 1420 plate reader.
Invasion assay
Prior to seeding, cell culture inserts were coated with 100µl of Cultrex® Reduced Growth
Factor Basement Membrane Extract (Trevigen), diluted to 5mg/ml, for 4hrs at 37°C to gel.
Cells were then seeded (1 x 105) in 500μL of serum-free media in inserts in the wells of a
6-well cell culture plate with 1ml of complete media (serum-free control). Cells were
treated with ethanol (vehicle control) or different concentrations of Dex and incubated for
24hrs. Following treatment, the inserts were carefully taken out, cells that did not migrate
through the pores and therefore remained on the upper side of the filter membrane were
gently removed, and the migrated cells were quickly stained with 400μL of 1% Crystal
Violet in 2% ethanol for 10min. The inserts were then submerged in water to remove excess
Crystal Violet and air-died. Different views of the cells attached to the membrane were
imaged using a Leica inverted fluorescence microscope. The crystal violet was then
released with extraction buffer, containing 10% acetic acid, and the absorption of the
samples was measured at 590nm using a Wallac Victor 1420 plate reader.
Animal care and handling
Wild-type Zebrafish (Danio rerio) were handled in compliance with local animal care
regulations and standard protocols of Canada. Adult fish were kept at 28.5°C and bred
according to protocols available in the Zebrafish Book (Westerfield, 1993).
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Implantation procedure, treatment, and imaging
Zebrafish eggs were collected after fertilization and kept in E3 embryo media (5mM NaCl,
0.17mM KCl, 0.33mM CaCl2, 0.33mM MgSO4, 10-5% Methylene Blue) at 28.5°C in an
incubator until ready to inject. Before injection 500,000 MDA-MB-231 cells in 500µl of
serum-free media were labeled with 10µL of DiI (red) (Vybrant; Invitrogen) at 37°C for
20min. MCF7 cells were labelled with the same procedure using DiO (green) (Vybrant;
Invitrogen). Cells were washed with 1ml of serum free media twice and resuspended in
50µl of serum free media, kept at 37°C for 20min, and placed on ice until ready to inject.
Before injection both labelled cell lines were mixed at equal proportions in an Eppendorf
tube. 48hrs post-fertilization (hpf) the embryos were dechorionated with fine tip forceps
and anesthetised with 0.168 mg/ml of Tricaine (Sigma). 50-100 of each labeled cell
line/9.2nl were loaded into glass capillary needles and injected into the yolk sac of each
embryo using a Nanoject II (Fisher Scientific). After injection, embryos were placed in E3
embryo media and 1hr post-implantation (hpi) were examined using a Leica fluorescence
stereomicroscope to exclude any embryo with cells outside of the implantation area.
Following injection, zebrafish were transferred to 96-well plates, with one zebrafish per
well. Dex was diluted to a final concentration of either 10µM or 100µM in E3 embryo
media and added to each well of the treatment fish. DMSO was added to the control fish.
24hpi and 24 hrs post treatment (hpt) the fish were anesthetized with 0.168 mg/ml Tricaine
in a 96-well plate, with one embryo per well. The embryos were imaged using a Leica
fluorescence microscope. This was repeated at 48hpi and 96hpi with fresh Dex being added
at 24hpi and 48hpi.
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All image analysis was completed using ImageJ software and was adapted from a
previously described method for animal bio-imaging assays (Ghotra et al., 2012). The
image for each embryo was imported into ImageJ, aligned to the same orientation, and
cropped to the same size. The images were converted to a 32-bit gray-scale and the
threshold was adjusted to eliminate background pixels. The injection sites were chosen as
the midpoint of the yolk sacs. Using the measure function, the exact coordinates for the
injection site were measured. The Analyze Particle tool was then used to record the
coordinates of each labeled cell focus within the entire embryo. The coordinates of each
tumour focus were corrected to the injection site coordinates using the formula: (XfociXorigin,Yfoci-Yorigin). For each corrected focus coordinate the distance travelled from the
injection site was calculated using the formula: √(Xcorrected2+Ycorrected2). The cumulative
distance (CD) of all foci was calculated per embryo and averaged within an experimental
group to determine mean CD. Each embryo was scored as having either cells metastasized
to the tail or no metastasis and the percentage of fish with metastases was calculated.
qRT-PCR Analysis
MCF7 and MDA-MB-231 cells were collected after Dex treatment and RNA extracted
using RNeasy Plus Mini Kit (Qiagen; 74134). Reverse Transcription of 1ug of RNA was
performed using the established QuantaBio qScript cDNA Supermix protocol. Relative
RNA expression was measured using GAPDH as an endogenous control. The following
sequences

were

used:

MMP9(Li,

ACGCACGACGTCTTCCAGTA-3′
TGFβ1(Chen

et

al.,

2015)

TAGTGAACCCGTTGATGTCC-3′;

and

Qiu,

Li,

&

Wang,

2017)

5′-

5′-CCACCTGGTTCAACTCACTCC-3′;

5′-TCGCCAGAGTGGTTATCTT-3′
WNT5A(Yamagata

et

al.,

and

5′-

2012)

5′84

TAAGCCCAGGAGTTGCTTTG- -3′ and 5′- GCAGAGAGGCTGTGCTCCTA-3′;
IL1B(Nickel

et

al.,

2018)5′-

AGCCATGGCAGAAGTACCTG

CATGGCCACAACAACTGACG-3′
-3′;

IL6(Zhao

et

al.,

and

2014)

5′5′-

GAGATGCCGTCGAGGATGTA-3′ and 5′- CTTCGGTCCAGTTGCCTTCTC -3′
Statistical analysis
Student t test was employed using Statistica software. For percent metastasis the twoproportion Z test was performed. All other results are expressed as mean ± SEM or mean
±s.d. and differences were considered significant at p values of <0.05.
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Results
TNBCs express higher levels of GR-α
Dex mediates its effects through the GR; hence, we assessed the relative levels of GR-α
across a panel of breast cancer cell lines. Three TNBC (MDA-MB-231, Hs578t, MDAMB-468), and three luminal subtype (MCF7, SK-BR-3, T47D) cell lines were used (Figure
2.1). The highest levels of GR protein were expressed in TNBC cells line with the highly
aggressive MDA-MB-231 cells displaying the highest levels, followed by the Hs578t cells
and the MDA-MB-468 cells, respectively. Expression was significantly reduced in the
luminal cell lines with MCF7s demonstrating the highest expression of the luminal subtype.
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Figure 2.1. Relative expression of GR-α in triple negative and luminal breast cancer cell
lines.
TNBC cell lines MDA-MB-231, Hs578t, and MDA-MB-468 and luminal breast cancer
cell lines MCF7, SK-BR-3 and T47D were lysed and subjected to Western blotting.
Endogenous GR-α levels were measured by immune-blotting. Densitometry analysis of
three separate experiments, indicating GR-α protein levels normalized to actin, (lower
panel) is represented as mean ± SEM.
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Dex increases cell numbers of breast cancer cells in vitro.
To assess whether Dex affects the survival and growth of breast cancer cells of differing
subtype, we treated cells representing both TNBC (MDA-MB-231, Hs578t), and luminal
subtypes (MCF7, SK-BR-3, and T47D) with vehicle (control) or Dex (1μM) for 24 hrs to
mimic clinical protocol (Figure 2.2). The two TNBC cell lines, MDA-MB-231 and Hs578t,
showed the greatest increase in total cell number at 38% and 24% compared to non-treated
cells (Figure 2.2 A & C). The highest cell number amongst the luminal breast cancer cell
lines correlated with GR-α expression in the MCF7s with 22% higher count in Dex-treated
compared to non-treated cells (Figure 2.2 B & C). The MCF7s have the highest GR-α
expression amongst the luminal cell lines (Figure 2.1). The SK-BR-3 and T47D cell lines
displayed the smallest difference in cell number between treated and non-treated at 8% and
7% difference, respectively (Figure 2.2 B & C). Hence, Dex-mediated effects on total cell
numbers correlate with the protein levels of GR-α (Figure 2.1).
To assess whether the increase in cell number was due to proliferative activity or
anti-apoptotic activity, we analyzed caspase 3 and 7 activity under the same conditions
using the TNBC cell lines (MDA-MB-468 and Hs578t) and the luminal (SK-BR-3 and
T47D) cell lines (Figure 2.2 D-E). All four cell lines showed decreases in caspase 3 and 7
activity indicating that the Dex-mediated difference in cell number between Dex-treated
and non-treated cells may be a result of a Dex-induced pro-survival, and not necessarily
increases in proliferation. The cell lines expressing the highest levels of GR-α also
demonstrated greater sensitivity to Dex-mediated inhibition of the caspases. The Hs578t
cells showed 60.7% decrease in caspase 3 and 7 activity. The luminal cell lines SK-BR-3
and T47D displayed 30.9% and 34.4%, respectively.
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.
Figure 2.2. Impact of Dex on total cell number 24hrs post-treatment.
(A) TNBC cell lines MDA-MB-231 and Hs578t and (B) luminal breast cancer cell lines
MCF7, SK-BR-3 and T47D were treated with vehicle (control) or Dex for 24hrs. Cells
were collected and counted for total cell number. (C) Graphic representation of the foldchange in Dex-treated cells relative to vehicle of each respective cell line. (D) The TNBC
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cell line Hs578t and (E) luminal breast cancer cell lines SK-BR-3, and T47D were treated
for 24hrs with vehicle (control) or Dex for 24hrs. Cells were collected and lysed. Luciferase
activities of the lysates were measured using equal amounts of cell lysate mixed with
Caspase 3/7 Glo buffer and luminescence was quantified by spectrophotometry. Graphs
show the mean value of at least three experiments, each performed in triplicate, upon which
statistical analysis was performed; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Dex increases migration of TNBC cell lines in vitro.
The migratory properties of a cell are key parameters in determining metastatic capacity.
To assess whether Dex could alter the migration of breast cancer cell lines in vitro, we
performed cyto-select transwell assays. TNBC cells, MDA-MB-231, were treated with
vehicle (control) or a dose range of Dex and cell migration was measured by microscopy
(Figure 2.3; upper panels) and quantified by spectrophotometry (Figure 2.3 A, lower
panel). A statistically significant increase in migration was observed compared to control
cells in the MDA-MB-231 cell line. We repeated the migration assay for the TNBC cell
line MDA-MB-468 with vehicle (control) and with Dex (1μM). We observed a statistically
significant increase in migration (Figure 2.3 B). The luminal breast cancer cell line T47D
did not display an increase in migration following Dex treatment (Figure 2.3 E).
To ensure that increases in cell number were not due to Dex-induced proliferation
or enhanced survival in the serum-free conditions, MDA-MB-231 and MDA-MB-468 cells
were seeded in serum free media on tissue culture plates and grown with vehicle (control)
or Dex (1μM) for 24hrs (the length of the entire migration assay). There was no change in
cell number between treated and non-treated cells in these media conditions (Figure 2.3 CD). Thus, it is unlikely that proliferation effects can account for the migration phenotype.
To ensure that the same would hold true for cells that were in complete media for the
duration of the assay (i.e., putative cells that migrated immediately after seeding), MDAMB-231 and MDA-MB-468 cells were grown with vehicle (control) or Dex in serum-free
media and then the media was replaced with complete media for an additional 24hrs. No
significant change in cell number was observed (Figure 2.3 C-D). Thus, it is unlikely that
Dex-treated cells that migrated had any proliferative advantage over non-treated migratory
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cells once in complete media (as both would be in complete media) during the assay
timeframe. It is notable that when MDA-MB-231 cells were left for an additional 24hrs
(total time in complete media = 48hrs), a statistically significant difference in cell number
was observed for Dex-treated cells suggesting a Dex-mediated proliferative or pro-survival
advantage at the site of migration (Figure 2.3 C).
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Figure 2.3. Impact of Dex on migration of triple negative and luminal breast cancer cell
lines in vitro.
TNBC cell lines MDA-MB-231 (A) or MDA-MB-468 (B) or luminal breast cancer cell
line T47D (C) were seeded (1x105) in serum-free media in cyto-select migration chambers
placed in complete media and treated with vehicle (control) or with Dex (dose indicated on
X axis) for 24hrs. Migration of the crystal violet stained cells through the membrane pores
94

was visualized by microscopic images (upper panels). Crystal violet-stained cells were
extracted and quantified by measuring the absorbance at 590nM (lower panels). (D) MDAMB-231 cells were grown on tissue culture plates for 24hrs with Dex (1μM) or vehicle
control in serum free media and collected for count of total cell number or media was
replaced with complete media for an additional 24hrs or 48hrs. Cells were collected and
counted. (E) MDA-MB-468 cells were grown on tissue culture plates for 24hrs with vehicle
control or Dex (1μM) in serum free media and collected for count of total cell number or
media was replaced with complete media for an additional 24hrs. *p<0.05
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Dex increases invasiveness of breast cancer cell lines in vitro.
Previous work in bladder cancer cell lines demonstrated that Dex decreased cell invasion
(Zheng, et al., 2012). To assess the effect of Dex on breast cancer cell lines in vitro, we
used a cyto-select transwell invasion assay in which the chamber wells were coated with a
collagen based extra cellular matrix. We treated MDA-MB-231 breast cancer cells with
vehicle (control) or with increasing concentrations (0.1-10μM) of Dex. 24hrs posttreatment cells that had migrated through the pores toward complete media were stained
with crystal violet and imaged (Figure 2.4 A). We observed an increase in invasiveness
with increases in Dex concentration. Cells were then lysed and analyzed by
spectrophotometry to accurately quantify invasiveness compared to control (Figure 2.4 A,
lower panel). Dex also increased the invasiveness of the TNBC Hs578t cells (Figure 2.4
B).
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Figure 2.4. Increase in invasiveness of breast cancer cell lines in vitro after Dex.
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(A) MDA-MB-231 and (B) Hs578t were seeded in matrigel coated cyto-select migration
chambers and treated with vehicle (control) or with Dex (at the indicated concentration for
24hrs). Cells were stained with crystal violet and their images were taken with Leica
microscope (upper panels). Crystal violet-stained cells were extracted and quantified by
spectrophotometry at absorbance of 590nM (lower panels). The absorption data from
which they were averaged are presented as the means ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p
≤ 0.001.
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Dex enhances metastatic properties of breast cancer cell lines in vivo.
To examine the effect of Dex on breast cancer cell behavior in vivo, MDA-MB-231 and
MCF7 cells were used in an in vivo zebrafish xenograft assay. Both cell lines were injected
into the yolk sac of the same fish and cells were able to invade outside of the yolk and form
quantifiable metastatic tumour foci. 96hpi and 96hpt approximately 10% of fish had
measurable tumour burden at distant sites (Figure 2.5 A-C). Interestingly, in both cell lines,
Dex treatment significantly increased the mean cumulative distance of the foci from the
yolk sac (Figure 2.5 B) and at the 96hr time point the number of fish with measurable
metastases was 4-fold higher than the DMSO control (Figure 2.5 C). Consistent with
differences seen in in vitro assays, MDA-MB-231cells treated with Dex travelled 6-fold
further from injection site whereas MCF7 Dex treated cells travelled 3.6-fold further than
DMSO treated cells. MDA-MB-231 cells also had ~5% increase in final tumour burden
over the luminal MCF7 line.
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Figure 2.5. Metastasis of breast cancer cells in zebrafish xenotransplants.
(A) Representative brightfield and fluorescence images of embryos 96 hpt with either
DMSO, 10uM Dexamethasone or 100uM Dexamethasone. Images were taken at 40x
magnification. MCF7 cells are shown in green and MDA-MB-231 cells in red. (B) Mean
cumulative distance of the tumour foci from the yolk sac in MCF7 and MDA-MB-231
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cells. (C) Percentage of fish that had metastases outside of the yolk sac. Data represents
mean ±SEM. n= 14-33 fish. Scale bar = 300 µm.
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Dex treatment causes changes in inflammatory gene expression in TNBC cells but not ER+
cells.
Metastases from mice implanted with TNBC cells and then treated with Dex showed
protein enrichment of inflammatory pathways (Obradovic, et al., 2019). Here, we treated
TNBC and ER+ cells in culture with Dex and looked at expression of inflammatory genes
to determine if Dex directly causes upregulation of inflammatory pathways. The ER+
MCF7 cells had no difference in inflammatory gene expression after Dex treatment (Figure
2.6 A). After treatment, the TNBC MDA-MB-231 had significant downregulation of IL1β,
with both concentrations, and MMP9 after 10µM. Interestingly, Dex significantly
increased WNT5A expression with both concentrations and increased IL6 expression after
the 10µM treatment (Figure 2.6 B).
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Figure 2.6. Differentially gene expression in breast cancer cells.
Relative gene expression of MCF7(A) and MDA-MB-231 (B) cells after 96hours Dex
treatment in vitro. Data represents mean ± s.d, *p<0.05, **p<0.01, ***p<0.001. n=3.
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Discussion
Metastatic breast cancer cells present several key characteristics, namely 1) the ability to
survive by eluding apoptosis and continuing to grow and proliferate at the primary tumour
site; 2) The ability to invade through surrounding tissue and 3) the ability to migrate in
circulation or within neighboring tissue (Mehlen & Puisieux, 2006). These characteristics
may be intrinsic or acquired through mutation (Mehlen & Puisieux, 2006). Alternatively,
these characteristics could potentially be augmented by drug treatment. Thus, the effect of
clinical therapies and adjuvant drugs on breast cancer cell characteristics is of clinical
significance to the progression of metastasis.
In chemotherapy regimens, the steroid Dex is administered in advance of
chemotherapy to alleviate allergic and hypersensitivity reactions as well as nausea and
vomiting in patients (Weiss et al., 1990; Wu et al., 2004). This work demonstrates that
administration of Dex increases cell number, migratory capacity and invasiveness within
24hpt relative to vehicle-treated control cells in vitro (Figure 2.2-Figure 2.4). Previous
reports claim that Dex increases cell proliferation in solid cancer cells (Khan, Lopez-Dee,
Kumar, & Ling, 2013; Zheng, et al., 2012). These previous studies used only cell viability
assays and no counts were performed. While we did perform cell counts, neither our data,
nor those reports, excludes the possibility that increased numbers in Dex-treated cells
versus non-treated cells is due to increased survival and not proliferation. At most we show
that Dex permits cells to continue dividing better than those that did not receive Dex
(Figure 2.2 A-B). Thus, differences in cell number compared to control could be
attributable to enhanced cell survival with Dex. Zheng et al also report that their claims of
increased proliferation were not corroborated by increases in the proliferative markers of
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cyclins and CDKs (Zheng, et al., 2012). Pang et al also qualify data concerning Dexmediated increases in tumour size that did not show increased expression of Ki67 as most
likely being due to an increase in survival (Pang, Kocherginsky, Krausz, Kim, & Conzen,
2006). Furthermore, and consistent with these findings, we demonstrate that Dex decreased
activity of caspases 3 and 7 compared to control cells (Figure 2.2 D-E). These differences
in caspase activity may account for variance in the cell number of Dex-treated cells
compared to control populations. Further analysis with BrdU incorporation or Ki67
expression could give insight into this matter of concern.
We also demonstrate that Dex-treated cells had increased motility as evident in
migration and invasion assays (Figure 2.3-Figure 2.4). A search of the literature shows
several reports on Dex as reducing migration and invasion (Hayashido, et al., 1996; Piette
et al., 2009; Shiratsuchi, Ishibashi, & Shirasuna, 2002; Zheng, et al., 2012). While these
reports are also in other tissue types, we sought to determine whether there were alternate
explanations for our data. One possibility is that the Dex-treated cells were surviving and/or
proliferating faster, producing more cells on the pre-migration and pre-invasion side of the
chambers compared to control chambers. Thus, even if equal percentages of cells migrated
or invaded thereafter, the Dex-treated chambers would have more cells to migrate or invade
and a selective advantage over control chambers. Another putative explanation is that while
Dex would confer no advantage in cell number pre-migration or invasion, Dex treated cells
would be ‘primed’ for increased proliferation or survival compared to control cells once
they reached the complete media post-migration or post-invasion. In this model equal
numbers of cells exist in both the control and Dex-treated cell chambers pre-migration or
invasion and equal numbers of cell migrate or invade. Once these cells reach complete
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media, however, the Dex treated cells proliferate sooner and thus account for differences
in the assay. We demonstrate that neither of these explanations can account for the
observed data in the conditions and brief timeframe that the experiment takes place (Figure
2.3 D-E). Given longer periods of time, however, we show that the latter explanation could
be true and further supports our earlier report that Dex enhances survival and/or
proliferation in breast cancer cells (Figure 2.3 D).
Our in vivo data supports the role of Dex in enhancing one, if not more,
characteristics of metastatic breast cancer cells. Zheng et al ascribed increases in tumour
mass in mice xenografts of Dex treated mice to increased survival of tumour cells resulting
in larger tumours (Zheng, et al., 2012). It is possible that increased survival of injected cells
in vivo contributes to final tumour burden. However, our data also shows a very significant
increase in the distance travelled with Dex treatment and our in vitro assays support the
ability of Dex to modulate cell motility.
It has been reported that Dex treatment causes upregulation of pathways involved
in inflammation and metastasis (Obradovic, et al., 2019), specifically WNT5A and ROR1
expression. This study only examined TNBC cells and so we wanted to determine if Dex
would have the same effect in ER+ MCF7 cells. Interestingly, the MCF7 cells showed no
significant difference in relative expression of any of the inflammatory genes examined
when cells were cultured in vivo. As expected, in the MDA-MB-231 cells, Dex caused a
significant increase in WNT5A expression, however MMP9 expression was downregulated. To further dissect the Dex-mediated mechanism of cell invasion, expression
levels of other MMPs should to be examined as well as MMP levels after Dex treatment in
vivo. IL1β expression was significantly downregulated whereas IL6 expression was
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upregulated which means Dex is only activating certain inflammatory pathways and though
MCF7 cells can metastasize in vivo it must be through another mechanism than TNBC
cells.
Our data support that Dex can affect multiple parameters supporting metastatic
events in vivo. Given the ubiquitous use of Dex in treating breast cancer patients with the
most severe forms of breast cancer, further research into elucidating Dex-mediated effects
on breast cancer cell behavior is warranted.
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CHAPTER 3 THE TOXIC EFFECTS OF COMBINATION TREATMENT OF
DEXAMETHASONE WITH CHEMOTHERAPEUTICS ON ZEBRAFISH
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Introduction
Dexamethasone (Dex) is a corticosteroid designed as an anti-inflammatory agent and is
often given to patients receiving chemotherapy treatments because of its very effective
antiemetic properties (Cassileth, Lusk, Torri, DiNubile, & Gerson, 1983; C. C. Chu et al.,
2014; Levitt et al., 1993). Although the efficacy of Dex as an anti-emetic has been studied,
the chronic adverse reactions of Dex in combination with chemotherapeutics have not been
thoroughly studies. Reported results are mostly limited to acute effects related to energy
levels, appetite, and sleep patterns after treatments and conclude that Dex is safe in
combination with chemotherapy (Cassileth, et al., 1983; Levitt, et al., 1993; Roila, 1993).
Reported side-effects of chemotherapeutics range from more mild effects like nausea,
inflammation, etc, to very severe such as heart failure, liver toxicity, and even death, and
although Dex was reported being administered before treatment in some studies (Burstein
et al., 2003) it is not mentioned in most. This leads us to question if Dex had any
interactions with these drugs to contribute to the organ toxicity observed in patients
(Burstein, et al., 2003; Goldberg, Antin, Guinan, & Rappeport, 1986; Gottdiener,
Appelbaum, Ferrans, Deisseroth, & Ziegler, 1981; McDonald et al., 2003; Subramaniam,
Cader, Mohd, Yen, & Ghafor, 2013). It is critical to determine if Dex is the optimal drug
to be given in conjunction with these drugs or if alternatives should be considered and one
way is to model the toxicity of Dex with chemotherapy treatments in an in vivo model that
could easily recapitulate drug toxicity.
Zebrafish (Danio rerio) are a freshwater fish species that are easily reared in
captivity and have been emerging as a faster, less expensive, and more high-throughput
model than using conventional animal models to determine drug toxicity (Rubinstein,
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2006; Zakaria et al., 2018; Zon & Peterson, 2005). The transparency of the embryos allows
easy monitoring of development and any defects that occur during drug treatment. Of
specific importance for many drugs are the cardiotoxic and hepatotoxic effects, and assays
in zebrafish have been established to determine toxicity in these organs (McGrath & Li,
2008). Normally, the heart starts beating at 26 hours post fertilization (hpf) and both atrial
and ventricle chamber precursors have formed by 48hpf (Bakkers, 2011). Conventional
assays for determining cardiotoxicity in zebrafish embryos are measuring heartbeats/min,
rate of arrhythmia, and size of pericardial sac. The liver is fully differentiated and
functional by 5 days post fertilization (dpf) and assays measuring size, opacity, and yolk
sac retention can be used to determine changes in liver metabolic activity (Augustine,
Gagnaire, Floriani, Adam-Guillermin, & Kooijman, 2011; J. Chu & Sadler, 2009; Dai et
al., 2014; McGrath & Li, 2008; Wilkins & Pack, 2013).
Two cytochrome P450 (CYP) enzymes, CYP3A4 and CYP2D6 are responsible for
the metabolism of the majority of drugs in humans and although zebrafish do contain a full
complement of CYP genes, the suggested homolog for CYP3A4, cyp3a65 in zebrafish, has
only about 54% sequence identity with CYP3A4 (Goldstone et al., 2010; McGrath & Li,
2008; Poon et al., 2017). However, Tseng and colleagues (Tseng, Hseu, Buhler, Wang, &
Hu, 2005) were able to show that Cyp3a65 is activated in the presence of xenobiotics,
including Dex, and others have shown that it is regulated by the aryl hydrocarbon receptor,
which regulates response to xenobiotics in mammals (Rowlands & Gustafsson, 1997;
Vliegenthart, Tucker, Del Pozo, & Dear, 2014). Together, these studies provide evidence
that drugs will be metabolized in similar ways as in human patients.
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In this study we treated embryos at 48hpf or 7dpf with increasing concentrations of
Dex in combination with either cyclophosphamide or paclitaxel to assess the embryotoxic
effects of Dex with chemotherapeutics. We chose to examine the effects of Dex with
cyclophosphamide and paclitaxel as they are currently widely used for treatment of both
early and late-stage breast cancer, have different mechanisms of action (paclitaxel: microtubule stabilization; cyclophosphamide: alkylating agent) (Brock & Hohorst, 1967;
Horwitz, 1994), and were tolerated at high doses by the zebrafish. We found that many of
the side effects reported in human cancer patients were exacerbated by the addition of Dex
in the zebrafish embryos, especially with cyclophosphamide. These studies show the need
to further investigate the interactions of Dex with chemotherapeutics that are given to
cancer patients as Dex is used ubiquitously as an antiemetic in clinical settings.

113

Materials and methods
Reagents
Dex (D4902), cyclophosphamide monohydrate (cyclophosphamide) (C0768), and
paclitaxel (T7402) were purchased from Sigma-Aldrich and diluted to their respective
stock solutions in dimethylsulfoxide (DMSO). The final concentration of DMSO used as a
solvent control was 0.88%. Embryo media (E3; 5mM NaCl, 0.17mM KCl, 0.33mM CaCl2,
0.33mM MgSO4, 10-5% Methylene Blue) was made as a 60x stock solution and diluted in
de-ionized water as needed.
Animal care and handling
Wild-type Zebrafish (Danio rerio) were handled in compliance with local animal care
regulations and standard protocols of Canada. Adult fish were kept at 28.5°C and bred
according to protocols available in the Zebrafish Book (Westerfield, 1993).
Embryo treatment and imaging
Zebrafish eggs were collected after fertilization and kept in E3 embryo media in an
incubator at 33°C until ready to start treatments. 48hpf or 7dpf, the embryos were
dechorionated with fine tip forceps, if not already hatched, and transferred to 12-well
plates, with 20 zebrafish per well. Three independent groups of 20 fish were treated with
each single or double drug combinations, that were diluted to their final concentration in
E3 media (DMSO: 0.88%; dexamethasone: 5µM, 10µM, or 25µM; Cyclophosphamide:
6mM). 3 days post treatment (dpt), 15 random embryos from each treatment group were
imaged, without anesthesia, using a Leica M205 Stereo Microscope. Whole well images
were taken at 10 times magnification. Images of the anterior half of the embryos were taken
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at 40 times magnification. Videos of the heartbeat (either 10 or 15 seconds) were taken at
100 times magnification using the time lapse function of the LAS-AF software. At least
two independent experiments were completed for each assay.
Image and video analysis
All image analysis was completed using ImageJ software. Each image was imported into
ImageJ and changed to the appropriate scale according to the scale bar acquired from the
LAS-AF software. The pericardial sac size, liver size, and yolk sac size were measured
using the “Area” measure function and results were exported to Excel for further analysis.
In the Dex and cyclophosphamide groups, some liver were undetectable and were give an
area of “0”. Videos were imported to VLC media player and analyzed at 0.8x speed to
accurately count the number of beats per 10 or 15 secs. This result was multiplied by a
factor of either 6 or 4 to get beats/min. Each fish was scored qualitatively as having
arrhythmia or normal heartrate. Arrhythmia was scored by watching the videos and was
determined to be when both chambers of the heart were not beating at equal rates and was
expressed qualitatively.
RNA extraction and reverse transcription
All 20 embryos of each treatment group were pooled together for RNA extraction and each
treatment group had 2 independent replicates of RNA. 3dpt embryos were collected in a
1.5mL eppendorf tube and as much of the treatment water was removed as possible. The
TRIzol™ (15596026, Invitrogen) protocol was followed for all remaining steps of the RNA
extraction. The QScript cDNA SuperMix (95048, Quantabio) protocol was used for reverse
transcription of 2ug of the RNA.
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Quantitative real-time polymerase chain reaction (qRT-PCR)
qRT-PCR was performed on a Viia-7 qRT-PCR system (Applied Biosystems) with Fast
SYBR green fluorescent label. cDNA was diluted 1:10 in nuclease-free water. Each
reaction contained the following: 1ul primer pairs, 4uL diluted cDNA, 5uL Fast SYBR
green and was repeated in triplicate to account for pipetting error. Gene expression is
reported as relative quantitation as compared to elongation factor 1-alpha (ef1α). Primer
sequences are listed in Table S3.1.
Statistical analysis
Student t-test, one-way Anova with Tukey post-hoc test, or chi-squared test for trend were
employed using GraphPad or SPSS software. All results are expressed as mean ± SEM.
and differences were considered significant at p values of <0.05.
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Gene Forward (5'-3')

Reverse (5'-3')

ef1α GAAGAAAATCGGTGGTGCTG

TGGCAACAGGTGCAGTTCTA

il-1β TTGTGGGAGACAGACAGTGC
il-8

TGTTTTCCTGGCATTTCTGACC

tnf-α ACAAGGCAATTTCACTTCCA
il-4

GGATCCTGAATGGGAAAGGGG

il-10 ACTCCACAACCCCAATCGAC
il6

GCTATTCCTGTCTGCTACACTGG

References

(McCurley &
Callard, 2008)
(Huang et al.,
GATTGGGGTTTGATGTGCTT
2013)
(Huang, et al.,
TTTACAGTGTGGGCTTGGAGGG 2013)
(Huang, et al.,
AGCTGATGTGCAAAGACACC 2013)
NCBI Primer
TTCCAGTCCCGGTATATGCT
BLAST design
NCBI Primer
GACCCCCTTTTCCTTCATCTTT BLAST design
TGAGGAGAGGAGTGCTGATCC (Zhao et al., 2014)
(Oehlers et al.,
2011)
NCBI Primer
GCAGGCGTTTTAGCATCGAG
BLAST design
NCBI Primer
GAACCCCTTTAAAAGACCCTGG BLAST design

mmp9 CATTAAAGATGCCCTGATGTATCCC AGTGGTGGTCCGTGGTTGAG
tlr1

ACAGAGGGACGGACGGATTA

tlr4

ATCTGTCAAGATGCCACATCAGA

Table S3.1. Primer Sequences.
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Results
Treatment regimen for Dex and chemotherapeutics on zebrafish embryos
To determine the toxic effects of Dex with chemotherapeutic drugs we used a zebrafish
embryo platform. We first determined the lethal dose for 10% of fish (LD10) and then found
the effective concentration for 50% of tumour bulk (EC50). EC50s were obtained by
xenotransplanting triple negative MDA-MB-231 breast cancer cells into zebrafish embryos
and treating the fish with decreasing concentrations from the LD10 until 50% of tumour size
was reached (Figure 3.1 A). Toxicity was assessed by treating the fish with the EC50 dose
for each drug, except for Dex which was treated with increasing doses, for 3 consecutive
days beginning 48hpf as shown in Figure 3.1 B. We examined the size and morphology of
the embryo and specifically focused on heart and liver toxicity as these are the most serious
side effects found in chemotherapeutics. An untreated zebrafish with normal heart and liver
development is shown in Figure 3.1 C.
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Figure 3.1. Schematic of toxicity assay with zebrafish embryos.
(A) Embryos are assayed into plates and drugs are added to each well. LD10 and EC50
concentrations were calculated using GrapPad Software (B) Schematic of timing of drug
additions. (C) Normal anatomy of 120hpf zebrafish. Inset shows location of heart, liver,
and yolk sac.
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Effects of Dex and cyclophosphamide treatment on embryo heart function
We chose to treat the fish with a range of relatively low doses of Dex to determine if
toxicity was dose dependent. It has also been shown that a low dose (10µM) of Dex
activated cyp3a65 in zebrafish but a high dose (100µM) actually repressed basal levels of
cyp3a65 transcription (Tseng, et al., 2005) so we wanted to make sure that the dose of Dex
was not too high as to block metabolism in the fish. The effects of Dex and
cyclophosphamide on size and blood flow of 3dpt embryos was determined using
stereomicroscopy (Figure 3.2 A). Cyclophosphamide significantly decreased overall
embryo length alone, and in combination with Dex (Figure 3.2. B). Blood flow rates were
scored as normal or abnormal, either faster or slower than normal based on visual
inspection of videos taken of the beating heart, and the combination treatment of Dex and
cyclophosphamide significantly increased the number of fish with abnormal blood flow
(Figure 3.2. C). These fish had visibly slower blood flow than DMSO treated fish.
Cyclophosphamide has been reported to cause effects such as valve function
failure, and congestive heart failure in patients (Burstein, et al., 2003; Goldberg, et al.,
1986; Gottdiener, et al., 1981), therefore, we assessed heart function in the embryos after
3 days of treatment alone or in combination with Dex. Gross examination of the anterior
area of the embryos indicated that cyclophosphamide alone did not induce a heart failure
phenotype (Figure 3.3 A), nor did it change the heart rate (Figure 3.3 B) or the number of
fish with arrhythmia (Figure 3.3 C) compared to DMSO treated fish. There was no increase
in the average size of the pericardial sac indicating no significant edema (Figure 3.3 D) and
did not increase the percentage of fish with enlarged heart sacs (Figure 3.3 E). In contrast,
the combination of Dex and cyclophosphamide significantly altered heart sac morphology,
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revealing an increase in the incidence of enlarged heart sacs and the average size of the
heart sac in a dose dependent manner (Figure 3.3 A, D-E). Dex alone increased the heart
rate (Figure 3.3 B) which is a normal response to corticosteroid treatment (Duchatsch et
al., 2018), however the heartrate was unchanged in the combination treatment. Dex alone
decreased the prevalence of arrhythmia with all doses compared to DMSO, and low doses
of Dex (5 and 10µM) with cyclophosphamide also had lower incidences of arrhythmia,
however the high dose of Dex (25µM) caused significantly more arrhythmia than any other
treatment group (Figure 3.3 C). Table S3.2 summarizes the data and stats for these results.
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Figure 3.2. Dex accentuates morphological defects in the embryo when combined with
cyclophosphamide.
(A) Effects of drug treatments on overall body condition of zebrafish. Images taken at 10x
magnification, 3dpt. scale bar= 500mm (B) Graphs representing embryo length and
number of fish with normal or abnormal blood flow. Data represents mean ± SEM.
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Statistical analysis was performed using one-way Anova with Tukey post-hoc and Chisquare test for trend. ***p<0.001. n=28-30 fish in 2 independent experiments.
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Figure 3.3. Dex and cyclophosphamide treatment causes cardiotoxicity in embryos.
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(A) Brightfield images taken at 40x magnification at 3dpt. scale bar= 500um. (B-E) Graphs
representing (B) heart rate (C), % of fish with arrhythmia (D), pericardial area (E) and %
of fish with enlarged pericardial sac. n=28-30 fish in 2 independent experiments. Data
represents mean ± SEM, statistical analysis was performed using One-way Anova with
Tukey post-hoc. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Table S3.2.

Summary of

defects

observed after treatment

with

Dex and

Cyclophosphamide.
Data represented as ration of affected/total number of fish or length in mm. Significance
represents analysis of trend. n=28-30 fish.
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Dex with cyclophosphamide altered liver appearance and yolk sac area
Change in liver size, liver opacity, and yolk sac retention can be indications of liver toxicity
in zebrafish (He et al., 2013) so these parameters were examined in the zebrafish treated
with Dex and cyclophosphamide combinations. Liver size was unchanged in the DMSO,
Dex, and cyclophosphamide single treatment groups (Figure 3.4 A-B), however the fish
treated with Dex and cyclophosphamide together had livers that were either smaller than
other treatment groups or undetectable. The undetectable livers were either too small to be
seen or obstructed by the large amount of edema in the embryos and were scored as “0”
area. The liver opacity was lower in all Dex and cyclophosphamide treatment groups, and
again undetectable livers were given a score of “0” (Figure 3.4 C). Yolk sac retention was
measured as the remaining area of the yolk sac at the end of the treatment period. As the
zebrafish grows, the yolk sac is absorbed and metabolized as the embryo’s nutrient source.
If liver function is disrupted, the yolk could be absorbed at a slower rate due to a reduction
in lipid transport lipoproteins that are produced in the liver and needed for export of lipids
from the yolk (He, et al., 2013; Quinlivan & Farber, 2017). Cyclophosphamide or Dex
alone did not have a change in yolk area, however all doses of the combination treatments
increased the yolk sac area remaining compared to the single treatment groups, ranging
from 1.5-4 times higher yolk retention (Figure 3.4 D). This is consistent with the reduced
size of the liver and indicates hepatotoxicity.
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Figure 3.4. Dex and cyclophosphamide combination exacerbates liver toxicity.
(A) Representative brightfield images taken at 34x magnification at 3dpt. scale bar =
500um. (B-D) Graphs representing (B) liver size, (C) liver opacity, (D) yolk sac area. n=at
least 14 fish in 3 independent experiments. Data represents mean ± s.d, statistical anysos
performed using One-way Anova with Tukey post-hoc, **** p<0.0001.
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Gene expression profiles of Dex and cyclophosphamide treated zebrafish
As Dex is given to patients as an anti-inflammatory agent, we hypothesized that
inflammatory pathways would be inhibited in the Dex treatments. Cyclophosphamide is
also described as an anti-inflammatory (Hurd, 1973) but because of the edema seen in the
combination group there was some expectation of upregulation of inflammatory pathways
with this treatment group. Also, cardiac edema and heart failure in zebrafish, caused by
treatment with toxins, has previously been attributed to increases in the activity of matrix
metalloproteinases (MMPs), especially MMP-9 (Zhang, Huang, Wang, Gao, & Zuo, 2013)
and therefore mmp9 gene expression was also examined after treatment.
Embryos were collected 3dpt for RNA expression analysis by qRT-PCR.
Surprisingly, embryos treated with Dex alone had a significant increase in tumour necrosis
factor-alpha (tnfα), interleukin 1-beta (il1β), and il10 gene expression and an increase in
il4, il6, il8, toll like receptor (tlr1), tlr4, and mmp9 expression, though not statistically
significant (Figure 3.5 A). In the combination treatment group, only mmp9 expression was
significantly elevated whereas expression of the other inflammatory genes was suppressed
to levels similar to cyclophosphamide alone (Figure 3.5 A). The heat map is shown as a
visual representation of the clustering of expression of genes by average linkage and clearly
depicts the expression differences between the treatment groups with Dex upregulating the
ILs, TLRs, and tnfα and Dex in combination with cyclophosphamide upregulating mmp9
(Figure 3.5 B).

129

130

Figure 3.5. Dex induces expression of inflammatory genes in zebrafish.
(A) qRT-PCR data of embryos after treatment with Dex and cyclophosphamide. Graphs
represent triplicate PCR reactions from two independent experiments. Y-axis represents
relative quantitation of gene normalized to ef1α. Data presented as mean ±SEM, statistical
anaysis performed using One-way Anova with Tukey post-hoc, * p<0.05, **p<0.01. (B)
Heat map generated from www.heatmapper.ca and shows average linkage between genes.
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The combination of Dex and paclitaxel has no significant cardiotoxic or hepatotoxic
effects:
Paclitaxel, another common chemotherapeutic, has reported side effects of changes in heart
rate and lowered blood flow (Florescu, Cinteza, & Vinereanu, 2013). To determine,
whether Dex causes also heart failure when combined with drugs other than
cyclophosphamide, embryos were treated with combinations of Dex and paclitaxel.
Embryos were first treated for 3 days starting at 2dpf. When examining the embryos at
high magnification there were only subtle visible differences in heart and liver morphology
and the enlarged heart sacs were not seen (Figure 3.6 A). Again, Dex significantly
increased the heartrate of the embryos and this effect was conserved when Dex was
combined with paclitaxel (Figure 3.6 B) but the pericardial area was not significantly
affected (Figure 3.6 C). There was also no significant arrhythmia or change in blood flow
with any of these treatments (not shown). While examining the organ development of the
embryos, it was observed that the livers were significantly smaller with Dex, alone and in
combination with paclitaxel, than in the DMSO treated group (Figure 3.6 D). The retention
of the yolk sac, however, was significantly decreased with Dex treatment alone and not in
the combination treatments (Figure 3.6 E). Because the embryo liver is more differentiated
after 5dpf, we added a treatment schedule of treating every 24hrs for 3 days starting at 7dpf
when the fish are in the larval stage (Figure 3.7 A). Treating larval zebrafish with the same
concentration resulted in paclitaxel having larger livers than the other treatment groups
(Figure 3.7 B and C) but Dex alone and Dex with paclitaxel had no effect on liver size.
There was no difference in the yolk sac area in any of the treatment groups (Figure 3.7 D).
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Figure 3.6. Effects of Dex and paclitaxel on organ toxicity.
(A) brightfield images taken at 40x magnification of embryo at 96hpf. (B) Graphs
representing embryo heartrate, (C) pericardial area, and (D) Liver area. Data represents
mean ± SEM, statistical analysis performed using One-way Anova with Tukey post-hoc,
***p<0.001, **p<0.01. Scale bar= 500µm, n=at least 14 fish from three independent
experiments.
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Figure 3.7. Effects of Dex and Paclitaxel on the liver at 10dpf.
(A) Schematic of drug treatment schedule (B) brightfield images of embryo at 10dpf taken
at 32x magnification. (C) Graph representing liver area (µm2), (D) Graph representing yolk
sac area (µm2x103). Data represents mean ± s.d, statistical anysis performed using Oneway Anova with Tukey post-hoc, ***p<0.001. n=at least 14 fish from three independent
experiments.
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Discussion
Zebrafish have long been used for drug toxicity studies since they are completely
transparent in early development, providing an excellent platform to study the side effects
of drugs in vivo. Our studies focused on the effects of drug combinations on embryo and
larval zebrafish organs, which have shown drug toxicity profiles similar to adult human
organs (Dai, et al., 2014; Wilkins & Pack, 2013; Zakaria, et al., 2018; Zhu et al., 2014).
We specifically focused on determining the effects of the anti-emetic steroid Dex when
used in combination with cyclophosphamide or paclitaxel, two drugs used in cancer
treatment. Our goal was to determine if side effects typically seen with chemotherapy
patients are exacerbated by the addition of Dex.
When Dex was added simultaneously with cyclophosphamide or paclitaxel our
work showed that Dex alters the effects of the drugs used. The fish that received both
cyclophosphamide and Dex had phenotypes indicative of heart failure with significantly
larger pericardial sacs, more edema, and abnormal blood flow (Figure 3.2. and Figure 3.3).
These fish also had much smaller livers than other treatment fish and more yolk retention
which suggested a decrease in absorption by the embryo and linked to a decrease in liver
function as the lipoproteins needed for yolk lipid export are produced in the liver (He, et
al., 2013; Quinlivan & Farber, 2017) (Figure 3.4). Further investigation is required to
determine if the yolk sac retention is in fact due to a disruption of liver function and
metabolism, due to overall systemic metabolic problems, or that these fish have slower
rates of activity and require nutrients at a slower rate.
Gene analysis showed that though Dex is used as an anti-inflammatory, Dex
treatment alone increased expression of il1β and tnfα in zebrafish embryos. The
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combination of Dex and cyclophosphamide did not activate the same inflammatory
pathways but did show a significant increase in mmp9 expression. It has previously been
shown that treating developing zebrafish embryos with Dex alone can cause altered
developmental morphology through increases in MMP activity (Hillegass, Villano,
Cooper, & White, 2008), however there has been no previous study showing the same
upregulation in combination treatments. As well, inhibiting Mmp-9 activity reverses
cardiac toxicity in fish treated with polycyclic aromatic hydrocarbons (Zhang, et al., 2013).
Increased edema in humans after ischemic stroke and cerebral hemorrhage has been
attributed to MMP-9 activity (Abilleira et al., 2003; Castellazzi et al., 2010; Rosell et al.,
2006). In our study, upregulation of mmp9 expression in zebrafish was amplified in the
presence of cyclophosphamide treatment which we suggest led to the increases in cardiac
edema that was observed. Future work to resolve whether Mmp-9 inhibitors can
circumvent cardiotoxicities in animal models undergoing cyclophosphamide and Dex
treatment would be the next direction for this work.
When combined with paclitaxel, however, Dex did not have the same cardiotoxic
or hepatotoxic effect as with cyclophosphamide, perhaps due to the discrepancy in dosing
of the two drugs or the differences in mechanisms of action. Previously publish research
does show a disparity between the effects of Dex in combination with different drugs. For
example, a previous study determined that Dex interacted negatively with the
chemotherapy drug, doxorubicin, by elevating glucose blood levels and making
cardiomyocytes more sensitive to doxorubicin side effects (Di Biase et al., 2017). On the
other hand, mice pretreated with Dex were protected from liver toxicity caused by
carboplatin treatment (Wang, Li, Rinehart, & Zhang, 2004a, 2004b). This highlights the
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need to examine the toxicity of Dex with individual chemotherapy drugs that are
simultaneously given to patients and to ensure minimal negative interactions with the
drugs. The use of Dex as an antiemetics needs to be studied further in mammalian models
and clinical trials to make sure that the patients are not unnecessarily sacrificing quantity
of life for quality.
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CHAPTER 4 TESTING THE EFFICACY OF NATURAL HEALTH PRODUCTS
USING A TRANSLATIONAL ZEBRAFISH MODEL

141

Introduction
Many epidemiological studies and experimental trials have shown that there is a
relationship between prolonged oxidative stress in the body and the development of
multiple health conditions, such as cardiovascular, renal, mental health, premature ageing,
as well as cancer (Liguori et al., 2018; Salminen, Ojala, Kaarniranta, & Kauppinen, 2012;
Young & Woodside, 2001). Oxidative stress has also been shown to interfere with cancer
treatments by inhibiting apoptosis (Shacter, Williams, Hinson, Senturker, & Lee, 2000).
On the other hand, clinical trials with antioxidants have been largely ineffective, with many
showing even harmful effects (Bjelakovic, Nikolova, Gluud, Simonetti, & Gluud, 2007;
Goodman, Bostick, Kucuk, & Jones, 2011; Steinhubl, 2008; Zhang et al., 2008). Halliwell
(2000, 2013) has described the discrepancy between epidemiological and experimental
studies and clinical trials as the “antioxidant paradox” and this has continued to be
discussed when treating diseases that are thought to arise from oxidative stress (Biswas,
2016; Bonner & Arbiser, 2014; Halliwell, 2000, 2013).
Oxidative stress is the result of an imbalance of the body's ability to readily detoxify
reactive intermediates (free radicals) or to repair the resulting damage caused by these
intermediates. Such disturbances in the normal state of cells can cause toxic effects through
the production of peroxides and free radicals that damage all components of the cell,
including proteins, lipids, and DNA (Pham-Huy, He, & Pham-Huy, 2008). To combat
oxidative stress, the body has evolved natural defense systems. The major antioxidant
enzymes directly involved in the neutralization of free radicals are superoxide dismutase,
catalase, glutathione peroxidase and glutathione reductase (Genestra, 2007; Halliwell,
2007; Pacher, Beckman, & Liaudet, 2007; Valko et al., 2007; Willcox, Ash, & Catignani,
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2004; Young & Woodside, 2001). Inflammation, on the other hand, is part of a complex
protective response involving immune cells, blood vessels, and molecular mediators.
Inflammatory responses can be triggered due to infections, tissue damage after injury, as
well as exposure to irritants (Coussens & Werb, 2002; Demaria et al., 2010; DeNardo &
Coussens, 2007). With increasing understanding of the oxidative pathways and
inflammation, undeniable evidence has been collected to show the tightly linked
relationship between the two (Figure 4.1) and their combined role in maintaining body
physiology (Incalza et al., 2018; Reuter, Gupta, Chaturvedi, & Aggarwal, 2010).
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Figure 4.1. Relationship between oxidative stress and Inflammation.
Oxidative stress and inflammation are very closely linked. Whether inflammation or
oxidative stress pathways get triggered first, it invariably influences the other pathway.
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It is, then, not hard to imagine how persisting oxidative stress in the body leads to
the same health conditions as chronic inflammation. Many studies show that oxidative
stress can activate inflammatory pathways such as the necrosis factor kappa B (NFκB),
signal transducer and activator of transcription 3 (STAT3), and interleukin-8 (IL-8)
signaling (Barry et al., 2009; DeForge et al., 1993; Kratsovnik, Bromberg, Sperling, &
Zoref-Shani, 2005). Given such an integral connection between the two processes, an
antioxidant paradox arises. For any formula to reproducibly perform as an antioxidant in
the human body, it must have the ability to modulate the immune system as well as balance
oxidative stress.
The optimal research model to determine a compound’s efficiency as an antiinflammatory and antioxidant would be an in vivo animal model with an intact immune
system. Zebrafish have been used in research since the early 1960s, but its success as a
human physiological model organism was precipitated by its genome sequencing in 2013
(Howe et al., 2013). The zebrafish has a very similar genetic structure to humans and has
complementary gene counterparts to 82% of all the human disease genes known to date
(Howe, et al., 2013; Strynatka, Gurrola-Gal, Berman, & McMaster, 2018; Varga et al.,
2018). They also have very similar organ structures and share similarities in physiology
with humans (Seth, Stemple, & Barroso, 2013). Today thousands of research laboratories
all over the world are modeling human pathologies to understand the mechanisms of
disease and how it occurs in humans. We therefore used the zebrafish model as an efficient
and affordable way to decipher the effect of compounds on disease processes.
Many anti-inflammatory drugs have severe side effects, such as edema, heart failure
and liver toxicity, when used over a long period of time (Cook, McDonnell, Lake, &
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Nowak, 2016; Duque Ede & Munhoz, 2016; Polderman et al., 2018; Sriuttha,
Sirichanchuen, & Permsuwan, 2018) which is why there has been an increased interest in
finding over-the counter, natural health products (NHPs) that can be taken at lower doses
and will not cause severe side effects.
Lifestyles’ Nutria plus capsules are a powerful antioxidant supplement formulated
to be taken as a daily supplement that will defend against inflammation and oxidative
stress. Nutria plus contains a variety of plant-based ingredients such as green tea, grape
seed and amla extracts, and other vitamins and minerals to provide maximum free radical
neutralizing properties. Extensive proprietary research and systematic scientific scrutiny
went into the design and development of Nutria plus (unpublished, proprietary). The
formulation was then evaluated for all the claims through direct physiological
measurements in a live zebrafish model that is a close mimic to human physiology.
Nutria plus was developed with this pioneering concept of balancing oxidative
stress alongside inflammation in the body. Our preliminary results show that Nutria plus
has the potential to prevent damage from UV and heal tissue that is already damaged due
to mild UV exposure, improve tissue repair and regeneration, and prevent abnormal
cellular growth.
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Materials and methods
Composition and formulations
The new formulation for Nutria plus was an evolution of an existing formula called Nutria.
Nutria was a sister antioxidant formulation to LifeStylesTM Intra product that was designed
to support all the biological systems of the body (Lifestyles, 2019). Acenzia Inc. developed
two Nutria plus formulas - one with high SelenoExcell (HSe) and the other with low
SelenoExcell (LSe). Each ingredient in both Nutria plus formulas has been carefully
selected based on previous studies of their antioxidant and anti-inflammatory capacities as
referenced in Table 4.1. The daily dosages of each ingredient as well as their potential
benefits are listed in Table 4.1. The HSe formulation was registered with Health Canada
with a Natural Product Number (NPN) of 80081633. Other non-medicinal ingredients used
in the formulation were gelatin, magnesium stearate, silicon dioxide, pregelatinized starch.
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Ingredient

Potential Benefits and References

Daily Dosage
(mg/day)
HSe

SelenoExcell

LSe

Reduces oxidative stress biomarkers, a measure of healthy
aging and reduced risk for chronic illness and certain cancers
(El-Bayoumy et al., 2002)

Grape

Seed

Extract

160

40

110

110

100

140

90

100

60

60

40

120

40

40

Proanthocyanidins from grape seed extract possess potent
free radical scavenging abilities (Bagchi, Swaroop, Preuss, &
Bagchi, 2014; Stankovic et al., 2008)

Green Tea Extract

Strong antioxidant. Rich in polyphenols, predominantly
catechins (Carrizo, Gullo, Bosetti, & Nerin, 2014). Skin
photoprotective effects. Skin photoprotection by natural
polyphenols: anti-inflammatory, antioxidant and DNA repair
mechanisms (Nichols & Katiyar, 2010).

Spirulina Powder

Antioxidant with immunomodulating activity (Finamore,
Palmery, Bensehaila, & Peluso, 2017).

Ascorbic Acid

Also known as Vitamin C, ascorbic acid is a powerful
antioxidant (Padayatty et al., 2003).

Amla

Fruit

Extract

Carrot
Extract

Has antioxidant, immunomodulatory and anti-inflammatory
effects (Yadav, Singh, Singh, & Kumar, 2017).

Root

Contains beta-carotene, a precursor of Vitamin A which is a
strong antioxidant (Kartha & Krishnamurthy, 1977; Palace,
Khaper, Qin, & Singal, 1999).
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Garlic

Bulb

Has anti-inflammatory and antioxidant effects (Rose,

Extract

Whiteman, Moore, & Zhu, 2005).

Red Beet Root

Betalain

Extract

inflammatory and chemo-preventative activity both in vitro

pigments

demonstrate

antioxidant,

40

40

40

40

20

20

20

20

20

20

740

750

anti-

and in vivo (Clifford, Howatson, West, & Stevenson, 2015)

Broccoli

Sprout

Extract

Sulphur containing glucosinolates show potential anticarcinogenic and anti-inflammatory effects (Sturm &
Wagner, 2017).

Prune

Fruit

Extract

Alpha

Phenolics from prunes show high antioxidant activity
(Kayano et al., 2004).

Lipoic

Has strong antioxidant activity (Tibullo et al., 2017).

Acid

Total

Table 4.1. Selection of active ingredients and quantities for two selected formulas of Nutria
Plus.
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In vitro antioxidant capacity assay
A 0.4mol/L glacial acetic acid solution (pH 5.8) was made in sodium acetate buffer
(Reagent 1). A 37.5ml of a 30mmol/L sodium acetate solution was mixed with 462.5ml of
a 30mmol/L acetic acid solution (pH 3.6). 324.3μl of a 30% H₂O₂ solution was added. To
51ml of this solution, 280mg 2,2′-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid)
diammonium salt (ABTS) (Sigma; A1888) was added and incubated for 1hr. When
solution was ready, a characteristic blue-green colour appeared (Reagent 2).
For each dry powdered Nutria ingredient or complete capsule formula (HSe and
LSe), approximately 100mg powder was transferred into a 50ml tube and resuspended with
ultrapure water to 10mg/ml. The tubes were vortexed and placed on a tube roller for 20min,
and centrifuged at 2,400g for 10min. The supernatant was immediately removed thereafter
and the pellet (if present), resuspended in another 10ml ultrapure water and place on tube
roller for another 20min. The centrifugation step was repeated, and the supernatant
combined to make 5mg/ml solution. Any pellet remaining was resuspended in ethanol to
10mg/ml and placed on the tube roller for 20min, and then centrifuged at 2,400g for 10min
to obtain a 10mg/ml ethanol extract.
The T92+ ultra-violet (UV) spectrophotometer was set up with the “Kinetics”
Method to measure wavelength at 660nm for 5 min. The instrument was zeroed using 1.6ml
of Reagent 1 in a 2 or 4ml disposable cuvette. A standard was obtained using 0, 0.25, 0.5,
0.75 and 1mmol/L ascorbic acid solution. 20μl of each standard was added to the cuvette.
While cuvette was in the cell holder, 160μl of Reagent 2 was added to the cuvette and
mixed once. At the same time, the absorbance reading was recorded at the 5th min. The
readings of each standard or sample was taken with the same method. Using the absorbance
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results for the standards, the standard curve was plotted on a spreadsheet. Multiple standard
curves were recorded across several experiments and all suitable data points were used for
the creation of the best fit line. The equation of this line was used to determine the ascorbic
acid equivalent for each sample across experiments performed on different days.
Zebrafish husbandry and embryos
Zebrafish Research Facility as well as the Animal Care Committee in Acenzia Inc. is
certified through Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA) and
all protocols used in the laboratories are monitored by the Animal Health and Welfare
Branch, OMAFRA. Fishes are housed and maintained using Tecniplast ZebTec system
with a controlled day-night (14hr light/10hr dark) light cycle. Embryos were obtained from
natural spawnings and developmental stages were reported as hours post-fertilization (hpf)
at 28.5°C.
Tail fin amputation assay
Zebrafish larvae were randomized and immersed in 1µg/ml green tea equivalent (GTE) of
the Nutria plus HSe and LSe formula or control (0.5% dimethylsulfoxide (DMSO)) in
filtered system water for 1hr prior to tail fin amputation. Larvae were immersed in tricaine
solution, then placed in petri dish with a drop of tricaine to prevent dehydration. Using a
sharp syringe needle, the tail fin was cut right after the tip of the tail. Larvae were imaged,
then placed back into its appropriate treatment solution in a 6-well plate at 35°C. The day
after amputation, approximately 75% of the previous day’s solution was replaced with
freshly prepared drug solutions.
Immediately following amputation and 2 days later, larvae were placed on a 1%
agarose bed under an inverted microscope for imaging (Leica M165 FC). Measurement
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was performed on tail fin images immediately after amputation and after two days of
treatment post amputation. Similar measurements were performed on tail fin images on
non-amputated control larvae that were incubated exactly the same way as the tail fin
amputated larvae. The control larvae were used to measure the growth of the fins during
normal larval development.
To measure a consistent area of the fin, the entire area of the fin beyond the cloacal
notch was measured. Area of fins were measured (in arbitrary units) using ImageJ
(National Institutes of Health). Analyzing fins of larvae without any fin amputation, we
calculated the normal growth rate (in terms of % growth) of the fins. These fish were
normalized to show no regeneration. Percent regeneration was calculated as follows:
Day 0 metric = Area amputated fin area / Area of non-amputated fin
Day 2 metric = Area of missing fin (at day 2) / Area of fin measure in nonamputated control fish (at day 2)
Percent Regeneration = 100 x [(Day 0 metric) - (Day 2 metric)]
UV exposure assay
At 3 days post fertilization (dpf), larvae (n=10) were treated with either 1μg/ml GTE of
Nutria plus HSe or LSe in 0.5% DMSO for 24hrs. Control larvae were treated with 0.5%
DMSO only. At 4dpf, the media was removed, and the half of the experimental larvae were
treated with 19s of UVC (approximately 25mJ/cm²) and the other half received no UV
exposure. Fresh solutions of Nutria plus were added back to the larvae and they were kept
at 28.5°C for 24hrs. At 5dpf, the larvae were stained with 5μg/ml Acridine Orange (AO)
for exactly 20mins and then washed with system water.
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Fish larvae were placed in tricaine solution and imaged on a 1% agarose bed under
the Leica stereomicroscope using a GFP filter. The fin of the fish was analyzed using
ImageJ’s Integrated Density measure. First, the fin area was outlined and then the area and
the Raw Integrated Density was measured. DNA damage per unit area was measured as
[Pixel of Raw Integrated Density / Area of Fin].
Angiogenesis assay
1dpf embryos were incubated in fresh 150μg/ml trypsin in a 28.5°C incubator for
dechorionation. Approximately 150-200 HCT-116 colorectal cancer cells were stained
with Vybrant DiI dye and injected into the yolk sac of dechorionated embryos. They were
then randomized into Nutria plus HSe, Nutria plus LSe or DMSO control groups of at least
50 embryos each. An additional group of larvae that did not receive cell xenografts was
included. The next day, embryos with cells that were improperly injected were eliminated.
At 3dpf, larvae were anesthetized in 168mg/L tricaine and only fishes with a clear
tumour bolus in the yolk sac were selected for fixation. Larvae were then fixed in 4%
paraformaldehyde at room temperature for 3hrs. Samples were next washed twice with
0.1% Tween-20 in PBS (PBST) and dehydrated in successive washes of 25%, 50%, 75%
and 100% Methanol in PBST. Next, the samples were rehydrated in successive washes of
75%, 50%, 25% Methanol and finally PBST. Samples were then equilibrated in alkaline
phosphatase buffer (100mM NaCl, 50mM MgCl2, 100mM Tris pH 9.5, 0.1% Tween-20 in
ultrapure water) at room temperature for 30min. Next, samples were stained in alkaline
phosphatase buffer containing 110μg/ml nitro blue tetrazolium (Promega; S3771) and
55μg/ml 5-bromo-4-chloro-3-indolyl-phosphate (Promega; S3771) on a 35 °C heat block
for approximately 15min until the sub-intestinal vessels can be properly visualized.
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Samples were then rinsed 2 to 4 times in stop buffer (0.25mM Ethylenediaminetetraacetic
acid in phosphate buffered saline, 0.1% Tween). Samples were then re-fixed in 4%
paraformaldehyde at 4ºC overnight. The next day, samples were transferred to 80%
glycerol in stop buffer for long term storage at 4ºC.
Subintestinal vessels of each larva were imaged using the Leica M165 FC
microscope on an agarose plate. For each larva, the total area, (excluding the caudal
cardinal vein) of the subintestinal vessels were outlined with the freehand tool and
measured using ImageJ. The average of the total areas measured for each group was
analyzed for statistical differences.
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Results
In vitro antioxidant capacity of Nutria plus ingredients
Nutria plus was derived from the formulation of Intra, an NHP supplement, and should
have minimal antagonizing biological effects. Each component of the formulation was
therefore evaluated for their contribution towards the antioxidant capacity of the
formulation and how each component interacted together as a formulation with Intra. Table
2 shows the Total Antioxidant Capacity (TAC) of each selected formula of Nutria plus and
how they performed in combination with Intra. The calculated TAC is the predicted value
based on the sum of the activity of each individual ingredient. Nutria plus as a formula (as
shown in Table 4.2 A) had a far higher TAC in comparison to the calculated cumulative
activity. The components of Nutria plus are working together to enhance the TAC.
Similarly, Nutria plus along with Intra had higher TAC (as shown in Table 4.2 B) in
comparison to both Intra and Nutria plus separately.
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Total Antioxidant
Capacity (TAC) per

Percentage

dosage

Increase in activity

Description

Intra

297.192

Nutria plus (HSe) Calculated

593.25145

Nutria plus (HSe) Observed

880.0122

Nutria plus (LSe) Calculated

766.1521

Nutria plus (LSe) Observed

906.1624

32.59% A

15.45% A

Nutria plus (HSe) + Intra [in ratio] Calculated 1177.2042
Nutria plus (HSe) + Intra [in ratio] Observed 1489.3852

20.96% B

Nutria plus (LSe) + Intra [in ratio] Calculated 1203.3544
Nutria plus (LSe) + Intra [in ratio] Observed 1501.1472

19.84% B

Table 4.2. Interaction of Nutria plus with Intra.
(A) Percentage increase in observed Nutria Plus TAC as compared to calculated (B)
Percentage increase in observed Nutria Plus + Intra as compared to calculated value.
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Evaluating the toxicity of Nutria plus in zebrafish embryos
To evaluate the biological effects of the Nutria plus formulation in the zebrafish model, we
needed to estimate the best dosage that should be used for testing in zebrafish. We used the
highest tolerated dosage with minimal toxicity (LD10 - lethal dose 10%). As Green Tea
Extract had the lowest LD10 (approximately 1 µg/ml) among the tested ingredients (data
not shown), we decided to use 1 µg/ml of GTE for all zebrafish studies.
Nutria plus prevents cellular death due to sun exposure
UV radiation from the sun consists of UVA (315-400nm), UV-B (280-315nm) and UVC
(200-280nm). Although UVC is absorbed by the ozone layer, the photochemistry of direct
DNA damage caused by UVB and UVC are similar - cyclobutane pyrimidine dimers and
pyrimidine 6-4 pyrimidone photoproducts (Cleaver, 2006). UV can also cause indirect
DNA damage through the production of reactive oxygen species (de Jager, Cockrell, & Du
Plessis, 2017). To evaluate the role of Nutria plus in protecting the skin from the deleterious
effects of sun exposure and UV damage, we used a zebrafish low dose UVC exposure
model. Zebrafish larvae show a rapid increase in cellular damage and apoptosis when
exposed to low dose UVC and it can be visualized through staining the larvae with AO
after irradiation. Figure 4.2 A and top panel of B show that with UV exposure, larvae
sustained significantly more DNA damage and hence cellular death per unit area compared
to larvae that were not exposed to UV. Importantly, this damage was significantly reduced
in larvae that received Nutria plus, demonstrating the beneficial effects of Nutria plus in
combating UV induced cellular DNA damage (Figure 4.2 B-C).
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Figure 4.2. Nutria plus prevents cellular death due to sun exposure.
(A) Normal larva stained with AO. (B) Larva exposed to UV and stained with AO. (C)
Graph representing the measured stain intensity in the tail fins of larvae in each treatment
as measured using ImageJ RawIntegrated Intensity. SEM representing at least n=10 in each
treatment. HSe=high SelenoExcell concentration, LSe=low SelenoExcell concentration,
***p<0.001, ****p<0.0001.
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Nutria plus enhances tissue repair after injury
In humans, distinct inflammatory responses at the site of injury help with tissue
regeneration (Cooke, 2019; Jiang & Liao, 2010). The first step is initial defense against
infection and then eventual resolution of inflammation for proper regeneration. An intricate
balance regulates this process, and if imbalanced, can form scar tissue. Zebrafish tail-fin
amputation model has been used to demonstrate how this process works (Li, Yan, Shi,
Zhang, & Wen, 2012; Ouyang et al., 2017; Petrie, Strand, Yang, Rabinowitz, & Moon,
2014; Thummel, Ju, Sarras, & Godwin, 2007). Here, we used a similar zebrafish model to
demonstrate the beneficial immunomodulatory effects of Nutria plus. Larvae that received
Nutria plus HSe and LSe, before and following amputation of the tail fin, showed an
increase, roughly 8% and 20%, respectively, over control area of regenerated tissues
demonstrating the beneficial effects of Nutria plus during wound healing and tissue repair
(Figure 4.3).
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Figure 4.3. Nutria plus enhances tissue repair after injury.
(A) Normal growth of larval tail fin over two days of observation. Days post amputation
(dpa) does not apply for unamputated larvae so corresponding dpf has been shown in the
bracket. (B) Left panel is showing normal growth along with regeneration of amputated
larval tail fin. The middle panels and right panels are showing growth along with
regeneration of amputated larval tail fin in presence of Nutria plus formulations. (C)
Graphical representation of the observed fin regeneration in control, Nutri plus HSe and
Nutria plus LSe. SEM representing at least n=20 in each treatment, ****p<0.0001.
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Nutria plus prevents abnormal cellular growth
Angiogenesis is the process in which new vessels are formed from pre-existing ones. Such
new vessel formation is developed locally to promote increased supply of nutrients to
growing tissues. Angiogenesis is a crucial event during the proliferation of cancer cells in
the body, as tumour tissues require nutrients and oxygen to grow beyond a particular size
(generally 1–2mm3) to develop into cancer (Carmeliet, 2005; Nishida, Yano, Nishida,
Kamura, & Kojiro, 2006; Ono, 2008).
Localized inflammation due to growth of tumour cells triggers the process of
angiogenesis. It has been shown using zebrafish that xenografts of tumour tissues result in
new and abnormal increase in vessel formation, mimicking the process of angiogenesis
observed in humans (Chiavacci et al., 2015; Nicoli & Presta, 2007). To evaluate the role
of Nutria plus as an anti-inflammatory and specifically as an angiogenesis inhibitor, we
implanted tumour cells into the yolk sac of zebrafish larvae and examined if Nutria plus
could reduce tumour-induced angiogenic vessel growth. Normal angiogenesis was
observed in zebrafish with no cells and no Nutria (Figure 4.4 A). With the addition of
cancer cells, the area of vein formation increased (Figure 4.4 B), however with the addition
of Nutria plus HSe and LSe, the area of vein formation was decreased back to control levels
(Figure 4.4 C-E).
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Figure 4.4. Nutria plus prevents abnormal cellular growth.
Representative pictures of larva with subintestinal vein formation with (A) no treatment
and no cells, (B) cancer cells are present. (C) Nutria plus HSe treatment and cancer cells
implanted, and (D) Nutria plus LSe treatment with cancer cells present. (E) Graph showing
the quantitative measurement of the area of subintestinal vein in square inches. SEM
representing at least n=10 in each treatment. *p<0.05, ***p<0.001.
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Mechanism of action
After extensive research, we developed a biological activity pathway map logically
explaining the expected mechanism of action of the product (Figure 4.5). Nutria plus is
designed to influence both oxidative stress and unwanted inflammation. UV exposure,
along with increased oxidative stress in the body, leads to cellular ageing through DNA
damage. Persisting inflammation in the body impairs tissue repair and regeneration after
injuries as well as persisting inflammation promotes abnormal cell growth, which can lead
to diseases such as cancer (Demaria, et al., 2010; DeNardo & Coussens, 2007; Pierce et
al., 2009).
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Figure 4.5. Mechanism of action of Nutria plus.
Nutria plus is designed to influence both oxidative stress and unwanted inflammation. UV
exposure, along with increased oxidative stress in the body, leads to cellular ageing through
DNA damage. Persisting inflammation in the body impairs tissue repair and regeneration
after injuries as well as persisting inflammation promotes abnormal cell growth, leading to
diseases such as cancer. Nutria plus has been shown to inhibit DNA damage, abnormal cell
growth and to increase regeneration of tissue.
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Discussion
Conventional treatments for acute and chronic inflammation include, as examples,
dexamethasone and nonsteroidal anti-inflammatory drugs which are very commonly
prescribed worldwide. Although effective in treating inflammation, these types of drugs
are notorious for causing serious side effects especially when used over a long period of
time (Fraiser, Kanekal, & Kehrer, 1991; He et al., 2013; Kanekal, Fraiser, & Kehrer, 1992;
Sriuttha, et al., 2018).
There is a growing trend to use NHPs for medicinal purposes to try to reduce the
incidence of side effects. NHPs are becoming more popular, especially for the treatment of
inflammation and as anti-cancer agents in different types of tumours, for example recent
studies have used Burdock (Arctium lappa) extract to treat melanoma tumours in mice and
pitcher plant (Nepenthes thorellii x (ventricosa x maxima)) extracts as an anti-cancer agent
for breast cancer cells (Nascimento et al., 2019; Ou-Yang et al., 2019). There is also
evidence of NHPs preventing oxidative stress and preventing hepatotoxicity after treatment
with doxorubicin, a chemotherapeutic (Song et al., 2019).
In this study we used a zebrafish model to examine the effectiveness of Nutria plus,
an NHP, as an anti-inflammatory and antioxidant. Using zebrafish as a model system is an
affordable option for in vivo studies, especially in an industrial research setting that requires
less expensive research methods. Using zebrafish to test NHPs has been well established
(Kao et al., 2010; Pitchai, Rajaretinam, & Freeman, 2019; Yin et al., 2018) so this was an
appropriate model to determine the efficacy of Nutria plus products.
Because Nutria plus is a sister formula to Intra, it was first imperative to determine
if the added ingredients of Nutria would in fact increase the antioxidant properties of Intra.
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Nutria plus HSe was shown to have approximately double the TAC when compared to
Intra alone, and interestingly had 32.59% higher antioxidant potential than the calculated
or predicted TAC, suggesting the ingredients work together as agonists to be more efficient
antioxidants. Nutria plus LSe was less efficient but still had a 15.45% increase from the
calculated TAC. When combined, Nutria plus and Intra were able to increase the TAC by
roughly 50% meaning the ingredients are not antagonizing each other.
To determine if Nutria plus was able to prevent UV damage and repair any damage
that has already occurred, embryos that were exposed to UV with and without Nutria plus
treatment were stained with AO, which is a dye that will intercalate with damaged DNA in
living cells to fluoresce green (dead cells will fluoresce red) and can be used in live imaging
of DNA damage and cell death in zebrafish (Kao, et al., 2010; Paquet et al., 2009; Tucker
& Lardelli, 2007). After UV damage, Nutria plus had significantly less AO staining than
fish without Nutria plus treatment, as shown by a significant decrease in green fluorescence
in the tail region of the embryo. This is suggesting that Nutria plus pretreatment is
preventing DNA damage or even stimulating repair of damage that was induced by UV.
To determine if Nutria is in fact preventing damage or only helping to repair existing
damage, it is necessary to have a study with embryos that are not pre-treated with Nutria
plus but do receive it after damage. It is also a possibility that Nutria plus is causing the
damaged cells to undergo apoptosis which would show an increase in the AO fluorescing
red instead of green, so this is something we are looking into further.
Inflammation and oxidative stress decrease the body’s ability to repair tissue
(Coussens & Werb, 2002; Das et al., 2015; Schafer & Werner, 2008), so we wanted to
determine if Nutria plus could be effective at restoring tissue repair mechanisms after an

166

acute injury. Nutria plus was able to increase the rate of regeneration of tail tissue after tail
amputation over embryos that had no Nutria plus treatment. Interestingly, the Nutria plus
LSe was able to regenerate at a faster rate than Nutria plus HSe, suggesting that a higher
dose of SelanoExcell is not more beneficial for tissue regeneration. Nutria plus was also
able to decrease the area of angiogenesis into the yolk when cancer cells were engrafted
but again the Nutria plus LSe was more effective than the HSe formulation. Given that the
HSe and LSe formula seem to be more effective with different processes it is necessary to
further investigate whether only one formula should be used ubiquitously or if formulas
should be personalized depending on medicinal need.
This preliminary research has shown potential for Nutria plus to be effective in
combating the negative effects of oxidative stress and inflammation. We caution that more
research still needs to be completed to determine if Nutria plus could be a replacement for
current anti-inflammatories, which often have harsh side effects, and whether it will be
effective for combating long term inflammation and oxidative stress. We also note that any
potential interaction with the effectiveness of chemotherapy drugs is an essential level of
testing that would need to be completed in pre-clinical models and then carefully tested in
randomized control clinical settings prior to any recommendations for patient use.
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CHAPTER 5 SPY1 PROMOTES CELL METASTASIS VIA β1-INTEGRIN-ERK1/2
SIGNALING
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Introduction
Breast cancer remains the second leading cause of cancer deaths in Canadian women (Bray
et al., 2018) with the late, metastatic stage being considered incurable. Breast cancer
initiates with hyperproliferation of mammary luminal cells to form a primary hyperplastic
nodule. These cells become highly disorganized and some can gain the ability to invade
through the basement membrane (Feng et al., 2018; Mittal, Brown, & Holen, 2018) which
begins the progression to metastatic disease.
Metastasis is a series of processes that allows cells to migrate away from the
primary tumour site and colonize distal organs. These processes include invasion through
the extra cellular matrix (ECM) and entrance into the blood stream, extravasation and
colonization of the distal site (Polyak, 2007). As discussed by Bill and Christofori in their
review of metastatic cell processes, the most favoured explanation for cell metastasis is the
epithelial-to-mesenchymal transition (EMT) which is the transformation of the cells from
an epithelial phenotype to a more stem-like mesenchymal cell (Bill & Christofori, 2015).
Characteristics of cells undergoing EMT include loss of E-cadherin expression and gain of
N-cadherin, nuclear localization of β-catenin, and an overall change in morphology
(Christiansen & Rajasekaran, 2006). While EMT is a demonstrated event during
metastasis, there is ample data in breast and other cancers to support that EMT is neither
required nor sufficient for metastasis to occur (Fischer et al., 2015; Lou et al., 2008; Zheng
et al., 2015).
Proper cell-ECM interactions are critical for normal mammary gland development
but are implicated in breast cancer progression and metastasis (Muschler & Streuli, 2010).
α and β integrin subunits heterodimerize and bind to elements of the ECM (collagen,
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fibronectin, etc) and induce signaling cascades involved in cancer processes. There is some
controversy whether these integrin units help prevent or contribute to metastasis. In MCF7
breast cancer cells β1-integrin can increase E-cadherin expression to prevent metastasis
(Parvani, Galliher-Beckley, Schiemann, & Schiemann, 2013; Truong et al., 2014).
However, in MDA-MB-231 metastatic breast cancer cells, invasion and migration was
significantly inhibited using both β1-integrin blocking antibodies and extracellular signalregulated kinase (ERK)1/2 or mitogen-activated protein kinase kinase (MEK) inhibitors
(Mierke, Frey, Fellner, Herrmann, & Fabry, 2011).
Early signs of breast cancer, such as hyperplasia and disorganization, are present in
the alveolar structures and can be recapitulated in vitro using a well developed 3dimensional (3D) overlay technique that allows mammary epithelial cells to grow within a
basement membrane derived from an Engelbreth-Holm-Swarm tumor and form acini,
alveolar-like speres (G. Y. Lee, Kenny, Lee, & Bissell, 2007). The mammary epithelial
cell line MCF10A form organized acini by day 12 with clear apical-basal polarity and a
defined luminal space (Debnath, Muthuswamy, & Brugge, 2003). These cells will not form
the same tight junctions found in primary human mammary epithelial cells (hMECs)
(Underwood et al., 2006), because they lack Crumbs3 (Fogg, Liu, & Margolis, 2005), but
are a very stable cell line that can be easily manipulated to study pathway regulation in
developing acini. The MCF10A cells were used to derive the MCF10AT1 (AT1) line that
has Ras activation and will form hyperplastic acinar structures. These lines are therefore a
very useful model of early breast cancer progression in vitro (Choong et al., 2010; Dawson,
Wolman, Tait, Heppner, & Miller, 1996; Santner et al., 2001).
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Lee et al. (2005) were first to show that human cancer cells could successfully
engraft and metastasize in zebrafish embryos. Melanoma cells were injected at the blastula
stage of the embryos and survived up to 8 days post implantation (dpi) (L. M. Lee, Seftor,
Bonde, Cornell, & Hendrix, 2005). It has since been observed that a cell’s metastatic
behaviour is conserved in this xenotransplant model providing a fast and cost-effective way
to model human metastasis in vivo. Zebrafish lack an adaptive immune system up until ~2
weeks post fertilization allowing human cells to engraft without rejection; however, the
innate immune system is active (at 2 days post fertilization (dpf)) which allows for the
human cells to interact with a microenvironment similar to that of humans (Amatruda,
Shepard, Stern, & Zon, 2002; Drabsch, He, Zhang, Snaar-Jagalska, & ten Dijke, 2013;
Etchin, Kanki, & Look, 2011; Ghotra et al., 2012). Metastatic cell processes are strongly
influenced by the microenvironment, so the zebrafish model is especially beneficial when
studying metastatic processes in breast cancer.
Spy1, a cyclin-like protein, can activate cyclin dependent kinases (CDK)
independent of the canonical phosphorylation status (Cheng, Gerry, Kaldis, & Solomon,
2005). Due to its unique conformation, the Spy1/CDK complex can uniquely
phosphorylate CDK substrates and promote faster progression through the cell cycle. Spy1
accelerates mammary tumourigenesis in mouse mammary transplants, and has elevated
protein expression in breast cancer tumours, and promotes chemoresistance to Tamoxifen
(Al Sorkhy et al., 2012; Ferraiuolo, Tubman, Sinha, Hamm, & Porter, 2017; Golipour et
al., 2008; Lubanska et al., 2014). In brain cancer, Spy1 protein levels positively correlate
with more aggressive tumours (Lubanska, et al., 2014). Although elevated Spy1 levels have
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been implicated in later stages of cancer, it has not been reported if Spy1 is involved in the
processes that contribute to breast cancer metastasis.
This study is the first to show a role for Spy1 in breast cancer metastasis. Breast
cells, manipulated to overexpress Spy1, were able to invade and migrate in vitro and form
distant metastases in an in vivo zebrafish model. Spy1 mediated invasion and migration are
independent of EMT and β1-integrin activity was essential for invasion but not migration
with Spy1-overexpressing cells. Protein expression analysis showed activation of the
ERK1/2 pathway and this activation proved necessary for invasion and migration of breast
cells. These findings are important advancements in the study of breast cancer progression
and metastasis by describing a new regulator of alveolar morphogenesis and cell
metastasis.
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Materials and methods
Animal Care
Wildtype Zebrafish (Danio rerio) were maintained and cared for following Canadian
Council for Animal Care guidelines, under the University of Windsor Animal Utilization
Project Proposal # 12-14. Adult fish were kept at 28.5°C and bred according to protocols
available in the Zebrafish Book (Westerfield, 1993).
Cell Culture and Reagents
MCF10A ATCC) and AT1 (Cell Lines Resource; Karmanos Cancer Institute, Detroit,
MI).were grown in DMEM and Ham’s F-12 media (Sigma) containing 5% heat-inactivated
Horse Serum (HyClone) supplemented with 5µg/mL insulin (Sigma), 0.5µg/mL
hydrocortisone (Sigma), 10ng/mL epidermal growth factor (Sigma), and 0.1µg/mL cholera
toxin (Sigma). MDA-MB-231 cells were cultured in Dulbecco's Modified Eagle Medium
(DMEM) with 10% fetal bovine serum (FBS). All cell lines were maintained in media
containing 2mmol/L L-glutamine (Sigma) and penicillin-streptomycin (Sigma) and were
maintained at 37°C in a 5% CO2 environment.
Lentiviral Infection
Lentivirus production and infection was carried out following a modified protocol from the
Welm group (Welm, Dijkgraaf, Bledau, Welm, & Werb, 2008). LentiXTM 293 producer
cells (Cat. No. 632180, Clontech CA) were transfected with polyethylenimine, the
supernatant was collected, filtered, and stored at -80C. MCF10A, AT1, and MDA-MB-231
cells were seeded at 20,000 cells/well, 10,000 cells/well, and 10,000 cells/well
respectively, in a 96-well plate and allowed to grow for 18-24hrs. The cells were infected
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with 6µl lentivirus/100ul media supplemented with 8µg/mL polybrene. All cells infected
with pLKO empty control vector and pLKO-shSpy1 knockdown vectors were maintained
in growth media containing 1ug/mL puromycin.
RNA extraction and qRT PCR
Total RNA was extracted using RNeasy Plus Mini Kit (QIAGEN) following the
manufacturer’s protocol and reverse transcribed using 200U Superscript 11 (Invitrogen),
0.5μg OligodT's and 0.5μg random nanomers (Sigma) according to manufacturer’s
protocols. Quantitative real-time polymerase chain reaction (qRT-PCR), using either an
ABI Prism 7300 or Viia7 thermocycler, with SYBR green (Applied Biosystems)
fluorescent detection and 200-250nM of forward and reverse primers was performed.
GAPDH was used as the endogenous control for all RT-PCR experiments. Data was
analyzed using ABI Prism 7300 or Viia7 software and graphed as relative quantification
(RQ) to control.
Transwell Cell Migration and Invasion Assays
Transwell cell migration assays were performed in 12 well cell culture plates using 8μm
cell inserts (BD biosciences, catalog#:353093). 1ml of complete growth media was added
to each well and the insert placed on top followed by incubation at 37°C for 1hr. 100,000
cells suspended in 500µl serum free media were seeded into each insert and cells were
allowed to migrate at 37°C for 24hrs. Cell inserts were removed and the interior of the
insert was washed with a distilled water dampened Q-tip, and then stained with 400µl of
crystal violet stain (Cell Biolabs, catalog#: CBA-100) for 10mins at room temperature. Cell
inserts were gently washed with distilled water and allowed to dry for 10 mins. Pictures of
the stained cell inserts were taken with a Leica M250 FA microscope. ImageJ was used to
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measure the relative intensity of the staining on the membrane. For the transwell invasion
assay the protocol is as above except that 100ul of Cultrex® (Trevigen #3433-010-01)
diluted to 6mg/mL with serum free media, was added to each well and allowed to solidify
at 37°C for 1hr before the cells were seeded in the well. For ERK1/2 inhibition, 10μM
SCH772984 (ApexBio, A3805) was added to the cells before being seeded into the
transwell chamber. MEK inhibitors, 10μM SB202474 (control; EMD Millipore, 559387)
or 10μM U0126 (MEK 1/2; EMD Millipore, 662005), were added into the well of the insert
with serum-free media. To block β1-integrin activity a β1-integrin antibody (Millipore:
MAB1959) at 20ug/ml was incubated with the cells for 1 hr prior to adding cells to the
insert. Human IgG antibody (Biorbyt Ltd.: ORB27741) at 20µg/ml was used as control.
Zebrafish Xenotransplantation and Analysis
Eggs were collected and kept at 28.5°C in an incubator in embryo media (E3) (5mM NaCl,
0.17mM KCl, 0.33mM CaCl2, 0.33mM MgSO4, 10-5% Methylene Blue) until ready to
inject. Immediately before injections, 500,000 cells/500µL serum free media were labeled
with 5µL of either DiO (green), or DiD (far red) (Vybrant, Invitrogen# V-22886). Fortyeight hrs post fertilization (48hpf) embryos were dechorionated with fine tip forceps and
anesthetized with 0.168mg/ml of tricaine (MS-222, Sigma). Approximately 50-100
cells/9nL were resuspended in DMEM (Sigma) and 9nL of cell suspension were injected
into the yolk sac of each embryo using Nanoject II (Fisher Scientific, cat # FSSP9706473)).
After injection embryos were kept in E3 embryo media and imaged 2hpi with a
fluorescence microscope (Leica M205 FA) to eliminate any fish with cells outside of the
yolk sac. At 24, 48 and 72hpi the fish were imaged again using a fluorescence confocal
microscope (Olympus Fluoview) or a fluorescence stereomicroscope (Leica M205 FA).
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Rate of invasion and migration was determined using a modified analysis protocol from
Ghotra et al. (Ghotra, et al., 2012) with ImageJ. Each image was imported into ImageJ,
aligned to the same orientation, and cropped so the injection sites (yolk sacs) would all
have the same figure coordinates. The images were converted to a 32-bit greyscale and the
threshold was adjusted to eliminate background pixels. The injection sites were chosen as
the midpoint of the yolk sacs. Using the measure function the exact coordinates for the
injection site were measured. The “Analyze Particles” tool was used to measure the
coordinates and area of each tumour foci. All measured results were copied into Excel files
for later analysis. Using Excel, the coordinates of each tumour foci were corrected to the
injection site coordinates using the formula: (Xfoci-Xorigin,Yorigin-Yfoci). For each foci the
distanced travelled from the injection site was calculated using the formula:
√(Xcorrected2+Ycorrected2). The cumulative distance (CD) of all foci was calculated per embryo
(Ʃfocin) and averaged within an experimental group to determine mean CD. A fish was
determined to have metastasis if there were tumour foci outside of the yolk sac. Foci found
outside the yolk sac were also counted to determine average metastases per fish.
Immunoblotting
Protein analysis was performed following a previously described protocol (Al Sorkhy,
Fifield, Myers, & Porter, 2016). Briefly, 50µg of total protein was loaded on a 10% SDSPAGE gel and ran at 120V for 2.5-3hrs until separation of protein bands. Protein was
transferred to nitrocellulose membranes at 30V for 2.5hrs. Membranes were blocked with
5% BSA for 1hr then incubated with primary antibodies overnight at 4°C. Secondary was
applied for 1hr at room temperature. Primary antibodies used were: Spy, Thermo Fisher:
PA5-29417; β1-integrin, Cell Signaling: 9699S; ERK1/2, Cell Signaling: 9102; Phospho181

ERK 1/2 (Thr 202/Tyr 204), Cell Signaling:4370; E-cadherin (24E10), Cell signaling:
3195 ; β-catenin, Cell Signaling:8480.
Immunofluorescence (IF) and Confocal Microscopy
A modified protocol from Dr. B. Sloane (Li, Mullins, Sloane, & Mattingly, 2008) was used
where cells were seeded onto Cultrex® covered coverslips in a 30mm culture dish and
allowed to form acini. Coverslips were collected at 4 days and 12 days, washed with 37°C
phosphate buffered saline (PBS) and fixed in either -20°C Methanol for 10mins or room
temperature 4% paraformaldehyde in PBS for 20mins depending on antibody
specifications. Fixations were quenched with 0.75% Glycine in PBS for 10mins. Cells were
permeabilized with 0.5% Triton X-100 in PBS for 10mins and blocked with a 1hr
incubation in IF buffer: 130mM NaCl, 7mM Na2HPO4, 3.5mM NaH2PO4, 0.1% bovine
serum albumin (BSA), 0.2% Triton X-100, and 0.05% Tween-20, pH 7.5. Cells were
incubated with primary antibody in IF buffer at 4°C overnight in a humidity chamber
followed by three IF buffer washes of 10mins. Cells were incubated in secondary antibody
in IF buffer for 1hr at room temperature in a darkened humidity camber. After three IF
buffer washes of 10mins, cells were incubated with TOPRO3 in PBS for 10mins followed
by a PBS wash for 10mins. Coverslips were air dried for 30mins and then fixed onto slides
with Prolong Gold Antifade reagent (Thermo Fisher P36930). Slides were imaged at 60x
with a fluorescence confocal microscope (Olympus Fluoview). Acini size and protein
expression were analyzed using ImageJ software.
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Results
Spy1 expression regulates mammary acini morphogenesis in vitro
To determine if Spy1 could induce early indicators of tumourigenic events in mammary
cell lines in vitro, we used the MCF10A mammary cell line and the H-Ras transformed
derivative, AT1. MCF10A cells form highly organized single-acinar structures when
cultured in ECM and are frequently used to model mammary alveolar morphogenesis in
vitro. Spy1 overexpression in the MCF10A cells caused larger acinar structures, as
compared to control cells, after 4 and 12 days in culture (Figure 5.1 A). The acini developed
into more multiacinar as opposed to single acinar structures (Figure 5.1 A).
The transformed AT1 cells on the other hand, are known to form hyperplastic acini
in vitro but have low invasive potential. The AT1 line expresses Spy1 protein at higher
levels than the MCF10As but lower levels than the MDA-MB-231s (Al Sorkhy, et al.,
2012) so we wanted to determine if overexpressing Spy1 in the cells could increase their
disorganization in 3D culture and perhaps show a more invasive phenotype. When Spy1
was exogenously overexpressed in the AT1 cells, they formed larger acini than control
cells after 4 and 12 days (Figure 5.1 B). There was no change in the frequency of
multiacinar structures with approximately 71% and 78% being multiacinar in control and
Spy1 cells, respectively (Figure 5.1 B).
We used shRNA-mediated knockdown in the AT1 cells (termed shSpy1 cells) to
determine if reducing Spy1 expression could revert these structures from a hyperplastic
morphology to a normal morphology. The acini formed with shSpy1 cells were smaller
than the control AT1 cells after 4 and 12 days in culture (Figure 5.1 C) and had a reduction
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in percentage of multiacinar structures from approximately 82% in control cells to 52% in
shSpy1 cells (Figure 5.1 C).
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Figure 5.1. Aberrant Spy1 causes abnormal mammary acini formation.
Representative images of MCF10A (A), AT1 Spy1 overexpression (B), and AT1 cells with
Spy1 knockdown, that have been infected with control, Spy1 overexpression or shRNA
Spy1 knockdown lentivirual vectors and grown in growth-factor reduced Cultrex® for 4
and 12 days. Graph represent quantification of acinar size at 4 and 12 days and % of multi
or single-acinar structures formed. Statistical anaysis performed using Students t-test, *
p<0.05, ***p<0.001. Error bars represent mean ± SEM, n= at least 140 acini counted over
3 independent experiments.
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Elevated Spy1 levels promote cell growth and disrupt acini organization
Acini were fixed for immunofluorescence assays to determine if the multi-acinar structures
formed in the presence of elevated Spy1 levels were caused by over proliferation (Ki67
expression levels), disruptions in cell-cell polarity (β-catenin and E-cadherin localization),
disruptions in apical-basal polarity (GM130 localization), or alterations in cell-EMC
interactions (Laminin V localization). These are all events that take place in early
tumourigenic and metastatic processes (Debnath, et al., 2003; Yoshida, Kimura, Harada,
& Ohuchi, 2001). The loss of β-catenin and E-cadherin expression at the cell junctions is
one of the hallmarks of cells undergoing EMT and seen in many metastatic cells (Onder et
al., 2008; Yoshida, et al., 2001). Cross-sections of MCF10A cells were obtained by
confocal microscopy after 4 and 12 days of growth in 3D culture. Overexpressing Spy1 in
these cells did not change in E-cadherin, β-catenin, or Laminin V localization (Figure 5.2
and Figure S5.1 A-C) as compared to control cells. They did have an increase in Ki67
expression, and GM130 mis-localization after 4 days in culture (Figure 5.2 A and C). This
supports that the acini were more proliferative and more disorganized than control acini.
Day 12 acini had no change in Ki67 expression with Spy1 overexpressing cells but had
more cells with mislocalized GM130 (Figure 5.2 B-C). Protein levels in MCF10A and
MDA-MB-231 cells confirmed that E-cadherin and β-catenin protein levels were
unchanged with manipulation of Spy1 expression (Figure S5.1 C) and SPDYA gene
expression was confirmed using qRT-PCR (Figure S5.1).
AT1 acini with Spy1 overexpression were also stained for β-catenin, Ki67, and
GM130 (Figure S5.2). Again, there was no change in β-catenin localization at day 4 but
there was an increase in proliferating cells (Figure S5.2C). Spy1 knockdown in AT1 cells
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showed no change in Laminin V or β-catenin localization (Figure S5.3,Figure 5.3) but there
was a decrease in Ki67 expression and an increase in the number of acini with hollow
lumen formation at 4 days but not at 12 days (Figure 5.3).
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Figure 5.2. MCF10A cells overexpressing Spy1 form hyperplastic, disorganized acini.
MCF10A control and Spy1 overexpression cultures were collected at Day 4 (A) and Day
12 (B) and stained with antibodies specific for b-catenin, E-cadherin, GM130 and Ki67.
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(C) Graphs represent quantification for % of cells with GM130 mislocalized, % of cells
expressing Ki67. Data represents mean ± SEM, n=at least 130 cells counted over 3
independent experiments, statistical anaysis performed using Students t-test, * p<0.05, **
p<0.01, ***p<0.001.
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Figure S5.1. MCF10A cells overexpressing Spy1 do not change cell-cell protein
expression.
(A) MCF10A control and Spy1 overexpression cultures were collected at Day 4 and stained
with antibodies specific for laminin V. (B) Graph represents quantification for % of cells
localizing β-catenin. (C) % of cells localizing E-cadherin. n=at least 130 cells counted over
3 independent experiments. (D) protein expression of E-cadherin and β-cateinin in
MCF10A cells with WT, control, or Spy1 overexpression and MDA-MB-231 cells with
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WT, control (pLKO), or shSpy1 expression. One representative blot of n=3. (E) graphs
representing relative quantitation (RQ) SPDYA/GAPDH mRNA expression in MCF10A
and MDA-MB-231 cells. n=3. Data represents mean ± SEM, statistical anaysis performed
using Students t-test, **p<0.01.
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Figure S5.2. Transformed AT1 cells overexpressing Spy1 are hyperproliferative but do not
exhibit EMT properties.
(A) AT1 control and Spy1 overexpression cultures were collected at Day 4 and stained
with antibodies specific for b-catenin, Ki67, and GM130. (B) Graphs represent
quantification for % of cells with GM130 mislocalized, % of cells expressing Ki67. (C)
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Day 12 acini were stained with β-catenin. Data represents mean ± SEM, n= at least 130
cells over 3 independent experiments, statistical anaysis performed using Students t-test,
***p<0.001.
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Figure 5.3. Depleting Spy1 reverts hyperplastic acini back to a more normal phenotype.
(A) AT1 control and shSpy1 expressing cultures were collected after 4 days and stained
with antibodies specific for b-catenin, Ki67, and GM130. Graphs represent quantification
for % of cells expressing Ki67, % of acini with hollow lumen, and % cells with GM130
mislocalization. (B) AT1 control and shSpy1 expressing cultures were collected after 12
days and stained with antibody specific for b-catenin. Graph represents quantification of
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the % of acini with hollow lumen. Data represent mean SEM, statistical anaysis performed
using Students t-test, *p<0.05, ** p<0.01, n=3.
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Figure S5.3. AT1 cells with Spy1 knockdown have no change in Laminin V or β-catenin
expresssion.
(A) AT1 control and shSpy1 acini were collected at Day 4 Laminin V. (B) Graph represents
quantification for % of cells localizing β-catenin. Data represents mean ± SEM, statistical
anaysis performed using Students t-test, n= at least 130 cells over 3 independent
experiments.
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Spy1 enhances the metastatic behaviour of mammary epithelial cells
Breast cancer cell metastasis is a multi-step process that is often initiated in the alveolar
structures of the mammary gland (Muschler & Streuli, 2010; Shousha, Backhous,
Alaghband-Zadeh, & Burn, 1986). The initial processes include the increased proliferation
and disorganization of alveolar cells, followed by invasion and migration of the cells
through the ECM most often thought to occur with cells undergoing EMT. Based on the IF
staining in Figure 5.2-Figure S5.3, manipulating Spy1 expression did not alter the
expression of proteins classically involved in EMT in mammary cells, however there was
disruption in the organization of the acini. We then used functional assays for migration
and invasion to determine if altering Spy1 protein levels resulted in a change in these
classical in vitro assays.
MCF10A cells were infected with either a control vector or a vector stably
expressing Spy1 and Boyden transwell migration and invasion assays were performed.
After 24 hrs, overexpression of Spy1 caused a significant increase in cell migration and
invasion (Figure 5.4 A). Since the invasive cells line MDA-MB-231 cells have increased
Spy1 expression compared to normal mammary cells (Al Sorkhy, et al., 2012), we knocked
down Spy1 using shRNA and found that invasion and migration through transwell
chambers was significantly decreased (Figure 5.4 B).
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Figure 5.4. Spy enhances metastatic behaviour of mammary cells.
(A) MCF10A cells with Spy1 overexpression and (B) MDA-MB-231 cells with Spy1
knockdown after 24hrs transwell migration assay. Micrographs taken with 10x objective.
Scale bar=100µm. Graph represents relative migration of Spy1 or shSpy1 compared to
control cells after 24hrs. Data represent mean ± SEM, n=3, *p<0.05, **p<0.01.
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Spy1 promotes breast cancer metastasis in vivo
To determine if elevating Spy1 levels would have the same effect on cell invasion and
migration in vivo, a zebrafish xenograft model was used. The optimal cell dilution and time
post injection was determined by injecting different quantities of cells and quantifying
every 24hpi. The optimal number of injected cells was more than 30 and cell metastasis
was highest 72hpi (Figure S5.4). 72 hrs after injection, the MCF10A cells overexpressing
Spy1 had travelled further than the cells expressing the control vector (Figure 5.5 A-B). In
addition, a higher percentage of fish with Spy1 overexpression cells had metastasis as
opposed to control cells and there were significantly more metastases per fish with Spy1
overexpression (Figure 5.5 C). Depleting Spy1 expression in the MDA-MB-231 cells did
not change the cumulative distance travelled by the cells or the percentage of fish with
metastasis, however there was a decrease in the number of metastases per fish with
knockdown (Figure 5.5 D-F). Spy1 depletion in AT1 cells caused a significant decrease in
the cumulative distance travelled by cells 24 hours post injection (Figure S5.5).
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Figure S5.4. Cell dilution to determine optimal number of cells for zebrafish xenograft.
Graphs represent (A) total Raw Integrated Density of xenographs. Each point represents 1
fish. Data represents mean, (B) % fish with metastases. n= at least 7 fish, ****p<0.001.
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Figure 5.5. Spy1 regulates breast cancer metastasis in vivo.
(A) Representative fluorescence stereomicroscopy images 72 hours after injection of
MCF10A cells expressing Control (red) and Spy1 (green) overexpression vectors. (B)
Quantification of the cumulative distance travelled by cells 72 hours post injection. Each
point represents one injected fish. (C) Graphs representing the % of fish that had metastasis
outside of the yolk sac 72 hours after injection and metastases/fish. n=29 fish from 3
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separate infections. (D) Representative fluorescence stereomicroscopy images 72 hours
after injection of MDA-MB-231 cells with Control (green) and shSpy1 (red). (E)
Quantification of the cumulative distance travelled by cells 72 hours post injection. Each
point represents one injected fish. (F) Graphs representing the % of fish that had metastasis
outside of the yolk sac 72 hours after injection and metastases/fish. n=29 fish from 2
separate infections. Data represent mean ± SEM, *p<0.05, **p<0.01. Scale bar=500µm.
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Figure S5.5. Knockdown of spy1 decreases invasion and migration in vivo.
(A) 24 hpi of AT1 cells infected with control or shSpy1 vector. Graphs represent
coordinates of each tumour foci for all control or Spy1 injected fish with 0,0 being the
injection site. (B) Graph representing the CD of control and Spy1 injected fish. Each point
represents the CD of one fish. n=51 (C) graph representing relative quantitation (RQ)
SPDYA/GAPDH mRNA expression. n=3, *p<0.05, data represents mean ± SEM.
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Spy1 increases β1-integrin and ERK1/2 expression
While Spy1 functionally increased invasion and migration (Figure 5.4), markers of EMT
were unchanged (Figure S5.1 and Figure S5.3). This led us to investigate alternate
pathways that would explain how Spy1 is regulating migration or invasion while
maintaining E-cadherin expression. Two very important interactions for metastatic
regulation are cell-cell and cell-ECM (Lock, Wehrle-Haller, & Stromblad, 2008). Because
Spy1 was not visibly affecting cell-cell adhesion, we further investigated Spy1 regulation
of cell-ECM interactions.
Increased Spy1 protein expression led to an increase in β1-integrin expression
(Figure 5.6 A), one the main modulators of cell-ECM interactions (Lambert, Ozturk, &
Thiagalingam, 2012; Lock, et al., 2008). Because β1-integrin regulation is through
activation of the integrin subunit binding to ECM, we used a β1-integrin antibody to block
activation of the integrin subunit and inhibit downstream signaling. Interestingly, blocking
β1-integrin activity did not affect migration but reduced invasion of MCF10A cells through
the transwell chamber (Figure 5.6 B).
One of the main downstream signaling pathways activated by β1-integrin binding
to ECM is focal adhesion kinase/ERK1/2 signaling which has been shown to upregulate
metastasis in breast cancer cells (Jiang, Pan, Cheng, Li, & Liu, 2016; Provenzano, Inman,
Eliceiri, & Keely, 2009). Previous work has shown that Spy1 is able to activate ERK1/2 in
breast cancer cells but this has never been explored in normal breast cells (Ferraiuolo, et
al., 2017). Protein expression revealed that exogenous expression of Spy1 caused an
increase in ERK1/2 phosphorylation which is needed for ERK1/2 activation (Figure 5.6
A).
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Small molecule inhibitors for ERK1/2 and MEK were used to determine if this
pathway is involved in Spy1 mediated invasion and migration. Migration through
transwells was significantly decreased with the ERK1/2 inhibitor and although decreased
with the MEK inhibitor, it was not statistically significant (Figure 5.7 A). Invasion was
decreased with both the ERK1/2 and MEK inhibitors (Figure 5.7 B).
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Figure 5.6. Spy1 increases β1-integrin and requires its activity for invasion.
(A) western blot of whole cell lysates from 10A cells overexpressing Spy1 were probed
with the antibodies indicated on the left side of each panel. Graphs represent densitometry
analysis of antibodies indicated on Y-axis. MCF10A cells expressing control and Spy1
overexpression vectors were seeded into transwell chambers for (B) migration and (C)
invasion. Graphs represent relative intensity measured using ImageJ. Data represents mean
± SEM, *p<0.05, ****p<0.001, n=3, scale bar=100µm.
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Figure 5.7. Spy1 requires ERK1/2 activation for invasion and migration.
Boyden (A) migration and (B) invasion assay with control and ERK inhibitors and control
(SBB) and MEK (U0126) inhibitors in MCF10A cells expressing control or Spy1
overexpression vectors. Graphs represent relative intensity measures using ImageJ. Data
represents mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, n=3, scale bar=200µm.
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Discussion
Breast cancer has become a highly treatable disease but is still the second leading cause of
cancer deaths in women (Bray, et al., 2018) worldwide. Once breast cancer metastasizes to
distal organs it becomes very difficult to treat and is most often fatal. Understanding the
mechanisms of metastasis may improve treatments for patients who have metastatic disease
and/or they may prevent earlier stage disease from progressing. In this study we show a
novel role for Spy1, a cell-cycle regulator, in mediating processes required for breast cancer
metastasis.
Disorganization and hyperplasia in mammary alveoli are early processes in breast
cancer metastasis and disruption in the cell-matrix interactions can lead to breast cancer
(Bussard & Smith, 2012; Muschler & Streuli, 2010). In our study, Spy1 significantly
increased disorganization in a 3D cell culture mammary acini model with a loss of apicalbasal polarity and significantly more proliferation in early acini development. However,
the cells were able to maintain the cell-cell interactions with no change in β-catenin or Ecadherin expression or localization. When cells were implanted into a zebrafish embryo
metastasis model, Spy1 was able to increase the formation of metastases in MCF10A cells.
Recent studies, in both breast and pancreatic cells, have shown that EMT may not
be a necessary process for cell metastasis (Fischer, et al., 2015; Zheng, et al., 2015). In our
study, breast cells overexpressing Spy1 are able to invade, migrate, and metastasize but
they do not go through classical EMT. The cells do not lose E-cadherin expression and do
not change to mesenchymal morphology. A possible mechanism of Spy1 mediated
metastasis may be the cohesive or collective cell migration as opposed to single cell
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dissemination that has been previously described (Christiansen & Rajasekaran, 2006; Clark
& Vignjevic, 2015; Jolly, Ware, Gilja, Somarelli, & Levine, 2017).
Protein expression analysis revealed exogenous expression of Spy1 protein can
increase β1-integrin expression and activate ERK1/2 signaling which, in turn, was shown
to be involved in Spy1 mediated invasion and migration as seen by the use of small
molecule inhibitors for ERK1/2. β1-integrin activity was necessary for invasion but not
migration in Spy1 overexpressing cells, as seen by blocking antibodies experiments. It is
possible that integrin signaling is needed to increase matrix metalloproteinase (MMP)
expression and function to degrade the ECM and facilitate cell invasion but maybe this
signaling is not needed to migrate when no ECM is present. In breast cancer cells the
fibronectin- α5β1-integrin interaction can induce MMP-2 and MMP-9 expression and
activation (Chao, Shepard, & Wells, 2010). This study did not determine which, if any, α
integrin subunits are also necessary for Spy1 mediated metastatic processes and this would
be a valuable future direction.
Because of the incurable nature of metastatic breast cancer, it is imperative to
determine the cellular processes that lead to cell metastasis and find better treatment
programs for the patients that have this fatal disease. We were able to show, for the first
time that Spy1 is a crucial regulator of cell invasion processes and that this regulation is
independent of EMT but requires β-integrin and ERK1/2 signaling.
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CHAPTER 6 DISCUSSION AND FUTURE DIRECTIONS
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Zebrafish as a model system for cancer processes and cancer drug toxicity
One of the main objectives of this work was to set up and optimize a zebrafish model as a
multi-faceted system to study human cancer processes as well as drug toxicity. This
included starting a colony, optimizing feeding and breeding protocols to obtain maximum
egg production for high throughput experiments, and optimizing many different assays,
that had previously never been utilized by our research group, to study different cancer
processes.
As shown in this work, we successfully validated the use of this zebrafish model
for many different cellular processes. This included the study of the effects of antiinflammatories on cell metastasis, the toxicity of breast cancer drug combinations, the
effectiveness of a natural health product (NHP) in reducing inflammatory processes, the
role of a cell cycle regulator on mammary cell metastasis, and in a previously published
study, drug resistance of breast cancer cells to tamoxifen (Ferraiuolo, Tubman, Sinha,
Hamm, & Porter, 2017). These diverse applications highlight the versatility of this model.
Being able to use the same animal model for multiple avenues of research is a huge
advantage, reducing research costs and research time that would otherwise be spent
optimizing multiple animal models.
Zebrafish were first proposed for use in research in 1934 (Creaser, 1934) and were
the first fish species to be involved in carcinogenesis research (Spitsbergen & Kent, 2003)
so using fish to study cancer is not a new concept. However, it wasn’t until into the 1990’s
and early 2000s when the genome of the zebrafish was sequenced that this model system
began to be appreciated as an accurate model for human diseases (Spitsbergen & Kent,
2003). Zebrafish have 70% genetic similarity to humans and 85% of all human disease
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genes have homologs in the zebrafish (Howe et al., 2013; Kettleborough et al., 2013;
Santoriello & Zon, 2012), which further supports the use of this model in mimicking human
diseases.
Our aim was to validate the use of zebrafish to study human cancer processes to be
a complimentary system to the mouse models available in our research facility. Mouse
models are an invaluable tool for cancer research as they closely mimic humans genetically
(Waterston et al., 2002). The main disadvantage with the mouse model is the cost of
housing and the labour required to maintain a large mouse colony, especially if that
involves creating/maintaining transgenic and knockout/in strains. Zebrafish are a relatively
inexpensive animal model with very low maintenance cost once the aquatic system is set
up. Each healthy female can produce ~200-300 eggs per week which allows for easy
maintenance of stocks.
There are also advantages in the ease of imaging zebrafish over mice. In mice, live
imaging of tumour cells requires a very expensive in vivo fluorescence/bioluminescence
imager that is not readily available to many researchers. However in zebrafish, the embryos
can be imaged, alive, with any light microscope (or fluorescent scope if labelled cells are
used) because the embryos remain mostly transparent until 3-6 weeks post fertilization
(Eskova et al., 2017). Furthermore, there are pigmentation mutants available such as the
roy-/-;nacre-/- (casper) or nacrew2/w2;albb4/b4;roya9/a9 (crystal) mutants that are completely
transparent throughout development. These points enable the live embryo to be monitored
for a long period of time, supporting the study of development and/or organ toxicity.
Transparent genetic strains are more difficult to maintain and hence have not yet been
added to our colony, however, now that our aquatic system is stable and our models have
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been optimized, the casper or crystal fish would be a great addition to continue with
metastatic studies as tumour foci could be visualized for a longer period.
One of the main advantages of the zebrafish in cancer studies is the fact that the
immune system develops in stages so human cells can be injected in the first 1-2 weeks of
development because the adaptive immune system is not yet mature and human cells can
engraft without host rejection. The innate immune system is active at this stage and
therefore the embryos are immunocompetent which allows for an intact microenvironment
for more accurate study of cancer process that rely on environmental signals; migration
and invasion, for example (Antinucci & Hindges, 2016; Tang et al., 2016; White et al.,
2008). If human cells are to be engrafted into mice, an immunodeficient model is needed
which is very costly and less biologically relevant because the immune system cannot
influence the engrafted cells in the way that it would in human cancers (Ito, Takahashi,
Katano, & Ito, 2012; Somasundaram et al., 1995). The largest disadvantage for the
zebrafish model for the study of breast cancer processes is the fact that zebrafish do not
possess breasts and there is no structure homologous to the breast outside of mammal
models. However, the model has many aspects which accurately mimic cancer processes
as they occur in human beings, such as tumour proliferation, invasion, migration, and
angiogenesis. Monitoring invasion and metastasis in patient-derived cells that have been
transplanted into the fish (also referred to as xenotransplantation), can be efficiently
conducted in the yolk because the yolk is separated from the embryo by a syncytial layer
(Kimmel & Law, 1985), thereby requiring cancer cells to actively invade from the yolk
into the developing organism to metastasize. This mimics the process by which cells escape
alveolar structures in human breast cancer because the terminal ductal lobular units are
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each separated from the other with stromal tissue (Cardiff & Wellings, 1999). In human
breast cancer, the most common metastatic site is to the bone, followed by the lung, brain,
and liver (Patanaphan, Salazar, & Risco, 1988) and in our lab, as well as others, tumour
foci most often set up in the tail bones of the embryo once the cells have invaded through
the yolk (Ren, Liu, Cui, & Ten Dijke, 2017; X. X. Wu et al., 2018). Another important
process in breast and other cancers, is tumour angiogenesis. We were able to model this
process in the zebrafish using alkaline phosphatase staining, which is a method that has
been previously used in zebrafish angiogenesis (Moshal, Ferri-Lagneau, Haider,
Pardhanani, & Leung, 2011). Hence, although we are not able to examine gross mammary
gland development in the zebrafish model, we are able to model the processes that are
important for tumourigenesis and metastasis.
These assays are currently being used in by our researchers to model other human
cancers, such as glioblastoma and prostate cancer and will continue to be an important
asset. To date we have only used a wildtype strain of zebrafish but in the future, we will be
developing casper strains to permit long term, specialized studies.
The use of anti-inflammatories in combination with breast cancer treatments
The anti-inflammatory properties of dexamethasone (Dex) make it an attractive antiemetic
to combat the side effects of chemotherapeutics. However, concern was raised about the
protective effects of Dex on breast cancer cells almost 20 years ago by the Conzen lab
(Mikosz, Brickley, Sharkey, Moran, & Conzen, 2001; Moran, Gray, Mikosz, & Conzen,
2000; W. Wu, Pew, Zou, Pang, & Conzen, 2005). Our lab has also previously shown that
in breast cancer cell lines, Dex has an antagonistic effect on cell death when used with the
chemotherapeutic, paclitaxel, through downregulation of the inflammatory regulator,
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NFκB (Crozier & Porter, 2015). To further dissect the effect of Dex on other cancer cell
processes, this work tested the effects of Dex treatment on cell migration and invasion in
vitro and cell metastasis in vivo.
Our in vitro data showed that Dex positively regulated cell metastasis in triple
negative breast cancer (TNBC) cell lines but not in ER+ cell lines. When we
xenotransplanted the TNBC cells, MDA-MB-231, and ER+ cells, MCF7, and treated the
embryos with 10 or 100µM of Dex we saw that both cell lines had a significant increase in
the frequency of fish with metastasis and the total distanced travelled away from the
injection site as compared to DMSO treated embryos. This difference between Dex effects
on MCF7 cells in vitro and in vivo could be due to both cell lines being injected together
into the same fish causing some interaction between the two cell lines to promote
metastasis of the MCF7 cells with Dex treatment. MDA-MB-231 cells have been shown
to secrete factors that recruit immune cells to promote metastasis (Erler et al., 2009) and it
is known that zebrafish immune cells, specifically neutrophils, can interact and promote
metastasis of human tumour xenografts (S. He et al., 2012). It would be interesting to
determine if this is the case with the co-injected cells by injecting MCF7 cells alone into
the zebrafish to see if cells are still able to metastasize after Dex treatment. This study
presents further evidence that in vitro assays are not sufficient for determining invasive
ability of cells but should be complemented by in vivo studies.
Gene analysis of cells treated with Dex in vitro show a significant increase in
WNT5A expression in MDA-MB-231 cells but not in MCF7 cells. WNT5A is a noncanonical Wnt ligand that is involved in planar cell polarity and epithelial-mesenchymal
interactions during normal embryogenesis (Oishi et al., 2003) and there is much debate
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whether WNT5A is able to promote tumourigenesis or act as a tumour suppressor as
detailed in a review by Zeng et al. (2016). A recent study with Dex-treated cells reported
that Dex enhanced metastasis through WNT5A and its receptor ROR1 (Obradovic et al.,
2019). In that study, WNT5A expression was elevated in metastases from mice treated with
Dex and downregulating ROR1 expression decreased Dex-induced metastasis (Obradovic,
et al., 2019). They did not examine MCF7 or any other ER+ cells lines but our work
suggests that WNT5A is not affected by Dex in the ER+ MCF7 cells and it is not regulating
migration. A valuable assay for us to dissect the role of WNT5A in Dex mediated
metastasis is to either treat cells with WNT5A inhibitors before xenotransplantation into
the zebrafish or treat the zebrafish media with inhibitors to determine if metastasis is
ablated. It is possible that in the zebrafish microenvironment WNT5A is activated in the
MCF7 cells and that could be determined by collected cells post-transplant and looking at
gene expression. A large number of embryos would have to be pooled together to get
sufficient human mRNA as so few cells are transplanted into the embryos.
It has been previously shown that IL-6 can upregulate transcription of WNT5A,
through STAT-3 signaling, and this can induce cell migration through the non-canonical
RHO/RAC Wnt pathway specifically during chronic inflammation and carcinogenesis
(Katoh, 2007). Also, that glucocorticoids have been implicated in inducing the expression
of the purinergic receptor, P2Y2R, which increases IL-6 secretion (Ding, Gao, Jacobson,
& Suffredini, 2010). It would be valuable to look at activation and expression of STAT-3
and P2Y2R after Dex treatment in our system to confirm that this is the active pathway
regulating breast cancer cell invasion and metastasis.
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Expression of il6 in the zebrafish embryos after Dex treatment was unchanged,
however il1β and tnfα were elevated after prolonged Dex treatment, perhaps through the
same P2Y2R mechanism as mentioned above (Ding, et al., 2010). Previously, the
glucocorticoid beclomethasone was noted to reduce il1β expression in zebrafish embryos
but treatment was only continued up to 25hrs so long term treatment was not examined
(Chatzopoulou et al., 2016). We did not collect fish after short-term exposure, at these
lower concentrations, so there may be an initial suppression of the immune response
followed by compensatory activation with longer exposure times.
The interaction of Dex with cancer cells is not the only concern when Dex is given
to breast cancer patients. The chemotherapeutics that are given with Dex have many
reported side effects but little has been reported as to whether Dex directly affects the
severity of the observed side effects, aside from the consensus that Dex is effective in
reducing nausea and appetite loss (Chu et al., 2014). In embryos treated with Dex and
common treatments for breast cancer, cyclophosphamide and paclitaxel, we saw that Dex
enhances cardiotoxicity and hepatotoxicity in zebrafish embryos and larvae with
cyclophosphamide but does not have these toxic effects with paclitaxel. For measuring
hepatotoxicity we used previously described assays (J. H. He et al., 2013; Vliegenthart,
Tucker, Del Pozo, & Dear, 2014) that measure liver size, opacity, and yolk retention. In
the Dex and cyclophosphamide treatment group the liver was very hard to distinguish
because of the amount of fluid buildup in the pericardial sac. It would be beneficial to use
a probe or stain that would aid in visualizing the liver. Aside from transgenic fish that have
liver specific reporters, there is the previously described glucose bioprobe conjugated to
the fluorophore Cy3 (GB2-Cy3) (Park et al., 2014). We are currently optimizing a similar
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probe to measure glucose metabolism and function in the liver based on the principle that
a healthy liver will uptake the GB2-Cy3 probe and we can compare the amount of
fluorescence in the control and treated embryos (Seth, Stemple, & Barroso, 2013).
Gene analysis after treatment showed an upregulation of mmp9 expression with the
combination of Dex and cyclophosphamide which may contribute to the observed increase
in edema as Mmp9 activation has previously been associated with edema in zebrafish
(Zhang, Huang, Wang, Gao, & Zuo, 2013). We attempted to use ERK inhibitors to block
edema formation as there is evidence that ERK regulates MMP-9 expression in human
brain edema (Arai, Lee, & Lo, 2003; Mori, Wang, Aoki, & Lo, 2002), however, Erk
signaling is extremely important in the developing embryo especially for response to
environmental stressors (Keller, Escara-Wilke, & Keller, 2008) and in our preliminary
studies, the ERK inhibitor accentuated the edema caused by the drug treatments so a more
direct method to block Mmp9 activation in zebrafish is being optimized for future studies.
One caveat to the study of cyclophosphamide in zebrafish is that a very high
concentration is needed to get an internal concentration in the fish that is relevant to what
breast cancer patients received. This is partly due to the nonionic nature of the drug and
this makes it poorly absorbed by the embryo (Brox, Seiwert, Kuster, & Reemtsma, 2016).
We are in the process of measuring drug absorption in the fish by HPLC and will follow
up to determine what concentration of each drug is absorbed and metabolized by the fish
in the single and combination treatments.
This work has shown that there is a clear need to continue studying the mechanisms
of Dex to be able to assess its true value as an antiemetic for breast cancer patients. If the
detrimental side effects of Dex are more lethal to the patient than those caused by the
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chemotherapeutics, there needs to be more effort to identify alternative antiinflammatories.
Due to serious side effects seen in Dex we wanted to determine if there were natural
health products (NHPs) that could be used to reduce inflammation and oxidative stress,
two processes that are prevalent in cancer, without contributing to serious organ toxicity
(Liguori et al., 2018; Willcox, Ash, & Catignani, 2004; Young & Woodside, 2001). Using
zebrafish assays, we found that Nutria plus with SelenoExcell, an NHP, was able to reduce
cell death due to UV exposure, increase rate of tissue repair after tail amputation, and
prevent angiogenesis of engrafted tumour cells. The Nutria plus with high SelenoExcell
concentration (HSe) formula is currently registered with Health Canada as an NHP. These
preliminary results are a good foundation to continue investigating Nutria plus HSe as an
anti-inflammatory and antioxidant however there is still a lot that can be done to ensure
that this NHP is safe to administer in combination with chemotherapies. Future studies will
include repeating the zebrafish toxicity assays with Nutri plus in the place of Dex to
determine if there is a reduction in heart and liver toxicities. We also need to dissect the
pathway regulation of Nutria plus HSe to ensure that inflammatory pathways are not being
activated with this NHP as they are with Dex.
The immune system is extremely important for normal development and has been
implicated in providing protection against malignancy in the breast (Strayer, Carter, &
Brodsky, 1986). However, in the context of cancer treatments, the immune system is
responsible for many of the unwanted side effects of chemotherapeutics, such as
inflammation and tissue damage (Chu, et al., 2014). Immune suppression is not only
dangerous for breast cancer patients but can also be dangerous when used as treatment of
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other diseases and conditions that cause sustained immune response. For example, immune
suppressant drugs have been implicated in the onset of hepatosplenic T cell lymphoma, a
rare form of aggressive cancer often seen in Chrohn’s and Lupus patients, transplant
recipients, and other immune disorders (Belhadj et al., 2003; Carvao, Magno Pereira,
Jacinto, Sousa Andrade, & Jasmins, 2019; Subramaniam et al., 2014). Future research will
be directed at finding effective anti-inflammatories that are safer for long-term use.
Spy1 Promotes Cell Metastasis via β1-integrin-ERK1/2 Pathway
This work is the first to implicate the cell cycle protein, Spy1, in regulating mammary cell
migration and invasion, both in vitro and in vivo. Exogenous expression of Spy1 in
MCF10A cells increased acini disorganization in a 3D in vitro assay. Immunofluorescence
of whole acini structures revealed that the cells overexpressing Spy1 lost their apical-basal
polarity but maintained cell-cell contacts with a mislocalization of GM130 expression but
no change in E-cadherin or β-catenin expression. There was an increase in proliferation
rates in the early developing acini structures (day 4) but not late in development (day12).
Laminin V expression was also unchanged which implies that the cell-matrix interaction is
still intact even though the cells are not polarized properly. Inversely, when Spy1
expression was downregulated in the transformed MCF10AT1 (AT1) cell line, the acini
structures were smaller and more organized. Alveolar hyperplasia and disorganization are
two processes in early breast cancer tumourigenesis before the cancer cells have breached
the basement membrane (Donaldson et al., 2018; Lerwill, 2004). These effects led us to
examine if Spy1 regulated late processes of tumourigenesis such as invasion, migration,
and colonization. Using transwell assays, we determined that aberrant expression of Spy1
increased the invasive and migratory potential of the cells. In the zebrafish xenotransplant
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model, we were able to show that Spy1 expressing cells had more invasion outside of the
yolk sac and colonization of the tail. Cell invasion, migration, and tail colonization was
attenuated with Spy1 knockdown in AT1 cells and metastases per fish was reduced in
MDA-MB-231 cells.
Even though Spy1 does not exhibit the classical markers of EMT (loss of Ecadherin at the cell membrane, β-catenin translocation to the nucleus), it does regulate
invasion and migration. Cell-ECM interactions are important for metastatic progression,
so we looked at integrin expression in MCF10A cell lysates with Spy1 overexpression.
Protein analysis revealed that Spy1 overexpressing cells had an increase in β1-integrin
protein and blocking antibodies were able to inhibit Spy1 mediated invasion but not
migration. The migration transwell assay does not contain any ECM components so it is
possible that β1-integrin is not activated in these cells even though they do have increased
protein expression.
Previously, it was shown in multiple myeloma that when cells adhere to fibronectin,
a β1-integrin ligand, Spy1 expression is actually downregulated which seems contrary to
our results (Fei, Hang, Hou, & Ruan, 2013) but preliminary data from others in our lab
show that Spy1 increases adhesion to collagen and plastic but not to fibronectin (Malysa,
2011). Cell-ECM adhesion assays were not performed in this work but it would be
beneficial to determine the adhesion properties of MCF10As overexpressing Spy1.
The activation of β1-integrin has been shown to be dependent on talin binding to
the cytoplasmic tail of the integrin (Chinthalapudi, Rangarajan, & Izard, 2018). It was
recently shown that ras associated protein 1 (RAP1), a small guanosine triphosphate
hydrolase, and phosphatidylinositol 4,5-bisphosphate synergize to allow talin binding to
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integrins and activating them (Bromberger, Zhu, Klapproth, Qin, & Moser, 2019).
Regulators of RAP1 include extracellular agents such cyclic adenosine monophosphate and
calcium (Bos, de Rooij, & Reedquist, 2001). A next step to further dissect how Spy1 is
activating β-integrin would be to investigate RAP1 activation.
RAP1, the β-integrin activator, is also involved in cell-cell adhesion processes
through regulation of E-cadherin at the cell junction as seen in ovarian carcinoma cells
where RAP1 inhibition led to a loss of E-cadherin from the cell surface (Price et al., 2004).
This is interesting because we see no change in E-cadherin expression at the cell junctions
when Spy1 is exogenously expressed yet we get invasion and migration of the cells. It
supports that Spy1-mediated effects do not require classical epitheial-mesenchymal
transition (EMT) signaling. There is a growing body of work to support that EMT is not
the only mechanism by which cells are able to metastasize, transitioning to ameboid
migration for example (Radisky & Radisky, 2007), and that EMT is better described as a
reversable process in which cells can exhibit a spectrum of epithelial or mesenchymal
properties (Fischer et al., 2015; Jolly, Ware, Gilja, Somarelli, & Levine, 2017; Zheng et
al., 2015).
β1-integrin signals downstream through many different pathways. One of these is
through phosphorylated ERK1/2. It is known that Spy1 can activate the MAPK/ERK1/2
pathway through a proposed feedback loop with ER in breast cancer cells (Ferraiuolo, et
al., 2017) but this pathway regulation had never been shown in normal mammary cells. We
suspect that Spy1-mediated invasion is MEK- and ERK1/2-dependent, but migration is
only dependent on ERK signaling based on our results where ERK1/2 small molecule
inhibitors decreased invasion and migration in Spy1 overexpressing cells but MEK
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inhibitors had no statistical effect on migration. Although, there was an observable
decrease so this needs to be evaluated further to make a definitive conclusion.
The complexity of ERK1/2 signaling in normal development and cancer biology
makes it a daunting task to try to dissect the direct upstream and downstream regulators in
Spy1 mediated invasion and migration and because we see differences in regulation of
invasion versus migration it is even more complex. More work needs to be completed to
verify the mechanism of ERK1/2 activation by Spy1.
Conclusion
Overall this work has been a study of inflammatory and metastatic processes in breast
cancer treatment and progression. Although, much more work is needed, I have shown that
the long-term use of immunosuppressants, in breast cancer patients and other disease
management, needs to be re-evaluated to determine if the detrimental side effects of the
current immunosuppressants out-weigh the effectiveness of treatment. I introduced Spy1
as a mediator of cell invasion and migration in normal and breast cancer cells. My hope is
that collectively, this work will contribute to the advancement of breast cancer research so
that in the future, protocols for breast cancer with distant metastases will include more than
palliative treatment and care, which is the current recommended protocol as reported by
Cancer Care Ontario (2018).
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